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v
WHat is a Witness seminar?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon.  Many members of the invited audience were scientists or 
others involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic and economic history 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree; and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 until September 2010. It has been part of the School of History, Queen 
Mary, University of London, since October 2010, as the History of Modern 
Biomedicine Research Group, which the Wellcome Trust funds principally 
1 See pages 143–6 for a full list of Witness Seminars held, details of the published volumes and other related 
publications.
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under a Strategic Award entitled ‘The Makers of Modern Biomedicine’. The 
Witness Seminar format continues to be a major part of that programme, 
although now the subjects are largely focussed on areas of strategic importance 
to the Wellcome Trust, including the neurosciences, clinical genetics, and 
medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting.  Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
Most of our volumes to date have been published under the series title, Wellcome 
Witnesses to Twentieth Century Medicine. As a reflection of our moving timespan 
into the twenty-first century we have changed the series title to: Wellcome 
Witnesses to Contemporary Medicine.




This is the first Witness Seminar to be held under the auspices of our new Wellcome 
Trust Strategic Award ‘The Makers of Modern Biomedicine’. While building on the 
style and success of our previous meetings and volumes (listed on pages 143–6), we 
are now focusing on five main themes in contemporary biomedicine; one of which 
is clinical genetics (further details are available on our Group’s website:  http://www.
history.qmul.ac.uk/research/modbiomed). Professor Peter Harper is our official 
adviser on this segment of the project, and the theme of cancer genetics, with a 
focus on polyposis, developed over the course of several conversations with him. 
Peter also advised us on suitable participants and chaired the resultant meeting. We 
are most grateful for his input. 
Thanks are also due to Professor Timothy Bishop for agreeing to write the 
introduction for this volume. For permission to reproduce illustrations in the main 
transcript and a range of material in the appendices, we thank: Ms Kay Neale for an 
invitation to St Mark’s Hospital to interview her in situ at the Polyposis Registry and 
for lending precious archival material and a photograph of the Hospital; Professor 
Jane Green for permitting us to reproduce illustrations from her PhD thesis; 
Professor David Harnden for contributing an essay in lieu of his attendance at the 
seminar and Ms Linda White of Greenspond Historical Society in Newfoundland. 
As with all of our meetings, we depend a great deal on Wellcome Trust staff to ensure 
their smooth running: the Audiovisual Department, Catering, Reception, Security 
and Wellcome Images. We are also grateful to Mr Akio Morishima for the design 
and production of this volume; the  indexer Ms Liza Furnival;  Mrs Sarah Beanland 
and Ms Fiona Plowman for proof reading; Ms Catriona Gilmour Hamilton 
(Oxford Brookes University) for her comments on the transcript; Mrs Deborah 
Gee for  transcribing the seminar; Mrs Lois Reynolds, Ms Caroline Overy and 
Mr Alan Yabsley for assisting with running the seminar and Mr Adam Wilkinson 
who assisted in the organization of the meeting. Finally, we thank the Wellcome 
Trust for supporting this programme. 
Tilli Tansey
Emma M Jones
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introdUCtion
This Witness Seminar records key activities in clinical cancer genetics in 
relation to hereditary colorectal cancer and related syndromes. From the mid-
1980s, the evolution of clinical cancer genetics in the UK focused extensively 
around the Cancer Family Study Group. The Group, of which I was Secretary 
(1990–2002), brought together clinicians and researchers to discuss their 
shared interest around families with many diagnoses of cancer. However, it was 
in the early 1990s that the Group’s prominence and activity increased, partly 
as clinical cancer genetics emerged as a discipline and partly as a recognition of 
the potential outcomes of the increasing efforts to document and dissect the 
human genome.
While case reports of families with large numbers of cancer cases have been 
documented for several hundred years, the 1970s and 1980s saw the systematic 
characterization of these syndromes. Henry Lynch in Nebraska, David 
Anderson in Texas, Madge Macklin in Canada and Eldon Gardner in Utah 
all recorded extensive sets of pedigrees with extreme over-representation of the 
most common cancers. Particularly notable was the early age of onset, the high 
risk of cancer and the potential for multiple cancer diagnoses in the same person 
(and not always at the same anatomical site). Some families exhibited an excess 
of breast cancer, others of bowel cancer – although in some of the breast cancer 
families, multiple women were diagnosed with ovarian cancer. 
Within the bowel cancer families, a broader spectrum could be observed as some 
of the families also involved endometrial and other cancers. In epidemiological 
terms, these families, some of which had 20 or more diagnoses of the same cancer 
could not be explained by extreme ascertainment and/or chance. Furthermore, 
the most distantly related persons in the families often lived in geographically 
remote parts and did not know each other, making common lifestyle or other 
environmental factors unacceptable as an explanation. Finally, in some pedigrees 
with multiple cases of colorectal cancer, the physical characteristics of the bowel 
were notably different –in that some persons had many hundreds, or thousands, 
of bowel polyps, unlike the general population, in which older-aged persons 
might have one or two. Overall, the broad characteristics of these tumours 
(besides the ages of onset) were consistent with the more common form of that 
cancer in the general population. Further, this characterisation indicated that 
a number of these syndromes were likely to be due to dominantly inherited 
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mutations segregating in the autosomal genome; based on the observed patterns 
of disease. It became, therefore, only a matter of time until successful efforts 
would be made to identify the mechanism of susceptibility in these families.
Researchers took advantage of the new recombinant DNA technology, which 
allowed routine analysis of a person’s genetic profile at pre-determined locations 
in the human genome. These locations were selected to form landmarks, roughly 
evenly spaced along each of the chromosomes (the ‘Human Gene Map’). This 
gene map provided the opportunity to identify the genes underlying syndromes 
associated with a number of clinical syndromes including those involving 
cancer. By collecting germline DNA samples from affected and unaffected 
members of such pedigrees and assaying systematically these locations for each 
person, an indication as to the chromosomal location of the critical gene could 
be made by identifying which of the known landmarks (‘genetic markers’) was 
observed to pass through the pedigree in a similar pattern to the postulated gene. 
This process, termed ‘linkage analysis’ provided an evaluation of the statistical 
evidence in favour of the gene being in that location as opposed to elsewhere 
in the genome. Successful identification of the location and follow-up in more 
families provided more detailed evidence for the location of the gene with the 
ultimate goal of identifying the responsible gene.
This Witness Seminar brings together researchers who were interested in trying 
to understand the basis for familial susceptibility to colorectal cancer. Their 
rationale for this focus varied. For those with an interest in clinical cancer 
genetics, these families represented major clinical challenges in working out 
how to manage such patients (assessments, screening, intervention etc.); the 
notably high risk of disease for those carrying a mutation, together with the 
lack of adequate screening tools indicated that careful thought and improved 
observation were required to develop protocols for clinical management. For 
biologists, study of these families offered the potential to identify the critical 
gene using techniques which were being refined and technically enhanced by 
the developing Human Gene Map at the beginning of the 1990s. Identifying 
and understanding the genes would be of direct relevance to the particular 
families in which the mutations segregated, with the potential that identifying 
the underlying biological mechanism would impact on our understanding of 
the more common forms of the cancer. The clinical geneticists also recognised 
that the number of families in their geographical region was limited and so 
efforts to compile empirical observations would require collaboration across 
many centres to provide any kind of numerical justification for proposed clinical 
protocols. The late 1980s and early 1990s reflected, therefore, a time of great 
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shared interest among researchers and clinicians; all with a wish to understand 
susceptibility in these families. The Cancer Family Study Group formed the 
bridge between research and clinical practice, by providing opportunities to 
discuss implementation of research ideas, interpretation of results and translation 
of the findings into clinical benefit. 
While the Cancer Family Study Group had been started a number of years 
earlier, around 1990 was the time when broader interest in the topic grew and 
our activities expanded. The enthusiasm and focus of all parties was evidenced 
by the regular attendance of a hundred or so people at each of the six monthly 
meetings. In the early days, the encouragement for the Cancer Family Study 
group came from Professor David Harnden, Professor Sir Walter Bodmer 
and Professor David Steel; bringing together the major cancer charities and 
the MRC. Following the successful linkage mapping of genes associated with 
colorectal cancer, for which the UK groups made significant contributions, the 
activities focused further on collaborative studies facilitated by a shared health 
service and the combined academic and clinical skills in the Group. Studies 
included efforts to identify optimal approaches for screening persons at the 
greatest risk of cancer, and to develop chemoprevention for colorectal cancer. 
The positive outcome to these preventative studies described in this seminar 
highlights the long-term impact of these efforts.
The combination of the intellectual excitement involving the acquisition of 
the tools and basic knowledge to interrogate the genome, the joint efforts of 
clinicians and scientists to characterise the causes of inherited susceptibility, the 
early insights into carcinogenesis and the potential to translate these findings 
into patient benefit in the short term make this, if not unique, certainly a 
particularly notable period in medical research. 
Finally, this Seminar records the activities in and around colorectal cancer but 
the activities of the Cancer Family Study Group were broader and included 
discussion of other related topics with the most significant activity overall 
involving hereditary susceptibility to breast cancer. The major contributions 
made to other studies including breast cancer will be discussed elsewhere.
Professor timothy Bishop 
Leeds Institute of Cancer and Pathology, University of Leeds  
St James’s University Hospital
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figures 1 and 2: Professor Peter Harper and Professor tilli tansey. 
Professor tilli tansey: Good afternoon ladies and gentlemen and welcome to 
this Witness Seminar on Clinical Cancer Genetics. I’m Tilli Tansey and I’m the 
head of the History of Modern Biomedicine Group which is based at Queen 
Mary University of London. It’s the successor body to an organization that 
was started by the Wellcome Trust in the early 1990s to create links between 
scientists, clinicians and historians of medicine, and to create material resources 
for the study of recent medicine, which we regard as post Second World War. 
The initial body was set up by Sir Christopher Booth and myself. I’m sure 
you’ll be very sorry to learn that Sir Christopher died just two months’ ago, 
but he was active and involved in these meetings almost until the end.1 We 
developed this Witness Seminar format in 1993 for a meeting on monoclonal 
antibodies. We get together a group of experts who are interested in a particular 
field or development and ask them to tell us about what really happened; the 
stories behind the published papers. What went on? What failed? Who was 
funding the research? Who were the drivers? Who were the resistors in different 
organisations? We have encouraged a number of ‘mirror’ meetings around the 
world so, although our meetings are predominantly British in focus, there are a 
number of meetings elsewhere that will also try to create a body of information 
about the development of particular topics and subjects across the world. 
1 Sir Christopher Booth (1924–2012) was a clinician, medical researcher, educator and medical historian. 
He was Professor of Medicine at the Royal Postgraduate Medical School, Hammersmith Hospital, from 
1966 to 1977 and Director of the Medical Research Council’s Clinical Research Centre at Northwick 
Park from 1978 to 1988. He was co-founder, with Professor Tilli Tansey, of the History of 20th Century 
Medicine Group at the Wellcome Trust in 1990, now the History of Modern Biomedicine Research Group, 
Queen Mary, University of London. For obituaries, see Anon. (2012), Richmond (2012) and Peters et al. 
(2012).
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The meetings are recorded, transcribed and ultimately published. They are all 
made freely available on the web and also published in hard copy via print on 
demand. Nothing is published without your say so, so after this meeting you 
will get to know me and my team very well because we will be in touch with 
you throughout the editorial process. To date we’ve held over 50 such meetings 
and our efforts have been rewarded by a recent large strategic award from the 
Wellcome Trust called Makers of Modern Biomedicine which you can see 
advertised on the screen behind me.2 This is the first such meeting under that 
new award that we are holding. We have five particular identified themes for that 
award, one of which is genetics, and we also have a dedicated adviser for genetics, 
Peter Harper.3 One of the first things he’s advised us to do is to hold this meeting. 
So, without further ado, I’ll hand over to Peter.
Professor Peter Harper: Thank you, Tilli and, again, welcome to all of you. I 
should say that there are one or two people who, with weather mainly as a factor, 
can’t be here. We’ve got John Burn, hopefully on a phone link in a later part of 
the meeting, so we hope that will work. Ian Tomlinson I gather can’t be here 
and I think another weather casualty is Tim Bishop, which is a shame because 
it means that some of you will have to think about things like linkage and what 
Tim might have contributed.4 I’m Peter Harper, a now-retired medical geneticist 
from Cardiff, and I should say this is not a field that I am really expert in – which 
is perhaps why I’m chairing it – it is one I’ve watched grow up and flourish from 
its early stages in this country.
It’s perhaps worth saying a word or two just about how this Witness Seminar came 
about. Ten years ago we held a seminar entitled Genetic Testing, that concentrated 
really on laboratory aspects of human and medical genetics and some folk, myself 
included, felt there was room for another one on clinical genetics.5 Five years ago 
we were lucky enough to be able to hold that further seminar.6 I’ve got a copy 
2 The History of Modern Biomedicine Group’s website homepage is: http://www.history.qmul.ac.uk/
research/modbiomed (visited 23 January 2013). 
3 See biography on page 110–11. 
4 Professor Ian Tomlinson is Principal Investigator and Group Head of Molecular and Population Genetics 
at the Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of 
Oxford; http://www.ndm.ox.ac.uk/principal-investigators/researcher/ian-tomlinson (visited 17 January 
2013). For Professor Bishop, who wrote the introduction, see page 18, note 39 and biography on page 105. 
5 Christie and Tansey (eds) (2003). 
6 Harper et al. (2010). 
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here if anybody wants to see it but it’s on the web.7 Needless to say, when we 
had that seminar there were still lots of things that there wasn’t time to cover, 
including cancer genetics. Rather than just have a little bit about cancer genetics 
in a more general seminar I felt very strongly, and Tilli agreed, that it deserved a 
seminar of its own. So here it is. 
Now, even devoting a specific seminar to cancer genetics it pretty soon became 
clear that one couldn’t cover all of the field. The first kind of pruning we made was 
to decide to concentrate on the more clinical and applied aspects because there 
was so much basic cancer genetics research, it would fill days and days. And then, 
even with that focus, it looked like being difficult to give really good time to both 
familial colorectal and familial breast cancer, and so, very arbitrarily, we decided to 
concentrate on familial colorectal cancer and polyposis and to leave breast cancer 
mainly to the more general aspects in the second part of the seminar. 
So this was really how that came about; the outline programme you’ve had 
circulated but there’s a rather more detailed outline that’s been put on your chairs 
which hopefully gives a bit of focus to the topics we’re hoping to cover during the 
meeting. But if something important is not listed we’ll make sure it comes up.8
7 See http://www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/volume39/index.html 
(visited 18 January 2013).
8 A draft outline programme was circulated to seminar participants to comment on a month in advance of 
this meeting. Table 1 is the final version of that programme used as a framework for this seminar. 
Historical context
Pre-1975 material on clinical cancer genetics
Clinical cancer genetics development in the Uk
Cancer Family Study Group
Case study
Polyposis: 
clinical aspects and registers
other forms of familial colorectal cancer
Research and clinical practice
Gene mapping and isolation 
Practical applications
People and organizations
Who does what, and where? 
Professional bodies and monitoring groups
table 1: outline of programme for Clinical Cancer Genetics: Case study and Context, 
c.1975–c.2010. 
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One item particularly which I think does deserve to have some discussion is 
the new aspects of therapeutics resulting from genetic advances. Do please 
remember that you’ll have the opportunity to put more detail in the written 
volume and things like photos and whatever, so that is material which can be 
added; really, as Tilli said, the purpose of this afternoon is to get your own 
experience as witnesses to an important and rapidly developing field. 
Now that, I think, is all the immediate background that’s needed but perhaps 
it’s sensible to go on straight away to a brief introduction to pre-1975 material. 
1975 was only chosen very arbitrarily but we really wanted to make sure that the 
focus was on the actual experience of those people who are here rather than on 
the more distant past. But, on the other hand, I think it’s right and proper that 
we should acknowledge that clinical cancer genetics didn’t just start then, and 
there were important people and important work beforehand. So I would like 
to ask any of you who can to just bring up very briefly some of the important 
early workers in the field, because I don’t think we should forget them. There 
are one or two of them that come to my mind, all in North America actually. 
figure 3: Clinical Cancer Genetics Witness seminar.
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I’ll just throw out their names: people like Alfred Knudson,9 Henry Lynch,10 
Eldon Gardner11 and Madge Macklin.12 But who would like to say a word or 
two about any of these or others? 
Professor sir Walter Bodmer: The first proper description of polyposis as a 
dominant was by Lockhart-Mummery, from St Mark’s Hospital, in a paper in 
1925 in The Lancet which long predates anything that came later.13 Of course 
Gardner thought he was looking at a different disease. Then there were the 
families that Henry Lynch later looked at, that original family described by 
Warthin.14 I remember very well when Lynch was talking about these things – 
everybody thought they were just anecdotes that you didn’t take very seriously. 
So there was actually very little substantial evidence, there were no proper breast 
cancer families as far as I’m aware until somewhat later.
Harper: I hope that the St Mark’s group a little bit later on will be able to give 
us a history of it from their perspective, because a lot of these things did begin 
in London. Are there other people that need to be brought out from the past? 
9 Dr Alfred Knudson (b. 1922) is particularly known for his influential ‘two-hit’ theory of tumour 
formation; see note 96. See also his biography on page 112 and Knudson (2005). 
10 Dr Henry Lynch (b. 1928) is renowned internationally for his research in familial colorectal and 
associated extra-colonic cancer. Between 1970 and 1990, at the University of Nebraska, Lynch defined 
hereditary non-polyposis colorectal cancer (HNPCC), now also known as Lynch syndrome (type II). See 
his biography on page 113–14.  
11 The cancer geneticist Professor Eldon Gardner (1909–1986) established the existence of a hereditary 
form of cancer of the lower digestive tract, which became known as Gardner syndrome. See Gardner and 
Stephens (1950), and also Gardner’s biography on page 108–9. The Eldon Gardner papers, 1936–1986, are 
held at the archives of the University of Utah. 
12 Dr Madge Macklin (1893–1962) was influential in the sphere of hereditary breast cancer research. See 
her biography on page 114.  
13 Lockhart-Mummery (1925). Mr J P Lockhart-Mummery (1875–1957) was a leading surgeon at St 
Mark’s Hospital. His son, Sir Hugh Evelyn Lockhart-Mummery (1918–88), also became a surgeon at the 
hospital. See their biographies, on page 113. Founded in 1835, St Mark’s Hospital, London, specializes 
in the treatment of intestinal and colorectal disorders, and researches the causes and treatments of these 
disorders both nationally and internationally; http://www.stmarkshospital.org.uk/about-st-marks (visited 
7 January 2013). For a full history of this institution see Granshaw (1985). Archival records for St Mark’s 
Hospital, 1840–1996, are available at St Bartholomew’s Hospital Archives, reference 405 K, and also at 
London Metropolitan Archives, references A/KE/258/005 (1909–1927), A/KE/546/011 (1929–1931) and 
A/KE/543/010 (1938–1948). 
14 See Lynch and Krush (1971) and Warthin (1913). Dr Aldred Scott Warthin (1866–1931) was a 
pioneering researcher in hereditary familial cancer. See his biography on pages 116–17.
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Professor Gareth evans: About 1860 there was a Parisian doctor, Broca, who 
described a very strong pattern of breast cancer in his wife’s family and said that 
this was hereditary.15 That’s often cited as one of the first examples. I know we’re 
off the subject of bowel cancer but just for the sake of completeness.
dr Pål møller: Traité Des Tumeurs was written by Paul Broca and published in 
Paris in 1866.16 
Professor shirley Hodgson: Also, Lionel Penrose’s publications about breast 
cancer in the 1940s.17 
Harper: One person I’d like to mention is Madge Macklin.18 She was Canadian, 
although she worked for part of her career in the northern United States. I’m 
sure I’m right in saying that there was a 1959 paper of hers on breast cancer 
where she both described large families and did an overall study showing 
increased risk in first degree relatives.19 But maybe there’s something more to be 
said about Madge Macklin? 
Professor Jane Green: My comment really has to do with Henry Lynch. I 
am so impressed with how he persisted with teaching everyone that there was 
such a thing as hereditary colon cancer, even when many people thought that 
the evidence was against that, that it was environmental clusters and so on. He 
really impressed me with how, when the genes were found, he just kept on as he 
always had, that he had understood this for a long, long time.20
15 Broca (1866). Pierre Paul Broca (1824–1880) was a French physiologist, today most widely recognized 
for his identification of ‘Broca’s area’ – the part of the brain generally associated with speech – and his 
founding role in the constitution of anthropology as a scientific discipline. In addition to his cerebral and 
ethnographic work, he published a wide range of medicine-related studies during his lifetime, including 
contributions to anatomy, surgery and pathology, this latter constituting the two-volume work cited above. 
See also Schiller (1992). 
16 Dr Pål Møller wrote: ‘The book was not available in Norway, but I persuaded the French to lend me the 
original for a week in the 1990s. It was considered valuable and delivered through a lot of formalities…. 
None of those today claiming to have discovered inherited breast-ovarian cancer has to my knowledge ever 
referenced that book.’ Note on draft transcript, 22 October 2012.
17 See, for example, Penrose et al. (1947). Professor Shirley Hodgson’s father was the geneticist Lionel 
Sharples Penrose. For an in-depth obituary see Harris (1974). 
18 See note 12. 
19 Macklin (1959). 
20 See note 10. 
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Hodgson: Just very briefly, I remember him saying that he’d been told by his 
superiors that he should stop doing these terrible familial colon cancer clinics 
that were wasting everyone’s time, and do some ‘real medicine’. 
Harper: There’s one query that I might put out: there was a study by Arthur 
Veale when he was at the Galton Laboratory and I can’t remember whether he 
used St Mark’s material for that or what, but it was again a pretty early study.21 
ms kay neale: You’ve just reminded me of the name of the person who helped 
Dr Dukes and Dr Bussey to determine the dominant nature of polyposis.22 
Bodmer: It was Lockhart-Mummery who pointed out it was dominant already 
in 1925.23 If you read The Lancet paper…
neale: Okay, I stand corrected. 
Bodmer: There is a paper by Harrison Cripps in 1882, which I have often 
quoted in the past, who described two cases of what were clearly polyposis and 
noted they were rare cases, and a brother and sister who very clearly showed it 
was a Mendelian dominant.24 But, of course, they got much more data later.
neale: St Mark’s Polyposis Register started in 1924 as a result of John Percy 
Lockhart-Mummery having an interest in family diseases and Dr Dukes having 
an interest in polyps turning into cancer.25 
21 Arthur Veale was New Zealand Medical Research Council Fellow and an Honorary Research Assistant at 
the Department of Eugenics, Biometry and Genetics – the Francis Galton Laboratory of National Eugenics 
– at University College London and also an Honorary Research Fellow in Genetics at St Mark’s Hospital, 
London. He was also responsible for setting up the first medical genetics services in New Zealand. St Mark’s 
Polyposis Register was the subject of Veale (1960). His doctoral research Veale (1961a) was later published 
as Veale (1965). For a significant essay of Veale’s on clinical cancer genetics, see Veale (1961b). See also 
Palladino (2002), in particular pages 147–8. 
22 Dr Cuthbert Dukes (1890–1977) was the first pathologist at St Mark’s Hospital, appointed in 1922. See 
his biography on page 107. For Dr H J R Bussey (1907–1991) see pages 21–3 and note 64.
23 See note 13. 
24 Harrison Cripps (1882). 
25 Ms Kay Neale explains how the register of 1924 became the ‘registry’ during the 1950s; see page 20. See 
also Dukes (1952). Note that seminar participants used the terms ‘register’ and ‘registry’ interchangeably at 
times, with only Ms Kay Neale clearly explaining the distinction between the terms in relation to St Mark’s 
Hospital. See also pages 19–25 and Appendix 2 on pages 88–96 for further details of the evolution and work 
of St Mark’s Hospital’s Polyposis Register/Registry. 
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møller: In addition to what Shirley mentioned, I would like to say that Henry 
Lynch always referred to the Warthin paper from 1913 as the start of inherited 
colorectal cancer, and one of the points that I would like to bring up today is 
nomenclature.26 We call it colorectal cancer, as did the Warthin paper, but later 
the MSH2 mutation was as much associated with endometrial cancer as with 
colon cancer. The initial phases were built on the concept ‘one gene, one disease 
in one organ’, which is completely wrong. They are all multifactorial, multi-
organ cancer-predisposing factors and Henry Lynch understood colon cancer 
better but he didn’t talk much about the endometrial cancer.27 
Harper: Are there any other studies from continental Europe – the early ones 
– that we should just mention, before we get into the detail on polyposis and 
colorectal cancer? 
What you might call the founding event of clinical cancer genetics in the UK 
was the Cancer Family Study Group. Walter, I’m on the point of asking you 
to tell us as much as possible about it, particularly because I had hoped that 
somebody from the north of the UK too, such as Tim Bishop, might be able 
to say something. David Harnden, I also should say, quite a long time ago sent 
26 See note 14.
27 Dr Pål Møller wrote: ‘He [Lynch] did come to the conclusion, however, that there were two forms of 
inherited colorectal cancer: site specific inherited colorectal cancer and inherited colorectal cancer, including 
extra-colonic cancers as well. He described this in a book chapter in 1985 and suggested the names Lynch 
syndromes 1 and 2 respectively.’ Note on draft transcript, 22 October 2012. See also Lynch and Lynch 
(1985).
figure 4: Professor sir Walter Bodmer. 
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apologies but he has sent a little summary which we hope we will be able to 
include in the published volume.28 But Walter, tell us about the Cancer Family 
Study Group.
Bodmer: Just to give a bit of background; I came to the Imperial Cancer 
Research Fund (ICRF)29 in the summer of 1979, and it was earlier that year that 
Ellen [Solomon] and I published the first really clear idea that you could use 
linked markers extensively to get a complete genetic map and identify diseases 
that way.30 It was natural to me when I came to the ICRF to have an interest 
in setting up genetics in that sense and I mentioned that in the first report that 
I produced in 1979.31 We had meetings of the then directors of the various 
cancer institutes, which included the Paterson, the Beatson Institute for Cancer 
Research and ICRF.32 David Harnden at that time was director at the Paterson 
lab.33 It was probably through meeting in that way and hearing what people 
had said that I gathered that he and Ray Cartwright had set up a cancer families 
study group, but that had more or less fizzled out and hadn’t continued.34 So 
David Harnden and I agreed that we would restart something that was called 
the Cancer Family Study Group, that would meet every six months alternately 
between the Paterson labs in Manchester and the ICRF labs in London.35 The 
first of those meetings was on 30 January 1984 according to my diary. They 
28 See Appendix 4 on pages 122–5 and biography on pages 109–10. 
29 The Imperial Cancer Research Fund merged with the Cancer Research Campaign (formerly the British 
Empire Cancer Campaign when it was founded in the 1920s) to form Cancer Research UK in 2002; 
http://www.cancerresearchuk.org/about-us/who-we-are/our-story/our-history/ (visited 16 October 2012). 
See also Austoker (1988), which has an epilogue by Sir Walter Bodmer. 
30 Solomon and Bodmer (1979). 
31 Imperial Cancer Research Fund (1979), in particular pages 2–3. 
32 The Paterson Institute for Cancer Research is based at the University of Manchester; http://www.
paterson.man.ac.uk/About/ (visited 29 October 2012). Sir George Thomas Beatson founded a research 
department at the Glasgow Cancer Hospital in 1912, which became the Beatson Institute for Cancer 
Research in 1967. The current institution conducts research into cancer cell behaviour and has close links 
with the University of Glasgow for the clinical application of its research findings; http://www.beatson.gla.
ac.uk/About/Introduction.html/ (visited 11 January 2013). See also the same website’s history page. 
33 See note 28. 
34 Professor Ray Cartwright was Director of Leeds University’s Leukaemia Research Fund Centre for 
Clinical Epidemiology, 1987–2003. 
35 See also introduction.
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continued for quite a while and are part of what’s now, I’ve forgotten what it’s 
called, within the British Society for Human Genetics (BSHG).36 The idea was 
not that it was a talking shop and a conventional meeting; the idea was mainly 
that it should stimulate collaborative studies on families aimed at finding 
linkages. So that’s the origin of the Cancer Family Study Group which more 
or less continued most of the time, as I recall, during which I was at the ICRF.
Harper: One of the really important things about the group was that it involved 
a number of other centres, including ourselves in Cardiff, who wouldn’t have 
otherwise been involved.37
Bodmer: That’s really a later story that we can talk about, the gradual build-up 
of cancer family clinics, of which St Mark’s was the founder. I can mention that 
now, because gradually it was to some extent with support from the ICRF that 
there was activity in a number of different places. And that came later.
Harper: Am I right that the provision of samples was an important aspect, or 
one of the aims of the group?
Bodmer: The aims of the group were to collaborate with collecting materials 
so you could do linkage studies, which obviously meant collecting samples, but 
the idea was that it should be collaborative. It did stimulate some collaborative 
studies on that. Others may have recollections of further things that were done.
Harper: Who’d like to come in at this point about the early days of the Cancer 
Family Study Group? 
Professor ellen solomon: As always with these historical things, it’s hard to 
put yourself back in time; once you know something you know it and one 
can’t return to quite the state of ignorance one was in at that point. It’s quite 
fascinating to watch the way it happened and I think it was a combination of 
things. Linkage was the tool we had then and it was just taken as given that were 
we to get enough families with a dominant disorder, we would find it. 
36 The BSHG is a professional forum for geneticists founded in 1996; http://www.bshg.org.uk/society/
about_us.htm. The Cancer Genetics Group, part of the society, is a ‘national, multidisciplinary organisation’ 
for ‘those with an interest in hereditary predisposition to cancer including clinicians, counsellors and 
scientists’; http://www.ukcgg.org/ (both websites visited 11 January 2013). Formerly the Cancer Genetics 
Group was the Cancer Family Study Group. See note 39 and also Sir John Burn’s comments on page 57. 
37 The Department of Medical Genetics at the University of Wales’ College of Medicine of which Harper 
was Professor of Medical Genetics from 1971 to 2004. 
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Harper: Can I ask in terms of archiving the records of the group: have its early 
records and correspondence about its founding, been securely archived?
Bodmer: I should think the answer is almost certainly no. If there is anything 
on the records of the meetings it would be in my own papers.38 
evans: I can only really comment on the fact that I know that when I took over 
as secretary of what was then the Cancer Genetics Group there were no archives 
that I was handed on. However, I know that Tim Bishop was secretary for many 
years, probably starting before 1990 when I was first attending the meetings, 
so it’s possible that Tim does have some things squirreled away that at least go 
back into the late 1980s.39
38 The Walter and Julia Bodmer archives project is taking place at Oxford University’s Bodleian Library, 
where Sir Walter has donated his archive. The cataloguing of Sir Walter and Lady Bodmer’s papers has been 
funded by the Wellcome Trust’s Research Resources in Medical History programme. Further details are 
available at http://blogs.bodleian.ox.ac.uk/theconveyor/2011/05/11/the-walter-and-julia-bodmer-archives-
project/ (visited 24 April 2013). The catalogue is scheduled to be published and the archival material 
available early in 2014. 
39 Professor Timothy Bishop has provided his archival papers of the Cancer Family Study Group (CFSG) 
for deposit with the records of this Witness Seminar at the Wellcome Library, London, at GC/253. The 
collection includes administrative papers, correspondence between members, and externally with the NHS 
and Imperial Cancer Research Fund, among other public and professional organizations. A membership list 
for 1988 is included, as are the records of the Steering Group meeting in November of that year. Within 
the correspondence are items concerning debates about protocols for DNA samples’ storage and also the 
transition of the CFSG to the Cancer Genetics Group from 1999 to 2000. 
figure 5: Professor Gareth evans. 
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Bodmer: Just let me get the dates right: the Genetic Epidemiology Laboratory 
in Leeds under Ray Cartwright was set up in 1987 and by 1988 ICRF had 
appointed Tim Bishop as the director – so the ‘late 1980s’ means about one 
year.40
Harper: Therefore the key documents would perhaps be from quite a few years 
before that, about the founding of the group?
Bodmer: Yes, it had been going for about five or six years by that time.
møller: I was asked to build a cancer genetics clinic in Norway in 1988 
because I had graduated in HLA genetics and was known as the guy doing the 
multifactorial genetics; that was why. Looking around the world at that time, 
the organization I found of interest was the European Mathematical Genetics 
Meeting where Tim Bishop played a central role, together with Gerard te 
Meerman in Groningen and Francoise Clerget-Darpoux in Paris.41 They were 
very much engaged in the initial descriptions of what this was about.
Harper: Perhaps this is an appropriate point just to ask: at what point did the 
Cancer Family Study Group turn into the Cancer Genetics Group?42 How did 
this evolve? 
evans: Sir John Burn is the person who was pivotal in that change.43 Gradually 
through the early 1990s the group became more and more genetics-oriented, it 
was always very genetics-oriented in terms of the linkage of families but there were 
a lot of surgeons like the esteemed Robin Phillips here, and gastroenterologists, 
and many other people who attended the group regularly when it was meeting 
in London and Manchester.44 But then, gradually, it became much more a group 
for geneticists, genetic counsellors and there were some psychosocial researchers 
40 See note 34. Professor Timothy Bishop clarified that ‘The Genetic Epidemiology Laboratory is now the 
Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine.’ Note on draft transcript, 
27 February 2013. 
41 Dr Pål Møller wrote: ‘Clerget-Darpoux later became a central player in the erection of the International 
Genetic Epidemiological Society (IGES).’ Note on transcript, 22 October 2012. Dr G J te Meerman 
has, since 1981, been the Assistant/Associate Professor in Mathematical Genetics and Bioinformatics 
at University Medical Center Groningen and University of Groningen; http://www.rug.nl/staff/g.j.te.
meerman/cv (visited 11 April 2013). 
42 See note 39. 
43 Sir John Burn attended the second half of the meeting. See page 55. 
44 See comments from Sir John Burn on page 57. 
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involved. It was a stage, when Tim Bishop was secretary, and John was president, 
that John decided that really the group would be better affiliated to a mainstream 
genetics society, as a sort of subgroup to strengthen it in some way because it had 
really lost some of the original multidisciplinary feel. It was put to the members 
of the Cancer Family Study Group at the time that this would be a good idea 
but it would probably mean changing the name to the Cancer Genetics Group, 
which became affiliated to the BSHG.45 
Green: I’d like to mention something about the beginnings of cancer genetics in 
Newfoundland because we began really with the presentation of large families, 
recognizing that there was something in these families that was different than the 
average. One family called it ‘The Curse of the Smiths’. Each affected family felt 
the same way and cancer genetics really began in 1982, in order to provide for 
each family’s needs. I worked in an ocular genetics clinic and a family with Von 
Hippel-Lindau (VHL) disease was referred to the clinic and within a month we 
had all the specialists together, to begin a multidisciplinary clinic. In each case, 
the beginnings of the study of a particular hereditary cancer was because of the 
needs within a family. Newfoundland, at that time, had very large families. In 
many of these families 10, 12, 15 siblings was not uncommon and, if you have 
family sizes like that, the hereditary cancer families were obvious. Because of the 
settlement patterns and distribution of the population in Newfoundland, it has a 
45 See note 36. Papers relating to this transition are available in Professor Timothy Bishop’s archives of the 
Cancer Family Study Group, which are being deposited with the records of this seminar at the Wellcome 
Library GC/253. These materials confirm that the Cancer Family Study Group formally became the Cancer 
Genetics Group in 2000. 
figure 6: Professor Jane Green. 
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very interesting genetic history.46 Newfoundland – the island part of the province 
– is 111,000 square kilometres: it is almost half the size of the UK and the peak 
population, which would have been in the late 1970s, was 575,000 people. It is about 
512,000 now. Everyone lived along the coastline and the coastline is almost 18,000 
kilometres – a very indented coastline with many small islands offshore. People had 
settled primarily in the late 1700s and early 1800s.47 Newfoundland wasn’t one 
isolate, Newfoundland was many isolates. Every community was almost its own 
genetic isolate and so if you had somebody who immigrated to Newfoundland 
and had one of these mutations, the children, the grandchildren, the majority of 
the descendants tended to be in the same area and if there was something like 
hereditary cancer, whether it was polyposis or hereditary non-polyposis colorectal 
cancer (HNPCC) or multiple endocrine neoplasia (MEN), it was obvious that 
there was something different about that family. So in each case, even though it was 
only a small branch of the family that was referred, they were huge families, and 
immediately clinical services developed and were provided by the specialists that 
were in Newfoundland. Because the families were so large and because they were so 
well characterized, they became very valuable in various linkage studies and studies 
to define the clinical characteristics and variability within the diseases. In terms of 
cancer genetics services for families, I didn’t really realize how early in fact this was. 
Clearly for us the first question was: What is present in the family? How can we 
look for it and find it early? And how can we treat early? Then, because the families 
were so large, if there was a way with linkage or knowing the gene then obviously 
that would streamline the service and make it that much easier for these families.48 
Bodmer: As I recall, there were certainly people, I thought, from Newfoundland 
and from Iceland who came regularly to the Cancer Family Study Group in the 
UK. That was starting early in 1984. Certainly Iceland and, I thought, some 
from Newfoundland.49
46 For historical context see Heagerty (1928) and Hunter et al. (eds) (1986). See also the current, online 
version of the latter text; http://www.library.mun.ca/hsl/healthbib/index.php (visited 24 April 2013). 
47 Mannion (ed.) (1977).
48 See Green (1995). 
49 For clinical cancer genetics in Iceland, see Tulinius (1985). The Icelandic Cancer Registry has operated 
since 1954; http://www.krabbameinsskra.is/indexen.jsp?id=aboutics (visited 6 February 2013). Professor 
Jane Green has suggested that, if there were participants from Newfoundland, of which she is uncertain, 
‘The people from Newfoundland would have been Dr William Marshall, Dr Bodil Larsen, and possibly 
Sharon Buehler, who were all in Immunology, and very interested in a large Newfoundland family with 
common variable immunodeficiency, Hodgkin’s disease and other malignancies.’ Note on draft transcript, 
11 March 2013. See also Buehler et al. (1975).
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Harper: Were there other defined groups, can anybody tell us, at that point? I’m 
not aware of any in the United States that were equivalent. Well, I’m thinking 
more not of individual workers but of groups or informal societies. 
evans: I can address that. It’s straying into the breast cancer field but probably 
the one international group is the Breast Cancer Linkage Consortium which was 
set up in 1989, prior to the identification of the BRCA1 gene in 1994.50 That 
spawned a huge amount of collaborative research across Europe, Australasia, 
North America and there was a European grant that was obtained in order to 
keep that group going and it eventually foundered about eight or nine years 
ago when there was no more funding, but it spawned new groups such as the 
Collaborative Oncological Gene-environment Study (COGS) initiative, which 
is looking at modifiers of breast cancer risk.51 But I suppose that was the biggest 
group that I’m aware of, which was about getting together people – clinicians, 
molecular biologists, etc. to pull together family research to identify genes. 
Many, many countries were involved with that.
Bodmer: When did that start?
50 Founded in 1989, in France, the Breast Cancer Linkage Consortium (BCLC) was an international 
network of scientists, whose membership cooperated to share information about inherited breast and 
ovarian cancer; http://www.humgen.nl/lab-devilee/BCLC/history.htm, (visited 30 October 2012). See also 
Miki et al. (1994). 
51 COGS commenced in May 2009, with the aim of identifying ‘individuals with an increased risk of breast, 
ovary and prostate cancer’. The study is funded by the European Commission and the 7th Framework 
Programme; http://www.cogseu.org/index.php/general-information (visited 30 October 2012). 
figure 7: dr Pål møller (left) and Professor Julian sampson (right). 
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evans: That would have been, I guess, 1991/1992.
møller: In 1991, I joined the third meeting of this international collaborative 
group on hereditary non-polyposis cancer (ICG-HNPCC), today called Lynch 
syndrome.52 The group issued the Amsterdam criteria to clinically define 
inherited colorectal cancer.53 Hans Vasen in Leiden, the Netherlands, became 
the ever-lasting secretary.54 Tim Bishop was instrumental in the early years for 
developing the concept of inherited colorectal cancer, because at that time it 
was all statistics.55 Also, I would like to add to what Jane said, that we have had 
the same experience in Norway about genetic isolates, not only along the coast 
side, but inland as well. 
Harper: I think it’s time to now move on to our case study: polyposis and 
familial colorectal cancer. Maybe it’s just worth me saying why we did decide 
on this rather than say, breast cancer. From my perspective there were three 
reasons: first, it shows very well the links and interplay between the various rare 
Mendelian cancer syndromes and common cancers; also it’s a good example of 
the close collaboration of clinical workers and laboratory workers in mapping 
the genes; and there are very clear benefits in terms of applying the new advances. 
So, for all those reasons, I felt that if one was having to choose a particular area, 
polyposis and familial colorectal cancer was the best. But I am fully aware there 
are going to be other people, but of course they’re likely to be some of the 
52 Dr Pål Møller further elaborated: ‘When ICG-HNPCC merged into InSiGHT and reduced the meeting 
schedule to one intercontinental large meeting every second year, the European members of ICG-HNPCC 
continued to meet annually (in Mallorca) and took the name the Mallorca group. In addition, to coordinate 
European research, we undertook to issue clinical guidelines which are by and large followed in, close to, all 
European countries.’ Note on transcript, 22 October 2012. See Vasen et al. (2007) and Lynch et al. (2003). 
53 At the first Amsterdam meeting of the ICG-HNPCC, criteria ‘for a clinical diagnosis of HNPCC based 
on family history were established’, quoted from Lynch et al. (2003). In subsequent meetings the original 
criteria were revised. Bodmer et al. (1994) defined the criteria thus: ‘…at least three relatives with colorectal 
cancer, one of whom should be a first relative of the other two (but the three should all be related to each 
other), at least two generations affected and at least one of the relatives should be below 50 years of age’, 
quote on page 219. 
54 Hans Vasen is now Professor of Inherited Tumours at Leiden University Medical Center in the 
Netherlands. He is also the Administrative Director of the International Society for Gastrointestinal 
Hereditary Tumours (InSiGHT) and Editor-in-Chief of Familial Cancer; https://www.lumc.nl/con/7010/6
5176/91008101620439?setlanguage=English&setcountry=en, (visited 30 October 2012). 
55  See also introduction.
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people who are not here, who disagree with that. Anyway, I think we ought 
to go back and give the St Mark’s Hospital group a chance to tell us how their 
clinical studies of polyposis and the register evolved.56 
neale: Sir Walter has already told us that J P Lockhart-Mummery first described 
the dominant inheritance of polyposis at St Mark’s because he did have an 
interest in hereditary diseases. It was Veale who later confirmed it by looking 
at more families.57 That’s where that link came in. In the 1920s Dr Dukes, 
the Consultant Pathologist, decided that because of this knowledge St Mark’s 
should start to collect information about all families where there were patients 
with multiple polyps and a hereditary history of bowel cancer.58 In 1918, J 
P Lockhart-Mummery did take out a colon and join the small bowel to the 
sigmoid colon and that was the first surgery that was done to try and prevent 
bowel cancer in a polyposis patient.59 But it was really in the 1940s, post-war, 
56 See also Appendix 2 for further information about St Mark’s Polyposis Register on pages 88–96. 
57 See note 21.
58 See note 22. 
59 Lockhart-Mummery (1919). 
figure 8: st mark’s Hospital, c.1994 under its former title and location on City road 
(1854–1995). the hospital was previously located on aldersgate street from 1835 and is now 
situated in northwick Park, as part of the north West london Hospitals nHs trust site. 
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when we had more knowledge about anaesthetics and blood transfusions – 
antibiotics, of course, were also beginning to come on the scene – that it was 
safe for the surgeons to take out the colon and join the small bowel to the 
rectum. And by 1953, I think,60 it was decided that this was a safe operation to 
do and at that stage the surgeons, being by this time J P Lockhart-Mummery’s 
son Sir Hugh Lockhart-Mummery61 and Sir Henry Thompson,62 they decided 
that they should persuade the relatives of people with polyposis to come and be 
screened so that they could have surgery before they got cancer. So that’s really 
how the registry started. I guess it was a register up to that point, but once they 
started to employ the staff to encourage people to come and be screened, it 
became the registry.63 
60 See note 134.
61 See Granshaw (1985), page 285 and note 13. 
62 Mr Henry Reynolds Thompson (1908–85) was Resident Surgical Officer at St Mark’s Hospital in 1939. 
In 1947 he was appointed surgeon to St Mark’s, Woodford Jubilee and Forest Hospitals. 
63 Ms Kay Neale wrote: ‘Before the early to mid-1950s, when a treatment became available, there was no 
active encouragement to get relatives screened. Until that point the information was collected for research, 
after that it was a combination of research and clinical care.’ Note on draft transcript, 5 April 2013. Lindsay 
Granshaw notes, ‘Polyposis families were followed up with particular care. Dukes and his assistant, H J R 
Bussey, worked out an elaborate filing system to enable new cases to be entered and their families traced’. 
See Granshaw (1985), page 270; for registry see also pages 345–52. 
figure 9: ms kay neale (left) and Professor robin Phillips (right). 
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Harper: May I ask at this point: screening was colonoscopy of some sort, was it?
neale: Screening would be by rigid sigmoidoscopy, there were no colonoscopes 
at that stage. The colonoscope came in the 1970s. So it was rigid sigmoidoscopy 
just looking at the rectum, then it was in 1960, I think, that Dick Bussey did his 
thesis on what we now call familial adenomatous polyposis, and his definition 
of polyposis was that there should be more than 100 adenomas throughout 
the colon and rectum.64 Over the years there’s been a lot of discussion about 
whether that is an accurate statement and I think Dr Bussey’s purpose in saying 
that was that we would collect, for research purposes, information on the people 
that we were absolutely certain had this condition. Of course, now that the 
gene has been identified, we know that there are people with fewer polyps and 
not necessarily quite so spread who do have mutations in the adenomatous 
polyposis coli (APC) gene. But his aim was that we would have a pure group of 
patients on which to do the research.65
Harper: That’s a remarkably far-sighted attitude in terms of linkage research, 
isn’t it? Perhaps a bit less so in terms of patients, but, in terms of making sure 
you don’t mix things up with linkage, it’s very valuable. Can you tell us a little 
bit more about Dick Bussey because he seems to have been a very pivotal person. 
neale: Dick Bussey was a grammar school boy who came from a family that did 
not have the resources to put him through university. He started working with 
Cuthbert Dukes when he was 17 years old and Dukes soon recognized that he 
had someone who was both intelligent and meticulous. He encouraged Bussey 
to go to university to do a degree in chemistry and then later, of course, he did 
his PhD in polyposis, in familial adenomatous polyposis (FAP).66 I don’t know 
what else to say about him. He was an amazingly gentle person, I only ever 
64 Bussey (1970). Cuthbert Dukes employed H J R Bussey who worked in his former laboratory in 1924. 
In her history of St Mark’s Hospital, Lindsay Granshaw writes, ‘Bussey was then 17, but proved to be the 
longest-serving member of the staff of St Mark’s. He later acquired a BSc and PhD (and was awarded an 
OBE) and was still at the hospital after 60 years of working for Dukes and his successor Basil Morson, 
and on his own research (in particular familial polyposis).’ Granshaw (1985), quote on page 223. See also 
obituary for Dr Bussey on pages 95–6. 
65 Ms Kay Neale wrote: ‘I should like to clarify that in the Registry, patient information is filed in family 
files. These are categorised in two groups; one in which we are confident about the diagnosis and the other 
in which the diagnosis is in doubt. Patients in which the diagnosis is in doubt are cared for according to their 
clinical need but not included in research where a genetic diagnosis is required.’ Note on draft transcript, 
23 October 2012.
66 See note 64.
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heard him cross once. As much as I questioned him or didn’t understand what 
he was saying, he would patiently go over it again and say that if someone didn’t 
understand something it was the fault of the person not explaining it properly, 
not the person who was being a bit dim. [Laughs] I worked with him for many 
years. I became very friendly with him. 
Harper: How did the register originate? Was this St Mark’s patients or was it 
from a wider range from the beginning?
neale: Well, it started with St Mark’s patients but Dukes, of course, would 
lecture and publish in the journals of the day.67 He soon acquired an international 
reputation and so people would send pathological slides or descriptions of cases 
67 Ms Kay Neale wrote: ‘The first colectomy with ileorectal anastomosis for FAP at St Mark’s Hospital 
was done on 8th December 1948. Dr Dukes wrote, ten years later, “It would be difficult to find a more 
promising field for the exercise of cancer control than a polyposis family, because both diagnosis and 
treatment are possible in the precancerous stage and because the results of surgical treatment are excellent.”’ 
Note on draft transcript, 23 October 2012. See Dukes (1958), quote from page 413. 
figures 10 and 11: dr Bussey’s original Polyposis register patient record cards, 
st mark’s Hospital, london.
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of polyposis from all over the world, and Dr Bussey would record them all 
and catalogue them. So sometimes we had full families; sometimes we would 
just have the slides titled something like ‘Girl from Thailand’. But of course in 
those early days we did not know if polyposis was an international condition. 
Dr Bussey had cards that he called his ‘cohort cards’, because of course this is 
before computers, and the cohort cards would list the years of birth of patients 
who had polyposis and the part of the country that they lived in. We weren’t 
even sure if there were cases of polyposis throughout the UK, although now we 
know they are all over the world.
Harper: Did you have from the very early stage a systematic approach to 
contacting healthy relatives or was that something which came a bit later?
neale: It was started in the 1950s and there’s a wonderful record in St Mark’s 
archive which describes Dr Dukes and somebody else driving down, I think, 
the A23 road on a Saturday morning looking for the relatives of a family – of 
course, we wouldn’t be allowed to do this today. He came across one member 
of the family who wouldn’t talk to him at all. The next house he went to, the 
lady there was surrounded by 23 children. She had something like eight of her 
own, and eight she’d taken in from a sister who had died from polyposis, and a 
few more from somewhere else.68 I know that Henry Thompson one day went 
to visit someone at home who wouldn’t agree to be screened, and Thompson 
was an Oxford blue boxer and the person that he went to visit was from an 
East End London boxing family.69 And he said that he would challenge the 
man who wouldn’t be screened to a boxing match and the purse would be the 
examination. [Laughter] So there were lots of stories like that from the early 
days when the surgeons really went out of their way to find these people.70 
Harper: Have surgeons changed since then?
neale: Surgeons have changed enormously since I started at St Mark’s in 1974. 
I think the big difference that I’ve found since I first started working at St 
Mark’s is that we, the research workers, as I was when I first started there, were 
not employed as nurses. I was employed as a research worker and we were not 
68 The archives that Ms Neale refers to are the family files still retained at St Mark’s Hospital.
69 See note 62.
70 Public attitudes towards cancer diagnosis are discussed by, for example, Patterson (1987) in the context 
of modern America. 
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allowed to step over the chalk line unless we were told. The patients belonged to 
the surgeons. I don’t know really exactly when it was, but gradually as the new 
generations came in they really did appreciate the help that was given to them by 
the research workers and gradually we became people with clinical responsibility. 
Harper: Does that reflect the surgical perspective as well?
Professor robin Phillips: Kay knows an awful lot more about it than I do but I 
can only say, from my perspective that the old generation of surgeons essentially 
did private practice where they earned their money. They came and they would 
do the odd operating list or odd clinic or whatever within the NHS hospital. The 
situation was exactly as described – the management of polyposis patients was 
in the different surgeons’ hands and all the different surgeons would manage it 
differently. There was nothing that was standardized, they weren’t really trying 
to sort that out. It was only later on that we managed to move the funding and 
the care of polyposis patients into the NHS, and the modern standard of care 
is that we have an oversight committee that agrees the management of every 
polyposis patient and permits them to be cared for by different consultants 
under the oversight of this polyposis committee. It’s a multidisciplinary team 
which would be a standard of care. So we have very much standardized care in 
the last 25 years, I guess, and have lots of studies looking at clinical issues in 
order to find out what we should be doing for the patients.
neale: When I started working with Dr Bussey and Dr Ritchie in 1984, 
the three of us were funded by money from research funds. Dr Bussey and 
Dr Ritchie were funded by the St Mark’s Hospital Foundation.71 Dr Ritchie 
actually worked voluntarily and just received her petrol costs.72 I was funded 
by Cancer Research UK, not Imperial Cancer Research Fund, to work in the 
Polyposis Registry. The ICRF became CRUK – thank you, Sir Walter. So there 
were just the three of us. Now we have a team of two nurse practitioners, a 
nurse specialist, a nurse endoscopist, a full-time and part-time administrator, 
all funded by the NHS, and I’m funded by Imperial College.73 The department 
71 The charitable body associated with the Hospital; http://www.stmarksfoundation.org/index.
php?page=about (visited 23 January 2013). 
72 Dr Sheila Ritchie was Registrar for the Polyposis Registry from 1973 to 1989. 
73 Ms Kay Neale wrote: ‘[The registry] is now mainly funded by NHS staff fulfilling a clinical role but 
continuing to record patient information which is also used for research.’ Note on draft transcript, 5 April 
2013. The registry has been funded from various funds, including Cancer Research UK, The Newman 
Trust and The St Mark’s Hospital Foundation; http://www.polyposisregistry.org.uk/stmarks/SMhome.htm 
(visited 23 January 2013). 
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actually has become an NHS department and I can imagine that once I retire 
it will continue to run – I mean, I’m hoping it will continue to run in the 
same way that it’s always run. That will depend on the director, I guess, at the 
moment it’s Professor Phillips. It is expected that the Assistant Director, Miss 
Sue Clark, will become director when Professor Phillips retires.
Phillips: There are problems because a lot of these cohort cards are on top of 
the shelf, there isn’t the storage space supplied by the NHS to be able to look 
after some of it. We have the information transferred from the old cards into 
computerized systems but we always have to wonder what we’re going to do 
with the old cards.
neale: They’re Dr Bussey’s original cards. When we first got a computer in the 
polyposis registry, Dr Bussey could find information quicker in his cards than 
we could on the computer because the computer clicked over so slowly. But 
those cards now do still exist but are not used.74 Of course, they do have all 
the patient information so it may be difficult. I don’t know where one would 
archive that.
Bodmer: I remember those cards and I remember seeing Dr Bussey with the 
information. He was rather resistant to computerization as I recall. 
Harper: Before we move over to the gene mapping and isolation side, does 
anybody want to say anything about any other polyposis registers that might 
have existed either elsewhere in UK or in continental Europe?
evans: Well obviously St Mark’s was the exemplar. And because St Mark’s actually 
had people from all over the UK under them, I think there was not so much of an 
initiative originally to set up regional registers. That did happen to some extent 
starting around 1989/1990 and Manchester has had a familial polyposis register 
since 1990 and we actually published just this year a paper on the impact of that 
register on the survival of people similar to the St Mark’s results, showing an 
improvement in life expectancy based on a register approach.75 We were rather 
shocked when we did a survey of all the other parts of the country and found 
that no other polyposis register was active apart from St Mark’s. Unless someone 
can tell me that my registrar, Susan Huson, was wrong, I know that registers 
were certainly set up in Newcastle and in other parts of the country. Because 
74 See Appendix 2 for reproductions of samples of Dr Bussey’s cards and an explanation from Ms Kay Neale 
about their contents, recorded in a separate interview with her on 29 April 2013. 
75 Wilding et al. (2012). 
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of lack of funding, many of them have just ceased to really exist in an active 
sense – that is, actively following and chasing patients. Now it’s just genetics 
departments doing it through their normal approach rather than through a 
specific register.
Professor Julian sampson: Mary Littler set up some registers for a number 
of Mendelian cancer syndromes, including polyposis, in Wales.76 They were 
initiated before I arrived in early 1989 so it must have been about 1985/86? 
Harper: She published her paper in 1989 in the British Medical Journal.77 
sampson: I think pretty rapidly from 1989 to 1990, we computerized the 
registry in Wales for FAP, not at that time for other inherited cancers. We 
developed a computerized family-based register so that the working record was 
the pedigree rather than the individual patient. At that time Walter [Bodmer] 
and others had identified a number of linked markers for FAP and our register 
had the facility to write the linkage input files directly from the family pedigree 
as the base-record. This was only a temporarily necessary step, but writing those 
input files was quite a business if you had to do it without a programme that 
would set them up for you.78
76 During this period Mary Littler was Research Officer at the Institute of Medical Genetics, University of 
Wales College of Medicine. 
77 Littler and Harper (1989). 
78 Professor Julian Sampson qualified that this temporary step had only been necessary ‘until the gene was 
cloned’. Note on draft transcript, 27 February 2013. 
figure 12: Professor shirley Hodgson. 
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Hodgson: I think the idea for having a centralized registry to arrange follow-
up and surveillance for family members was the ideal, but it needed to be 
staffed by individuals who would enter the data and arrange to communicate 
the recommendations for screening to the relevant individuals. In the 1990s, 
a number of places such as St George’s and Guys had ad hoc registers, which 
ran based on the local genetics register.79 We did have many discussions in the 
Cancer Family Study Group and with health service providers about trying to 
obtain funding on a higher level, but this was never attained, largely because it 
wasn’t clear who should be providing such funding. The other thing was, and 
Kay will help with this, but of course there was the Danish Polyposis Registry. 
Do you know when that was set up?
neale: In the early 1970s, I think.
Hodgson: By Bülow and his other colleagues in Scandinavia.80
neale: The Swedish registry was started about 1975 by Dr Thor Alm.81 
solomon: Someone will have help to help me with the timing of this, but there 
must have been something similar set up in Edinburgh? 
Bodmer: I don’t know about that but just going ahead a bit, when it came to 
doing the linkage studies and we were looking for the families, the other group 
we collaborated with was one in Liverpool and that was at the Broadgreen 
Hospital and I’ve got the paper here.82 
møller: We had a polyposis register in Norway which was always kept separate 
and was never to this day integrated in genetic clinics. When I started out with 
all the other inherited cancers, I was actually told by the union for medical 
genetics that I was no longer part of them because cancer genetics was too 
specialized.
79 South West Thames Regional Genetics Service – now part of St George’s Healthcare NHS Trust – 
was established in 1986; http://www.southwestthamesgenetics.nhs.uk/. Information about Guy’s and St 
Thomas’ NHS Foundation Trust genetics service is available at: http://www.guysandstthomas.nhs.uk/our-
services/genetics/overview.aspx (both sites visited 17 January 2013).
80 The Danish Polyposis Registry was founded in 1971. See Bülow (1986). 
81 The Swedish Polyposis Registry commenced in the late 1950s. See Björk et al. (1999) and also Alm 
(1975). 
82 Bodmer et al. (1987).
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Phillips: You may want to discuss the separation or the integration of the 
Polyposis Register from HNPCC and other cancers and perhaps why it 
happened. Certainly, to this day, polyposis at St Mark’s is kept entirely separate 
from the others and there are very good reasons for it. It’s a clinical problem 
and the patients have clinical problems – they need clinicians to look after 
them – whereas a lot of the other conditions, including the Lynch syndromes, 
are management problems. They can have managers rather than clinicians 
looking after them. They can be looked after remotely, they don’t need clinical 
experience about their particular case or the observation of the polyps in their 
stomach, or at what stage you are getting worried about it. You need to have 
the clinical experience to understand that, it can’t be offloaded elsewhere. So we 
very much kept those separated. 
Harper: I’d like now to perhaps open the discussion on mapping and isolation 
of the genes because that’s a key part of this seminar.
Bodmer: Just to comment on that: the first Leeds Castle polyposis meeting was 
in 1985 and we established in the ICRF a St Mark’s unit which was for all aspects 
of colorectal cancer.83 In 1984, in the unit’s first report, they talked about genetic 
studies on polyposis coli and other family susceptibilities, so while there was this 
tremendous emphasis on polyposis, it was not uniquely so.84 As far as I recall, 
even in the first polyposis meeting, there would have been a discussion of other 
cancer families. To give at least my own perspective on how the mapping took 
place and what I see as the history: as I mentioned, I went to the ICRF in the 
summer of 1979 and I had already decided, and Ellen came at about the same 
time, that I should do something in the cancer field, because I wasn’t until that 
time involved. Looking at cancer families was an obvious thing and obviously 
I’d heard about the polyposis unit and what was going on at St Mark’s. And 
remember that Cuthbert Dukes, while he was supported a lot by what was the 
British Empire Cancer Campaign, was also a key figure for the ICRF as well.85 
There was a very close relationship between the surgeons who were on the ICRF 
Council and the surgeons at St Mark’s that made the contact there quite easy. 
My records suggest that I really started having discussions about how to get 
83 This first international meeting of polyposis experts, at Leeds Castle in Kent, is described in more detail 
on pages 78–9. 
84 This unit was called St Mark’s Colorectal Cancer Unit. See Imperial Cancer Research Fund (1985). See 
also note 31. 
85 See note 29. 
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things going in around about 1981. That was certainly with John Nicholls who, 
you will remember, was much involved then, and probably also Basil Morson.86 
Ian Todd, of course, I knew extremely well and so he was always involved in 
the background but only became more involved when it came to setting up 
the unit.87 He was extraordinarily helpful then and agreed to become the first 
director of the unit, which was very important because it provided a back-up 
for the registry that eventually became integrated into the unit. But in fact the 
first work on collecting blood samples was done by my late wife, Julia.88 She was 
involved, and Kay has reminded me, she would have been working with Sheila 
Ritchie at that time.89 Julia started collecting blood samples from FAP patients 
early in 1982 with a view to doing linkage studies. The first paper was actually 
in the British Journal of Surgery in 1985 because there had been suggestions that 
there would be a linkage with HLA.90 It was the thing we could look at quite 
easily and by that time we had only relatively few markers. The collection of this 
material at that early time made it much easier to do the mapping quite quickly 
in 1986 and early 1987. The trigger was when Vicky Murday came to St Mark’s 
as an early clinical geneticist. By that time, the Royal College of Physicians had 
hardly got the idea of how to train clinical geneticists who were dealing with 
adult diseases. Shirley can comment more on that. Vicky Murday was actually 
formally an appointment in the colorectal unit but working in my lab towards 
the end of 1985, early 1986.91 It was Vicky who pointed out the paper that had 
appeared in 1986 by Herrera et al. that had described a single case of an individual 
with mental retardation who also had FAP and had a chromosome 5 deletion.92 
That immediately suggested that that was the place to look for linkage and we 
were lucky in that it was. With Peter Scambler and others we were able to get one 
86 Professor John Nicholls was Consultant Surgeon to St Mark’s from 1978 to 1999, then Senior Surgeon 
from 1999 to 2006; http://www.aininfo.co.uk/LGIA/JN.htm (visited 11 April 2013). In 1956 Basil Morson 
succeeded Cuthbert Dukes as Director of the Research Department at St Mark’s Hospital. 
87 Sir Ian Todd was Senior Surgeon at St Mark’s Hospital in 1983. See Neale and Bülow (2003), page 1. 
88 Sir Walter Bodmer wrote: ‘…it was this work that largely enabled the rapid linkage studies because so 
many of the DNA samples needed had already been collected.’ Letter to Ms Caroline Overy, 6 October 
2012. See Lady Bodmer’s biography on page 105. 
89 See note 72. 
90 Bodmer et al. (1985). 
91 Dr Victoria Murday had been appointed as a Research Fellow in St Mark’s Hospital Colorectal Unit by 
spring 1985. See Imperial Cancer Research Fund (1985), page 239. 
92 Herrera et al. (1986).
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probe that was actually key to the linkage. It actually very quickly showed a close 
linkage in the family material that we had. That was published in August 1987 
alongside the work that Ellen was doing on allele loss.93 So that mapping actually 
happened pretty rapidly because of the fact that the samples had already been 
collected, which was absolutely key. The existence of the register, the existence of 
the family data, the fact that one could go there with the collaboration, get the 
blood samples and the DNA was absolutely key to be able to do the mapping.
Harper: Walter, may I just ask at this point: was there any hint of evidence from 
linkage studies with protein markers apart from the HLA?
Bodmer: No.
Harper: Or was it really straight from DNA?
Bodmer: There was nothing of any use and the HLA stuff was really only to get 
things going. It was exceedingly unlikely that that would have been anything 
to do with it. There was even a suggestion of an association with a particular 
haplotype and so it was really as an exercise to get the other linkage studies going. 
That’s the essential story. Ellen maybe can talk more about how we then further 
pursued the question of trying to find the gene, which was a collaborative study 
and which was helped actually by finding a patient who Gareth can talk about 
that turned out to be a very mild case of polyposis with a rather long deletion 
in the region that overlapped where we knew the polyposis gene was. Arguably, 
that patient was probably the first case of polyposis that was actually diagnosed 
by the molecular technique before the gene itself was found.94 The gene was 
actually found by two American groups independently and they just had the 
luck of the draw that they had a smaller deletion than we did. As soon as the 
gene was found it was possible very quickly with the resources we had at hand 
to find mutations in it. I hope Robin Phillips won’t mind my saying that I think 
the surgeons at first were extremely unwilling to accept that a mere laboratory 
scientist might be able to detect FAP more easily and more securely than they 
could. I once remember being asked, ‘Don’t you have to be careful in case the 
genotypes change with time?’ [Laughter]. Anyway, maybe I should pass it on to 
Ellen Solomon.
93 Solomon et al. (1987). 
94 Sir Walter Bodmer wrote: ‘... there really is no reference for this as I am not sure that case was ever 
published at all … the outcome of our later molecular mapping work [was] described in Varesco et al. 
(1989)’. Note on draft transcript, 9 March 2013. 
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solomon: I’m going to pedal backwards just a little bit to the early 1970s and 
the patient with the 5q deletion and how extraordinary that was. In parallel, 
Knudson, of course, had published his work on loss of heterozygosity (LOH) in 
familial tumours and producing retinoblastoma, and Ray White then published 
an extremely seminal paper showing that you got LOH in retinoblastoma.95 So 
it became very clear that with something like FAP – a clearly dominant disorder 
– one could ask the same thing: as to whether the tumours in non-familial 
cases sustained loss of heterozygosity. So at the same time that the linkage was 
being done at the ICRF, we looked for LOH in FAP tumours and indeed there 
was linkage, as we now know, on chromosome 5. So it was a double-pronged 
approach to confirming that locus and, I think, one that has stood the test of 
time very well for many of the tumours. 
Bodmer: Of course, that fed into the Knudson hypothesis.96 You mentioned Al 
Knudson earlier, he really established the idea that the genetic mutations that 
gave inherited susceptibility in the germline would also be found somatically. 
95 See Knudson (1971). 
96 Dr Alfred Knudson summarized the principle of his ‘two-hit’ theory of cancer tumour formation as 
follows, in 2005: ‘Dominantly heritable cancers of several types were known and seemed to promise real 
“cancer genes”. It was clear that inheriting one of these genes was not sufficient for tumor formation. There 
was a problem with the mechanism of penetrance,’ and he explained the limits of his theory, ‘Two genetic 
“hits” could not explain the most important category of cancer, the carcinomas. However, in some instances 
they could explain the origin of benign precursors to these carcinomas, which may yet be shown to play a 
role in all carcinomas.’ Knudson (2005), quotes from pages 7–8. See also, for example, Devilee et al. (2001). 
See also note 9. 
figure 13: Professor ellen solomon.
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That was a very important conceptual step forward to see that this hypothesis 
was true also for common cancer like colorectal cancer. And just a very brief 
comment, if I may, I used to show a picture we had of a young girl’s chromosomes, 
which had the deletion in, in all my popular lectures on genetics and how we 
mapped polyposis and so on. I was giving a lecture – I think it was possibly in 
Chester, it was certainly in Wales – and I showed this picture and a lady came 
up to me afterwards and she said, ‘That’s my daughter’s chromosomes you’ve 
just shown.’ She was a teacher. It was as a result of that, because I think the girl 
hadn’t been explored further, I urged her to get in contact to make sure that she 
was followed up. And she was. 
Harper: I should say, Walter, that Chester is actually on the English side of the 
border. [Laughter]
evans: In fact, if you’re Welsh like me it’s still legal to shoot me with a bow and 
arrow after midnight if I’m within the walls of Chester. [Laughter]
Bodmer: I’m well aware where Wales is, but if you go and talk in Chester you’re 
quite likely to get a lot of people from Wales.
Harper: Very true. 
evans: So, yes, that girl is a fascinating case, especially in terms of genotype/
phenotype correlations. She obviously has a total deletion of her APC gene but 
she had very mild disease. On her first screen, no one could find any polyps. She 
has gradually developed polyps and I would say is in the bottom 10 per cent of 
affectation with polyps. So also, anecdotally, she was in the CAPP1 study and 
her mother was convinced that the aspirin had worked and in fact she did have 
a few polyps and they disappeared.97 We didn’t see any at the next screen. So 
she’s certainly been a case in point in terms of FAP and the study of FAP. She’ll 
be in her late thirties now.
97 CAPP (Colorectal Adenoma/carcinoma Prevention Programme) ‘is a programme of genetically targeted 
trials’, formerly known as Concerted Action for Polyp Prevention. CAPP1 started in 1993 with the 
participation of carriers of FAP in 34 European centres trialling the effect of 600 mg aspirin and/or 30 g 
resistant starch. Aspirin was shown successfully to reduce polyp size and therefore reduce the risk of cancer 
development. CAPP2 similarly trialled aspirin and starch preventative measures for carriers of HNPCC 
and ran from 1998 to 2007, with follow-up continuing until at least 2017; http://www.capp2.com/ (visited 
28 August 2013). See comments from Sir John Burn on page 81. 
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Bodmer: Could I just add briefly to that because I think it’s interesting taking 
us further ahead. Subsequently, a number of other gene deletions were studied, 
I think largely in a study that Oliver Sieber did with Ian Tomlinson in which 
we were involved and generally showed that when you had the gene deleted 
you had mild disease.98 And that was a very interesting observation because 
it showed that the mutations which are either missense and truncating had 
effectively had a dominant effect in the heterozygote. If you just knock the 
gene out, you don’t get sufficient effect from haplo-insufficiency. So it shows an 
interesting interaction between the clinical observations on sometimes only one 
patient and some of the genetic correlates. 
Harper: I’d like now to move across to Lynch syndrome, or HNPCC, it’s 
gone through a variety of names. Perhaps it would be good to ask Jane Green 
to tell us about her early experience that developed from the perspective of 
Newfoundland. 
Green: I think it really started from the polyposis family, which has what is 
called the attenuated phenotype of polyposis (AFAP). This very large polyposis 
family, which has a founder effect with seven families, 200 affected people, that 
98 Sieber et al. (2002). 
figure 14: Greenspond (near Wesleyville), newfoundland, 2005. 
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we have completely joined, is important in that regard.99 I was studying the 
first of these AFAP families from the north-east coast and travelling to review 
records in the old Twillingate Hospital first, and then there was a branch of the 
family that was further west – not far by sea but by road some distance – and I 
went to see the records of that family in a hospital called Botwood. There was a 
young family doctor there whom I had known because she had just graduated 
from medical school and she was very interested in the follow-up of the AFAP 
family. This was 1989 or 1990, and shortly thereafter she sent a referral letter to 
me which said ‘Please see another family with AFAP’ and this turned out to be 
one half of the family, later called Family C, which was the family that mapped 
hMSH2.100 
As with the polyposis family, the critical thing was to determine who actually 
was affected when they were talking about ancestors, because somebody may 
have had abdominal surgery for some other reason. Was it the same cancer that 
was in the family or was it something completely different? So that was why all 
the records were looked at very closely. I started out from the information about 
a young woman who had had colon cancer. Her father had died of stomach 
cancer and his four brothers had all died of stomach or colon cancer. Her 
father had been 54, the others had been between 29 and 39 and so it was quite 
devastating to that family. I took the history from her and she’d had two colon 
cancers but she also had endometrial cancer. As I looked at the other records, 
the majority of the women had had endometrial or ovarian cancer first and no 
one had large numbers of polyps in the first records that I reviewed. So very 
clearly, this was not the same condition that I had become used to, the AFAP. 
Almost at the same time, a surgeon had spoken to me in St John’s and said, 
‘There’s a gentleman upstairs who says ‘‘there’s too much colon cancer in my 
family.’’ Could I go and see him?’ He had his second colon cancer at 63 –his first 
colon cancer had been at 38. He also had prostate cancer and he died within a 
year, but he first gave me all the information that he had collected on his family 
and put me in touch with his daughter, whom I contacted subsequently, and 
his wife, so I had access to others in the family. I spent many hours on roads 
in Newfoundland going to different small communities and talking to people 
99 See Green (1995), in particular chapter four; Clinical and genetic screening in a family with atypical 
familial adenomatous polyposis, pages 194–233. See also Spirio et al. (1999). 
100 See page 39. See also Appendix 3, on page 97 for a reproduction of the ‘Family C’ pedigree from Green 
(1995). 
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in their homes.101 Every time somebody said, ‘I’ll speak to my grandmother 
because she knows more of the history,’ or ‘You need to know about that other 
part of the family’ and they would contact them. Even before the days of ethics 
101 See Green (1995), in particular chapter five; Development of a screening program for hereditary non-
polyposis colon cancer, pages 234–85. A popular account of Jane Green’s research and its impact in the 
international cancer genetics research community is given by Waldholz (1997), in chapter ten; Ishmael’s 
tale, pages 148–64.
figure 15: Geographic location of two branches of a newfoundland HnPCC family. the 
present-day trans Canada Highway shown in this illustration was completed in 1965. 
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concerns, people wanted us to get the full picture. They knew there were other 
people that could help with the family history. The gentleman, who was from 
Wesleyville, told me that one sister had two colon cancers and had died in her 
early 50s; the other sister had had endometrial cancer. 
As I put the pedigrees together they were very, very interesting because, as Pål 
said, there was very little about endometrial cancer in terms of Lynch syndrome 
at the time. This wasn’t polyposis – it fitted best with Lynch syndrome but the 
endometrial and ovarian cancers were striking in these two families. Now it 
turned out they were the first two HNPCC families I had seen but they also 
both came from the north-east coast, one from a more easterly area that had 
been settled first in the late 1600s where there were ship builders, and master 
mariners, who did go westwards along the coast. The second community was 
westward along the coast and I had suspected from quite an early time, even 
though there were no names in common at that point, that they might be 
related. It was two years before I went to the community of Moore’s Cove near 
Fortune Harbour, about 150 miles west of Wesleyville, and happened to see the 
proof in 1992. 
After talking to a woman in Moore’s Cove whose father had died at the age 
of 29 of colon cancer, and he was part of the family of the first proband, her 
husband finally came inside. The fishermen tended not to come in and talk 
to those like myself who were not originally from Newfoundland – and he 
said, ‘Now she must have a cup of tea before she drives home.’ Not knowing 
quite what to say to me he brought the Bible for me to look at. The Bible 
had nothing written inside the front cover; but it did have a sheet of paper 
inside the back cover, which was the marriage certificate of his wife’s great-
grandmother and it said, ‘Julia Ann T… of Wesleyville, married to John W… 
of Point Leamington.’102 The gentleman seen in hospital in St John’s was a 
T…. of Wesleyville – I could then go to the archives in St John’s and find the 
exact connection four generations back. So this was one very large family.103 
At that point, the family, then called Family C, was large enough to do the 
mapping. So it was the clinical picture and the knowledge of the migration 
patterns within Newfoundland, the settlement and migration over the centuries 
that gave the clues. The year before, in 1991, I was at the Bar Harbor course, 
102 The surnames of the individuals are anonymous for their privacy. 
103 Professor Jane Green further explained: ‘… this family with the two probands being third cousins 
once-removed, both descended from a couple who settled near Wesleyville in 1791.’ Comment on draft 
transcript, 2 April 2013. 
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in Maine.104 That was the year that the APC gene had just been identified, by 
Ray White’s group in Utah, and so several of the lecturers in that two-week 
course were talking about colon cancer.105 Representatives of Bert Vogelstein’s 
lab were there as well as those from the University of Utah’s Department of 
Human Genetics.106 They, the Utah group, were saying that they were very 
pleased to have found the APC gene and the importance of it. Some people 
there still said, ‘There is no such thing as a HNPCC gene’ but others said, ‘We 
just need a big enough family.’ Most families were identified as a large family 
on paper with many people deceased, so I drew on a napkin what I knew of 
the Newfoundland family with the two parts that I thought were connected 
and within six months I was able to confirm that they were. It was at that point 
that I was asked by Bert Vogelstein and Albert de la Chapelle if I was interested 
in collaborating and sending DNA samples to their laboratories to attempt to 
map and clone the genes.107 Most of the samples we already had collected but 
we did collect some further samples in the December of that year, when a young 
man, aged 27, had a new diagnosis of colon cancer. The family called me, and 
Vogelstein’s lab thought that that sample would be very important, so the family 
104 Bar Harbor refers to the campus of the Jackson Laboratory, a not-for-profit, independent genetics 
research centre which holds a variety of courses and conferences aimed at the international biomedical 
research community.
105 Groden et al. (1991). Jane Green wrote in her PhD thesis: ‘A fortuitous discussion at the short course 
in Medical Genetics at the Jackson Laboratory, Bar Harbor, Maine in July 1991 with members of Bert 
Vogelstein’s group initiated a collaboration between the laboratories at Johns Hopkins University and the 
University of Helsinki (with expertise and manpower for mapping and cloning genes, but lacking informative 
families), and myself (with two well-documented HNPCC families … but without the resources locally to 
carry out intensive linkage studies).’ See Green (1995), pages 477–8.
106 Dr Bert Vogelstein is Clayton Professor of Oncology and Pathology at the Howard Hughes Medical 
Institute and Director of the Ludwig Center for Cancer Genetics and Therapeutics at the Sidney Kimmel 
Comprehensive Cancer Center of the Johns Hopkins University School of Medicine, Maryland, USA. 
See http://www.hopkinsmedicine.org/kimmel_cancer_center/experts/Laboratory_Scientists/detail/642414
6D144F331F200D784A751851DB/Bert_Vogelstein. His laboratory is credited with discovering that the 
TP53 gene on chromosome 17 was a key to the characteristics of colon cancer cells. With his collaborators, 
Vogelstein has also demonstrated the role of APC mutations in colorectal cancer and, more specifically, FAP. 
For fuller details, please see http://www.hhmi.org/research/investigators/vogelstein_bio.html (both websites 
visited 17 January 2013). 
107 Albert de la Chapelle was the first Professor and Chair of the Department of Medical Genetics, 
University of Helsinki, Finland, 1974–1997. He is now Professor of Molecular Virology, Immunology and 
Medical Genetics at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio 
State University, USA; http://www.cancergenetics.med.ohio-state.edu/2729.cfm (visited 16 January 2013). 
See also Rowley (2003). 
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travelled through a snowstorm to provide the blood samples.108 From that point 
on, it was a question of working through the linkage and, since it was the 345th 
marker that demonstrated linkage, it took some time. Most of the linkage 
studies were actually done in Albert de la Chapelle’s lab in Helsinki. That was 
all very successful but it showed that there were labs who could do the work, but 
the labs had to have connections to families with available DNA samples and, as 
Dr Bodmer mentioned, with the clinical information that absolutely confirmed 
who was affected and who wasn’t. So I think that’s where the Newfoundland 
family turned out to be extremely helpful.
Harper: Thanks very much indeed. 
møller: I want to add a little to Jane’s story because some of us were very 
offended that the lab parties examining the family material took too much 
credit without recognizing the clinical research they benefited from. You [Jane] 
gave them the whole Family C. Then the ICG-HNPCC group had a meeting 
in Houston organised by Patrick Lynch, the son of Henry.109 At that time you 
had the gene by linkage, but you didn’t have the gene itself. So we actually felt 
it was a historic moment. We rose to our feet to celebrate this moment and we 
officially named the gene Colon Cancer 1 (COCA1). And we thought that was 
a very funny name to have invented in America. However, others had previously 
identified the MSH2 gene taking part in mismatch repair in other species like 
yeast and, following that path, came to independently identify MSH2 mutations 
in humans to cause colorectal cancer.110 
Harper: Perhaps it’s a good point to focus on the interplay between the linkage 
studies and the candidate genes? 
Bodmer: Just to comment on that, Modrich had shown that you got this 
mismatch repair phenomenon in cancers from colorectal patients and that 
immediately suggested that the mismatch repair genes were involved.111 In fact, 
we were working at the same time, 1993, with Peter Karran at the Clare Hall 
Laboratories and he had just shown that one of the cell lines that we worked 
108 See Waldholz (1997), pages 162–4.
109 Patrick Lynch is Professor at the Department of Gastroenterology, Hepatology and Nutrition, 
Division of Internal Medicine, University of Texas; http://faculty.mdanderson.org/Patrick_Lynch/ (visited 
17 January 2013).
110 Reenan and Kolodner (1992). 
111 Parsons et al. (1993). 
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with was deficient in that gene.112 We were about to make the point that maybe 
that was the gene for the families when, of course, what was published initially 
was the linkage to chromosomes 2 and 3.113 It was the candidate guess that 
those would be mismatch repair genes because of Modrich’s work that led to the 
identification of MSH2 and MLH1 specifically based on that homology with 
the yeast-paired genes in which Kolodner was one of the key people.114 I forget 
which way round it was that the two were discovered. Kolodner was the key 
person because he knew all about mismatch repair, and Fishel also – they were 
both on it about the same time.115 That was a very different story in its way from 
the FAP where there was no clue to the function, and the function of it actually 
uncovered the whole role of the WNT pathway in human cancers.116
Green: The first paper, in terms of mapping the locus for a colorectal cancer 
gene, was May 1993.117 In terms of identifying the gene, the first paper was 3rd 
December and the second the 17th December, which was extremely rapid.118 
It was exactly because, through looking for the LOH and because by that time 
the markers being used were CA repeats,119 what was seen was the result of the 
112 For a review of developments in colorectal cancer research during 1993 see Bodmer et al. (1994). See 
also Bicknell et al. (1994). The Clare Hall Laboratories are part of Cancer Research UK’s London Research 
Institute, Hertfordshire, north of central London; http://www.london-research-institute.org.uk/research/
groups/clare-hall (visited 17 January 2013). 
113 Fishel et al. (1993). 
114 Richard Kolodner is Professor of Medicine, Executive Director for Laboratory Science and Technology, 
New York Office – Ludwig Institute for Cancer Research, and Head of the Laboratory of Cancer Genetics, 
San Diego Branch – Ludwig Institute for Cancer Research, at the University of California’s Institute for 
Genomic Medicine, San Diego. His laboratory uses ‘the yeast Saccharomyces cerevisiae to study the genetics 
of DNA mismatch repair and to identify the genes and pathways that prevent genomic instability.’ See 
http://igm.ucsd.edu/faculty/profiles/kolodner.shtml (visited 17 January 2013). See also Prolla et al. (1994) 
and comments by Sir John Burn on page 57. 
115 Sir Walter wrote: ‘The history is complicated as there was a whole series of papers in 1993 first mapping 
the genes to chromosomes 2 and 3 and then identifying MSH2 and MLH1 as the relevant genes and at the 
same time the Parsons et al. (Modrich) paper showing micro-satellite instability in colorectal cancers.’ Note 
on draft transcript, 24 March 2013. See Parsons et al. (1993).
116 See, for example, Logan and Nusse (2004). 
117 Peltomäki et al. (1993). 
118 Fishel et al. (1993) was published on 3 December and, on 17 December, Leach et al. (1993). 
119 Cytosine/arginine repeats. 
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slippage and, because there were people who remembered yeast genetics, they 
were able to recognize what the gene could be and, sure enough, the MSH2 
gene was in the midst of the region of linkage.
Bodmer: But it was showing that you had what at first looked like LOH in the 
cancers from the patients, and Modrich’s work, as I recall, that really established 
that there was the mismatch repair deficiency in cancers from the patients that 
actually led to the candidate genes being found.120
Green: Right, but it was looking for LOH with those markers that allowed 
them to see that. 
Bodmer: Sure. We were doing LOH studies on cell lines at the same time and 
we had thought we’d found some funny LOH on chromosome 1. Actually, it 
turned out to be in that cell line because of the lack of MSH2 protein. I even 
remember the cell line: it was LoVo.121 
Green: Lauri Aaltonen in de la Chapelle’s lab had recognized the same mismatch 
repair deficiency type of picture, so that contributed as well.122 
Bodmer: My understanding was that if you looked at the Warthin family,123 
instead of finding colon cancer you tended to find gastric cancers and nobody’s 
mentioned that, maybe Jane knows more about that? The impression was that, 
actually, the spectrum of cancers that you found changed over the years because 
of the way they could be treated.
Green: I would agree with that because I could go back probably three 
generations and find records showing that there was certainly more gastric 
cancer earlier. There still are a few gastric cancers in that same family but that 
one sibship in particular with five affected brothers, three of them developed 
120 See note 113. 
121 ‘This cell line, designated LoVo, represents an in vitro model for human colon carcinoma.’ Quoted from 
Drewinko et al. (1976), page 467. 
122 Lauri Aaltonen is the Academy Professor for the Tumor Genomics Group within the Genome Scale 
Biology Research Program and Department of Medical Genetics, University of Helsinki, Finland, and 
Director of the Centre for Excellence in Cancer Genetics Research at the same institution; http://www.
helsinki.fi/biocentrum/groups.htm#aaltonen and http://www.helsinki.fi/coe/cancergenetics/index.html 
(both sites visited 17 January 2013). See Aaltonen et al. (1994). 
123 See note 14.
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gastric cancer and two of them had colon cancer, but the daughter had gastric 
cancer later on as well. So the frequency of gastric cancer has decreased, it was 
much higher earlier. 
Bodmer: The Warthin family was actually not specifically colon cancer, it was 
said to be a dominant cancer family with a variety of cancers.
Green: Well, if you saw the Family C, the women have about a 69 per cent 
chance of endometrial cancer, a slightly lower chance of colon cancer and about 
a 25 to 30 per cent chance of ovarian cancer [Appendix 3]. There are duodenal 
cancers, there are rare transitional cell cancers but in another founder MSH2 
family there’s very, very frequent transitional cell cancers of the renal pelvis, 
ureter and bladder. Because of these large families, we do tailor the screening 
according to what is seen in all the records. Whether we call it a registry or not, 
there are records of every patient that has ever been seen in these families and 
so if there’s a new referral of a family we can go back to the old, old records and 
tie it together. That helps with both the mutation detection and the clinical 
features in the families. With MSH2, there are also the sebaceous cancers and 
keratoacanthomas. It’s extremely varied presentation.
Bodmer: I thought that Jane mentioned that very interesting question of 
heterogeneity and it actually interacts with Chris Harocopos, who was involved 
in the colon cancer group. We actually happened to study a very large family 
in South Africa that all had the same mutation: hMLH1.124 There were well 
over 30 cases in that family and the study that was done with quite variable 
expression – which is now quite a popular thing to do – was to see if you could 
find modifiers to explain the severity by looking at other polymorphisms. There 
was some suggestion of that. So I think it’s just an interesting thing that when 
you’ve got those very large families and there is that variation in severity and 
type of the disease, there are alternative ways of trying to look. That, of course, 
is something that’s being done in the BRCA1 and BRCA2 families.125
Harper: I’d like just to discuss one or two of the related syndromes and one 
in particular which certainly astonished me. If anybody had said there was a 
recessive form of polyposis or colorectal cancer a few years back, I would have 
totally refused to believe it. But that is the case and I’d like to ask Julian Sampson 
here to say a bit about recessively inherited colorectal cancer with polyps. 
124 Felix et al. (2006).
125 See, for example, Couch et al. (2013).
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sampson: The condition MUTYH polyposis (MAP) fits, I guess, phenotypically 
between the Lynch syndrome and FAP that we’ve been discussing. Our research 
group in Cardiff hadn’t really had a molecular genetic research programme 
in colorectal cancer but we started to become interested in the possibility of 
alternative mechanisms underlying polyposis in addition to FAP.126 I was 
predisposed to think in terms of different genes causing similar phenotypes 
because we worked on tuberous sclerosis, which had been considered to be one 
disease, but we rapidly established that there were two different genes that cause 
tuberous sclerosis, albeit both associated with dominant traits.127 I see all the 
polyposis families referred to clinical genetics in South and West Wales, and 
one family came along to the clinic in Aberystwyth to see me, referred by a 
surgeon who thought they had polyposis but wasn’t sure. In fact, he was aware 
that his patient had a number of adenomas – I think he’d only taken out about 
12 adenomas over a number of years but more were still present. This person’s 
brother had died of colon cancer in his 40s and he wanted to know was this 
polyposis or not? It was interesting, there was no dominant family history of 
polyposis, the family came from a very small village in the Ceredigion region, 
but in fact their parents had moved there some time previously from, I think, 
the Manchester area, so I don’t recall that we were suspicious that there was any 
consanguinity associated with this family coming from a very small village. I’ve 
brought a copy along of the letter that I wrote after the clinic and obviously it 
struck me as very odd and I noted that the parents had died of heart attacks 
126 Professor Julian Sampson wrote: ‘We had been using molecular genetics for diagnosis of FAP from about 
1990 but did not start looking for new genes until about 1999.’ Note on draft transcript, 27 February 2013. 
127 See, for example, Povey et al. (1991). 
figure 16: Professor Julian sampson (left) and Professor alan lehmann (right). 
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in old age and hadn’t had any bowel problems and what I wrote was: ‘It was 
almost certain that there is a predisposing gene accounting for the findings in 
this family. The findings could be consistent with an attenuated form of FAP 
due to an unusual mutation or with mutation at a different locus altogether.’ We 
were thinking along these lines but, in our investigations, we were then actually 
rapidly waylaid by the identification of a missense variant in the APC gene in 
the family. About this time I was collaborating with Ian Tomlinson128 and we 
were looking at this question of whether non-truncating mutations in APC 
might predispose to colorectal adenoma and cancer.129 The Ceredigion family 
had a particular APC variant that was causing a lot of difficulty – E1317Q – 
that Walter will probably remember. So we did wonder whether this family 
actually had a variant form of FAP initially. But on further investigation we 
found that a further sibling also had multiple colorectal adenomas and that the 
E1317Q variant didn’t segregate with the colorectal phenotype. What we were 
then able to do, because I’d seen the affected individuals preoperatively, was to 
obtain polyps at colectomy. Initially what we thought we’d do was look at the 
pattern of somatic APC mutation in these polyps and see if there was something 
odd about it and there was because they were G to C transversion mutations. 
That was something I discussed with Ian Tomlinson and he looked at this data 
with Jerry Cheadle and I, because we were working on families with unusual 
APC variants.130 Ian helped to flag it up in our discussions but he didn’t seem 
to think it was quite as interesting as it really was. So Jerry and I pursued this 
and, similarly to the story that we’ve heard about in relation to mismatch repair 
deficiency in Lynch syndrome, we thought that this unusual pattern must really 
reflect some underlying DNA repair defect. By taking a lead from E. coli repair 
deficiency states we deduced that, in the case of this family, one of the base 
excision repair genes was likely to be mutated, and we screened those genes and 
found that this was indeed the case. This family had a defect in a base excision 
repair gene, MUTYH, that was manifesting as a polyposis phenotype that looked 
really similar to AFAP, and the segregation in the family was consistent with 
recessive inheritance. Initially we had difficulty finding any other similar families 
and we just published our findings about this single family, which I think took 
128 See note 4.
129 Lamlum et al. (2000). 
130 Professor Jeremy Cheadle is the Principal Investigator at the Institute of Cancer and Genetics, Cardiff 
University School of Medicine, where his research focus ‘is to identify novel genes that predispose to 
colorectal adenomas and colorectal cancer’. See http://medicine.cf.ac.uk/person/prof-jeremy-peter-cheadle/
research (visited 17 January 2013). 
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010
44
rather a long time to get published.131 People were disinclined to believe it 
initially but this was followed up with further studies from Ian Tomlinson and 
from our own group, collaborating with other clinical genetics centres in the UK 
and elsewhere, to pick out these families from polyposis registers.132 I think that 
many of these families had been wrongly thought to reflect gonadal mosaicism 
for APC in parents, producing a recessive-like or pseudo-recessive pedigree, but it 
rapidly became clear that this was a significant recessive form of polyposis. 
solomon: Did they have the same mutation?
sampson: In that particular family actually, the affected people were compound 
heterozygotes but we know there are both homozygous and compound 
heterozygous families for a wide variety of mutations now.
Green: Actually, several of our families that we now know have MUTYH 
mutations were what I guess you would call pseudo-dominant in that a parent 
did have colon cancer but because there weren’t pathological records available, 
we didn’t know if there were polyps or not. This was presumably a sporadic colon 
cancer coincidentally in a family with several children having multiple polyps. 
So we had expected that they really were FAP until there was the possibility to 
check for MUTYH mutations.
Harper: Julian, can you give an estimate of how common this is in relation 
to classical polyposis because if it’s even the slightest bit common, we’ve been 
misleading an awful lot of people with our genetic counselling when seeing 
isolated cases. 
sampson: I think a lot of these MAP families haven’t actually found their way 
into genetics clinics because of the rather attenuated phenotype and small 
family size. Within the Wales polyposis register, MAP accounts for about 15 to 
20 per cent of the families but the trait is recessive. On the whole these families 
are small, so they form a much smaller proportion of the affected patients. 
Many other registers actually have an even smaller proportion than that. The 
question is really, ‘Where are these patients?’ One of the things that’s become 
apparent with population studies, where you can very easily investigate the two 
commonest north European MAP-causing alleles in case control settings, is 
that really a lot of these patients don’t present with polyposis but can present 
just with colorectal cancer, or a very small number of polyps. The overlap with 
131 Cheadle and Sampson (2003). 
132 See, for example, Enholm et al. (2003). 
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Lynch syndrome is rather more than we initially realized. We’ve also looked at 
non-colorectal and non-GI cancers in these MAP families and certainly they 
have an overrepresentation of other tumour types, including some of the very 
rare skin tumours also associated with Lynch syndrome.133 It’s not uncommon, 
probably it’s as common a cause of colorectal cancer as FAP used to be before 
it was so successfully treated surgically but it’s underascertained genetically.134
Harper: Has it been found in many countries around the world?
sampson: In most places. I don’t think there’s a lot in the eastern part of Asia, 
so the Japanese don’t seem to be able to find very much, and the Koreans I don’t 
think can find very much either. 
Green: I’m just curious as to what you’ve seen as far as other cancers because 
we have a number of MAP families in Newfoundland. We happened to do 
a population-based study in between 2000 and 2005, when these MUTYH 
mutations were identified, so we looked for that in everybody that we didn’t 
have another genetic cause. There were some suggestions in the literature of 
possible renal cancer as one of the cancers and I’ve never seen anything else 
since. So are there other cancers we should be looking for in those families?
sampson: I don’t think so really. We know there is a risk of duodenal cancer, but 
the risks of other cancers really seem to be small, although statistically a few are 
elevated it is really very marginally and wouldn’t warrant any special screening. 
It really is a GI disease.
Harper: Alan Lehmann’s working from the DNA repair end and meeting up 
with all these clinical syndromes. How do you view it from your perspective?
Professor alan lehmann: I should say that I’m neither a clinician nor a cancer 
geneticist; I’m a molecular and cell biologist. I’ve been working on DNA repair 
disorders for many years and will give a view from out of the circle for a little 
while. One of the first genetic cancer-prone disorders for which a molecular 
basis was identified was xeroderma pigmentosum (XP), and that was way back 
133 Vogt et al. (2009). 
134 Professor Robin Phillips wrote: ‘In 1918, J P Lockhart-Mummery performed a prophylactic colectomy on a 
female patient, and an ileosigmoid anastomosis, and she lived 20 years before dying of cancer in the remaining 
sigmoid colon. The era of prophylactic surgery for FAP really started post war with the first colectomy and 
ileorectal anastomosis (a prophylactic operation to prevent colon cancer) taking place on December 8th 1948.’ 
Note on draft transcript, 5 April 2013. See also Granshaw (1985), pages 347–52, Ms Kay Neale’s comments 
on page 20, and in note 63; and Dukes (1952), in particular pages 302–3. 
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in 1968 by James Cleaver who is actually British although he did the work in 
the USA.135 He showed that XP was caused by defective DNA repair. Shortly 
afterwards, with regard to ataxia-telangiectasia, which is one of the chromosome 
breakage disorders, Malcolm Taylor came from David Harnden’s group in 1973 
down to our lab in Sussex to look at a number of disorders.136 Together with my 
colleague Colin Arlett, he showed that ataxia-telangiectasia cells were sensitive 
to ionizing radiation, again pointing to a defect in DNA repair associated with 
a cancer-prone genetic disorder.137 Ataxia-telangiectasia together with Fanconi 
anaemia and Bloom syndrome form the so-called chromosome breakage 
disorders.138 For all of those, there were indications way back in the 1960s and 
1970s that there was an association of defective DNA repair with chromosome 
breakage and with cancer, indicating linkages between chromosomes and 
cancer. Of course now there are many other DNA repair disorders, many, but 
not all, of which are associated with cancer proneness. DNA mismatch repair 
disorders are some very important examples, which really, I think, moved DNA 
repair from somewhere on the periphery right to the centre of carcinogenesis. I 
just want to ask a point, it may not be directly relevant to this discussion, but is 
there any explanation why with mismatch repair deficiencies – both the MSH2, 
MLH1 and the MYH types – is there this predominance of colorectal cancers 
when, if you were just going from the basic biology, you would predict cancers 
would be found in every organ of the body? 
evans: Is it possibly because those cells are turning over very much more quickly 
in the colon and rectum and in the endometrium, you’re getting much more 
rapid turnover of those cells than in many of the other organs that are at risk? 
135 Cleaver (1968). In 1968 James Cleaver was Assistant Research Biophysicist, then Assistant Professor of 
Radiology at the University of California, USA; http://cancer.ucsf.edu/people/profiles/cleaver_james.3557 
(visited 18 January 2013). 
136 For definitions of ataxia-telangiectasia and xeroderma pigmentosum, see Glossary pages 103 and 104. 
In 1973, Malcolm Taylor worked at the Department of Cancer Studies, University of Birmingham; note on 
draft transcript, Professor Alan Lehmann, 26 February 2013. 
137 Taylor et al. (1975). Professor Alan Lehmann wrote: ‘[Dr Colin Arlett] was group leader in cell biology 
and I in molecular biology. We worked together very closely for 25 years’ [at the School of Life Sciences in 
the University of Sussex]. Note on draft transcript, 27 February 2013. 
138 Professor Alan Lehmann wrote: ‘Cytogenetic studies revealed increased chromosome aberrations 
(e.g. breaks, exchanges, translocations) in cells from three highly cancer-prone genetic disorders: ataxia-
telangiectasia, Fanconi anaemia and Bloom syndrome. These are referred to as the chromosome breakage 
disorders. The chromosome abnormalities are now known to result from mutations in various genes 
involved in the cellular responses to DNA damage.’ Note on draft transcript, 26 February 2013. 
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lehmann: And skin, skin cells are turning over, perhaps not quite as rapidly, but 
very rapidly.
sampson: One strong possibility, I guess, has got to be that the mutational 
load in the colon is likely to be significant, and significantly different to other 
organs because of the microflora in the large bowel. I wanted to mention one 
other thing that I haven’t mentioned in relation to the MUTYH research which 
might be interesting from a historical point of view. This is just the nature of the 
collaboration for the functional work. In genetics, very often when you identify a 
gene by positional or candidate means, it lands you in an area of biology that you 
know nothing about and of course we, i.e. our group, knew nothing about DNA 
repair. Actually, the human MYH homologue wasn’t really being functionally 
studied at that time at all. I think it’s a difficult protein and we tried to express it 
ourselves and failed. So I contacted a collaborator, but did this by internet, which 
was the first time I had established a collaboration not by face-to-face contact 
but by simply surfing on Google and looking to see who knew about E. coli base 
excision repair, and Sheila David, who was in the Department of Chemistry in 
Utah, came up as one of the hits.139 So I was able to go and look at her lab, and 
nowadays all the labs have the photos, and you can actually see their social outings 
together. And she looked very nice; you know, she had sort of a woolly jumper 
on and obviously was very relaxed. And I thought, ‘This looks like the sort of 
person you can phone up and talk to.’ So I did. I just phoned her up and said, ‘I 
see you work on this gene.’ And she said, ‘Oh yes.’ I said, ‘We’ve got a disease for 
it, a human colon cancer syndrome.’ She was very, very excited because NIH [US 
National Institute of Health] was about to remove her funding [laughter] because 
they’d been on at her for years that she had to be more disease-focused and link her 
work into health in some way. As a result, she was really delighted and it boosted 
her career. I see she’s subsequently moved to a Chair in California, which I’m sure 
was very nice. [Laughter] Although we had a very productive collaboration, we’ve 
never met.140 It really was an internet-age collaboration.
Bodmer: Just two differently related comments on this last point. It’s very 
important to distinguish the dominant from the recessive things. The MYH 
mutations are effectively recessive even though you get compound heterozygotes. 
139 Sheila David was Professor of Chemistry at the University of Utah until 2006; http://www.chem.
utah.edu/faculty/david/david.html, before her appointment at the University of California, Davis, also as 
Professor of Chemistry; http://www.chem.ucdavis.edu/faculty/cf-info.php?id=81 (both web pages visited 
18 January 2013). 
140 Al-Tassan et al. (2002). 
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The mismatch repair gene mutations are clearly dominant and they are very 
different. I don’t think one can say one understands why, first of all, you don’t 
get the Lynch syndrome mainly in the colon, you get it in many other things 
too. I mean, you could ask the question, ‘Why don’t you get that breadth of 
things in the MYH situation?’ But I think it’s fairly different when you have 
a recessive and intrinsically increased mutation rate. In every cell is a totally 
different situation, which is what you have with all the well-known recessive 
defects. Alan Lehmann was talking about the situation when you have something 
dominant. Now my own view is that actually in the HNPCC, the mismatch 
repair is nothing to do with the increased mutation rate in the cells; it’s probably 
something to do with the effect already in the heterozygote, possibly then in 
the homozygote on apoptosis. That’s a point of some discussion because it’s 
quite unusual to find the repair genes mutated somatically. But the question I 
would have on the MYH, which has always puzzled me, is how either of those 
particular variants in recessive or compound heterozygotes give you the MYH 
syndrome? It struck me that there was a discrepancy between what you’d expect 
from the frequencies in the population, just from population studies, and what 
you actually find. That suggests that maybe you’re not actually picking up most 
of the cases because they’re below the radar screen in terms of severity, and I 
wonder whether you have any comments on that? 
sampson: I think it’s absolutely true and the only way that you do pick these 
cases up is by genotyping colorectal cancer populations. That’s been done and it 
probably accounts for 0.5 to 1 per cent of all colorectal cancers – it’s not a large 
percentage. But many of those cases don’t have the sort of phenotype that would 
flag them up to a genetics department.
Bodmer: Are they milder cases of colorectal cancer? Are they essentially mainly 
found as Dukes’ A or possibly Dukes’ B?141 When they get cancers, are they less 
severe cancers? 
sampson: I think that’s an interesting question. I don’t think that’s been fully 
resolved but certainly the prognosis seems to be slightly better for MUTYH 
bowel cancers than sporadic colorectal cancers. I think there’s only one good 
published study, which was in JNCI about a year ago.142 
141 Dr Cuthbert Dukes’ method of classifying rectal cancer related to how much the disease had spread: A 
(limited to the wall of the rectum), B (spread to extrarectal tissues) and C (present in regional lymph nodes), 
officially called Dukes’ A, Dukes’ B and Dukes’ C. See Dukes (1932). See also note 22. 
142 Lynch and Lanspa (2010). 
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Bodmer: There’s another feature of the HNPCCs because of all the mutations 
you do get – that’s a suggestion that we made many years ago but probably still 
holds up – they actually have a slightly better prognosis because of the immune 
response. 
sampson: And the tumours from MAP patients have a lymphocyte infiltrate 
very similar in appearance to that seen in HNPCC. 
Bodmer: Which could account for better prognosis.
møller: I will add to the arguments here that the only way to find MAP is to 
test the incidental cancers, because you avoid the definition of a dominantly 
inherited syndrome and you escape the definition of polyposis. Also, people 
are using the concept of population prevalence, as Jane mentioned, and we 
have large areas of very ancient inbred populations in Norway, Julian has in 
Wales, Gareth has in Manchester and John Burn would have said he had in 
Northumbria. So the concept of population prevalence is, to me, fading in the 
shade. We have to consider mean figures for population prevalences of genetic 
markers with caution. The other question was: Why just colon cancer? Why 
didn’t we ask why BRCA mutation carriers only get breast cancer? To me, this 
is about tissue differentiation. Some tissues have inactivated their safety systems 
if the major system fails. What we are seeing is that some organs are dependent 
on one system only and, if that fails, they don’t have a reserve system to be 
activated. That is so obvious an explanation to me and, until it has been proven 
false, then there’s no proof for any other explanation. I’ll stick to that.
evans: Very briefly, because it’s very relevant, I think that one of the things that 
we’ve forgotten is that Lynch syndrome can be recessive and that Turcot originally 
described a family which was almost certainly a mismatch repair homozygote 
family, and in particular PMS2 which is the least penetrant of all the genes, is 
highly penetrant when it’s in the recessive form.143 You see these families with 
devastating early-onset bowel cancers, brain malignancies and leukaemias, so 
you see the whole range of malignancy in early childhood and early adulthood, 
along with some other things like café-au-lait patches which means that families 
have sometimes been misdiagnosed with NF1, neurofibromatosis type 1, so it 
does show that recessive spreads a bit further than MYH.
143 Turcot et al. (1959). PMS2 is a mismatch repair gene.
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Harper: I’m reliably informed that shortly we will have John Burn at the end of 
a phone.144 The next section of this seminar is devoted to more applied aspects 
of clinical cancer genetics. Shirley Hodgson and then Gareth Evans will lead 
us into the evolution of cancer genetics services from perhaps a rather wider 
perspective than just the colorectal side, but thinking of clinical cancer genetics 
services as a whole. After that, it will be good to have some discussion on the 
different roles of various professionals in this. 
Hodgson: I was thinking about how to encapsulate what clinical cancer genetics 
is. It’s the sort of thing that people at cocktail parties come up and say, ‘What 
do you do?’ You wonder how to explain. I then thought, you can divide it up 
into a number of different aspects. First, there was a traditional aspect that I’ll 
just briefly allude to, which is ascertaining people who have a family history 
of, say, bowel cancer, and trying to work out from that what their cancer risk 
is, and then trying to work out whether or not screening or other prophylactic 
measures might be appropriate. That is what Joan Slack set out to do in the 
Family Cancer Clinic in London in the 1980s with Vicky Murday, based on a 
polygenic theory of colorectal cancer susceptibility.145 That’s certainly the bread 
and butter of what we do in the clinics now. Then there’s the conventional 
genetic counselling for Mendelian genetic conditions, including genetic testing 
for confirmation of the diagnosis, predictive testing for relatives of somebody 
with a known mutation, and identifying other cancer-predisposing conditions, 
such as people with Cowden syndrome. Then there’s the question as to whether 
you should be actively ascertaining the relatives of those affected people who 
may be cousins and distant cousins of the proband, and all the issues that we 
know about, including confidentiality, and who you disclose results to, and how 
144 Professor Sir John Burn was unable to travel to London because of adverse weather conditions in 
Newcastle and had to participate in the meeting remotely by telephone. 
145 Dr Joan Slack was a Consultant in Clinical Genetics and Senior Lecturer at the Royal Free Hospital 
and School of Medicine’s Department of Clinical Genetics. Ms Christina Harocopos wrote: ‘The clinics 
were initially set up at the Royal Free Hospital until appropriate clinic space could be found at St Mark’s 
Hospital.’ Note on draft transcript, 17 March 2013. See also Houlston et al. (1990): ‘In 1986 a Family 
Cancer Clinic was opened at St Mark’s Hospital as part of the North East Thames Regional Genetics 
Service for relatives of patients with colorectal cancer. The clinic was supported by the Imperial Cancer 
Research Fund and publicized in the national press. Clear guidance was given that screening was available 
for first degree relatives of patients who had developed colorectal cancer before the age of 45 and members 
of families in which multiple cancers had occurred.’ Quote from page 366. The Family Cancer Clinic is 
still screening, treating and counselling people at St Mark’s Hospital; http://www.stmarkshospital.org.uk/
family-cancer-clinic (visited 18 January 2013). 
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you should ascertain the at-risk relatives. That, of course, leads into questions 
we discussed a little earlier, which are the ideas of establishing a registry which 
would then be able to organize the ascertainment of people at risk, recalling 
people for screening, and so on. Setting up such registries is something which 
isn’t really the remit of a genetics department, but it is no-one else’s remit either, 
and obviously our work would lead into the need for a registry. Then there 
are the aspects of multidisciplinary clinics which I’m sure Eamonn will talk 
about, for multisystem diseases like VHL disease and so on, where you need 
a number of different professionals to look after and arrange surveillance for 
the affected people, as in the wider world; on the whole, medical clinics only 
deal with one system at a time. So it’s very helpful if individuals with these 
genetic conditions can be seen by a number of different clinicians at the same 
time. Then there’s the problem of how to try and ascertain families who are 
not aware of the genetic implications of a family history of cancer, and who are 
often not ascertained for genetic counselling, or for cancer susceptibility. There 
are a number of studies about this which have been done in ethnic minorities 
funded by Macmillan, in which I was involved – a study of whether you should 
try and be more proactive in ascertaining people from ethnic minorities with 
a family history of cancer where they’re not used to seeing geneticists, and also 
addressing other aspects of how to deliver this kind of service.146 There is the 
question as to whether much genetic counselling in family history clinics could 
be done by clinical geneticists or whether it could be done by counsellors or 
nurses. Or should it be done in other ways? Would telephone counselling be 
a good way of doing this? So there are a lot of questions in terms of service 
delivery.147 There are also the broader aspects: the most cost-effective strategy 
for ascertaining people at increased cancer risk; and deciding at what level of risk 
you should offer screening, which requires a dialogue with healthcare providers 
in the National Health Service. I’m sure Gareth will talk about that, because if 
you ascertain families whose risk of cancer is above a certain level, there needs 
to be a decision regarding who should be screened, how much that would cost 
and what the cost-benefits are. Clearly, there is a broad range of things that 
we find ourselves dealing with as clinical cancer geneticists and, as geneticists, 
we may not perhaps be appropriately trained to some extent to deal with all 
146 See, for example, Gulzar et al. (2007). 
147 Professor Shirley Hodgson wrote: ‘A study I did assessing clinical cancer genetics services in different 
European countries in the 1990s indicated that such services were much more developed in countries where 
counsellors and nurses were allowed to participate in such service delivery.’ Note on draft transcript, 10 
October 2012. See Hodgson et al. (1999).
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those different aspects. Of course, in the future we are going to be walking into 
another minefield in terms of other genes of very low penetrance, which people 
are going to find out about in genome-wide association studies, and testing 
for genetic variants, which is now becoming available commercially, so that in 
the future such tests are going to give us information about small alterations 
in risks.148 So that’s the background thinking and I just wanted to say a small 
amount about the way that colon cancer susceptibility counselling started in 
the UK. I know that Chris [Harocopos] can say more about this. Vicky Murday 
was very much involved with the first clinics that were set up with Joan Slack 
in 1986.149 This arose out of the work that Eileen Lovett had done many years 
ago when she looked at the families of patients at St Mark’s Hospital with colon 
cancer and found that their relatives had a higher incidence of colon cancer 
than the general population.150 The degree of increased relative risk was further 
analyzed by Joan Slack with Vicky Murday and Richard Houlston,151 and Chris 
Harocopos was also involved, in trying to quantify the increased risk of colon 
cancer in relatives of affected patients with different degrees of family history. 
From that grew the idea of having a clinic which would take people who had a 
family history of colon cancer and assess their risk on the basis of a polygenic 
model, if they didn’t have an autosomal dominant family history, of course. The 
Family Cancer Clinic offered colonoscopies to people who had more than a one-
in-ten risk of dying of colon cancer, and faecal occult blood testing for the less 
strongly predisposed individuals. They then went on to audit the management 
of those families and found really that their findings confirmed that their 
first premise was correct. These people were at increased risk and they were 
indeed finding more cancers and polyps in this group than you would expect 
in a general population. So it seemed that they were barking up the right tree. 
That led to a flourishing clinic at St Mark’s Family Cancer Clinic with a lot of 
148 Professor Peter Harper wrote: ‘Regarding genome-wide association studies, the early ones, from around 
2003 up to around 2008 – widely used in both the US and UK – were rather disappointing, largely because 
the markers were often too far from the relevant genes, but also because the statistical tests used allowed 
many false positives. Recent ones have shown many more robust disease associations, though in many cases 
the associations are quite weak.’ Email to Ms Emma Jones, 16 April 2013. See, for an example of an early 
genome-wide association study, Klein et al. (2005). For analysis of genome-wide association studies and 
discussion of their future relevance to clinical practice, see Hirschorn and Gajdos (2011). 
149 See note 145. 
150 Eileen Lovett, surgeon, was a Research Fellow at St Mark’s Hospital in 1975. See Lovett (1976). 
151 See note 145.
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support from Walter Bodmer and the ICRF.152 Then I came in when Vicky left 
and started to run the clinic from there.153 Of course, we got a lot of experience 
from it too in terms of finding families and being able to ascertain new families 
with different conditions who came through the doors. We could also audit the 
pick-up of polyps and cancers from people at different degrees of risk. In about 
the early 1990s I know that Bruce Ponder started a clinic in London, which 
was mainly, I think, more concerned with familial melanomas.154 Then it really 
evolved very rapidly and has become what it is today.155 But when it first started, 
there were very few referrals to genetics clinics for a family history of cancer and 
now it’s certainly nearly 50 per cent of all referrals, which of course has turned 
genetics services upside down. 
evans: To continue the story and I’m perhaps one of the first bespoke cancer 
geneticists, although it sounds like Vicky and Shirley were fairly bespoke as 
well. I was brought in, at the beginning of 1990 in Manchester, to set up cancer 
genetics services because there was really nothing there.156 There was the odd 
patient being referred, so I went round the country and saw what was available: 
Joan Slack set her clinic up in 1986; Bruce Ponder’s clinic was actually at the 
Royal Marsden, and he’d set this up in 1987, and Tony Howell set up a breast 
cancer family history clinic in Manchester in 1987.157 These were largely clinics 
152 See page 28.
153 See page 29.
154 Sir Bruce Ponder was CRC Fellow and Senior Lecturer in Medicine, Royal Marsden Hospital (1980–
1987), then Reader in Human Cancer Genetics and Head of the Section of Cancer Genetics (1987–1989), 
University of Cambridge. He has been the Director of Cancer Research UK’s Cambridge Research Institute 
since 1989 and is also the Li Ka Shing Professor of Oncology, University of Cambridge. He was invited to 
this seminar but was unable to attend. See Who’s Who 2012; http://ukwhoswho.com/view/article/oupww/
whoswho/U31108 and Ponder, Sir Bruce (Anthony John); http://www.cambridgecancer.org.uk/about-us/
directors-foreword/ (visited 16 October 2012).
155 The Royal Marsden’s Cancer Genetics Unit ‘offers services to individuals and families concerned about 
a risk of inherited cancer’; http://www.royalmarsden.nhs.uk/consultants-teams-wards/clinical-units/pages/
cancer-genetics-unit.aspx (visited 25 January 2013).
156 At the time, the organisation was the Central Manchester Healthcare NHS Trust; http://www.cmft.nhs.
uk/your-trust/our-history.aspx (visited 13 March 2013). 
157 Professor Gareth Evans wrote that Bruce Ponder’s clinic was based at the Royal Marsden in London and 
that it was ‘mainly for breast and ovarian cancer predisposition’. Note on draft transcript, 21 February 2013. 
Anthony Howell is currently Professor of Medical Oncology at the Manchester Breast Centre, University 
of Manchester, and works closely with Professor Gareth Evans; http://www.breastcentre.manchester.ac.uk/
Tony_Howell/Professional_biography (visited 20 February 2013). 
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that were set up for research, to get the families, and to research the families. 
Very quickly after 1990, which I think was a fairly pivotal year with discovery 
of genes, there started to be publicity around inherited cancer, and the public 
became more aware of it and we started to see referrals coming in.158 To some 
extent the amount of referrals was based on whether there was a service, so if 
you didn’t have a service you didn’t get referrals. So we, in Manchester, saw an 
exponential rise in referrals for breast cancer between 1990 and about 1995, and 
it’s pretty much plateaued since then.159 We followed the same exponential referral 
pattern for bowel cancer, which started in about 1994/95 and peaked in about 
2000. I think virtually all parts of the country have seen the same exponential 
referral patterns with it plateauing off, except for parts of the country that set 
things up a bit later. It’s important to talk about the role of all the people in the 
service. Most centres will have a pretty much full-time cancer geneticist who 
does very little else, although there are examples of centres such as Birmingham, 
I think, who have a more regional aspect to their referral and working methods 
so they’re not necessarily as specific.160 There are centres that will have two, or 
two-and-a-half, cancer geneticists. But the role of the genetic nurse specialist, 
the genetic counsellor, which was developed through the courses in Manchester 
and Cardiff,161 deals with an enormous amount of the work that goes on: the 
initial contact with families, constructing the pedigrees, etc. Most centres have 
counsellors that are pretty much specifically cancer genetics although again there 
are those that mix and match and do a bit of other genetic diseases. Gradually 
the services have been set up around the country, so every genetics department 
has a service. I remember Cardiff really setting up your [Harper’s] service from 
scratch through a very successful research project. Was it Wellcome-funded? 
I can’t remember which. Or it was MRC-funded, one of those.162 You set the 
All Wales Cancer Genetics Service up on the back of, basically, a randomized 
158 For newspaper publicity, see, for example, Mihill (1991) and Angler (1991).
159 See also the work of Professor Gareth Evans’ research group at the University of Manchester in breast 
cancer prevention in connection with the charitable organzation Genesis Cancer Prevention Centre; http://
www.genesisuk.org/ (visited 9 April 2013). 
160 West Midlands Regional Genetics Service, Birmingham Women’s NHS Foundation Trust; http://www.
bwhct.nhs.uk/wmrgs (visited 5 March 2013). 
161 MSc degrees in genetic counselling are taught at the universities of Cardiff and Manchester, for example. 
162 Professor Peter Harper confirmed that his service was locally funded. Note on draft transcript, 9 May 
2013. 
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control trial.163 It took until about 2000 before the whole country had some sort 
of cancer genetics service embedded within NHS departments. We don’t really 
yet have a clinical guideline for bowel cancer, although I think it probably will 
happen. My involvement with breast cancer has been through NICE [National 
Institute for Health and Clinical Excellence] having a Guideline Development 
Group for familial breast cancer.164 Since 2002 I was chairman of this Guideline 
Development Group and I’m now clinical lead. That group really decides pretty 
much what should happen around the country in terms of management, in 
terms of who gets surveillance, who gets MRI screening surveillance, who has 
access to risk-reducing mastectomy, who should always have access to genetic 
testing. Now it’s only guidance, so it can be ignored, but the idea is to get rid of 
the postcode lottery of Josephine in Cornwall getting her genetic test while her 
sister in some other part of the UK doesn’t get one.
Harper: John, would you like to comment in terms of, not just the North East, 
but how you have seen the overall development of cancer genetics services over 
the past 20 years?
Professor sir John Burn: I think it’s already been picked up that cancer was very 
much not on our genetics agenda when we were coming into the subject in the 
1970s and 1980s. When I set up my consultant service in Newcastle in 1984, I 
don’t think I saw any patients at all. I became involved through Alistair Gunn, 
who was a very active, well respected colorectal surgeon, who had worked at St 
Mark’s and wanted to get a sense of the FAP world.165 We got a bit of money from 
the region to employ Pam Chapman and we also got some money via Walter 
Bodmer’s efforts through ICRF to pay for her, and we started working on FAP. I 
was actually very rapidly enthused by the topic because I realized we could make 
such a huge difference. Despite the fact that St Mark’s had a national register, as I 
expected, we found about 70 families, of which only three were on their register 
because we were obviously so remote. Also, it was apparent to me that in the FAP 
163 This unit is part of the All Wales Medical Genetics Service, which provides specialist genetic services to 
individuals and families with, or concerned about, rare genetic conditions; see http://www.wales.nhs.uk/
sites3/home.cfm?orgid=525 (visited 11 February 2013). 
164 In July 2010, the Department of Health requested that NICE prepare a clinical guideline for diagnosing 
and managing female patients with inherited breast cancer. The draft guideline was issued in June 2013; 
see http://www.nice.org.uk/cg164 (visited 15 August 2013). 
165 Dr Alistair Gunn died on 24 December 2010. His forthcoming obituary in Plarr’s Lives of Fellows 
had not been published at the time of writing; http://livesonline.rcseng.ac.uk/biogs/E001820b.htm 
(11 February 2013). 
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world there wasn’t a genetic perspective; it was being approached from a surgical 
perspective, and I was very keen to bring in the DNA markers and get into that 
side, which you’ve already, I think, talked about. We set up a very comprehensive 
service through Pam and through Alistair Gunn; so we actually set up a system 
of telling people, based on our probability calculation, who should or should 
not be offered endoscopy and how frequently. I very studiously avoided getting 
drawn into the other areas of cancer. Obviously, like Gareth and others, I was 
involved in things like NF [neurofibromatosis] but breast cancer really was fairly 
minimal, although I did get a bit involved in p53.166 But it wasn’t really until I 
set up the CAPP studies with Tim Bishop and John Mathers, to start looking at 
chemoprevention in FAP, that I became much more closely involved with Tim, 
who I believe couldn’t make it to this meeting either, but he’s obviously been a 
leading player in the field for all that time as a genetic epidemiologist for ICRF 
and CRUK.167 We had some families in the North East and one in particular 
called the Durham family, which a GP called Ted Knaggs had described in a paper 
in the Journal of Medical Genetics in 1972,168 and this was just after Henry Lynch 
had described 55 cases of colorectal cancer in one family.169 Essentially we all sort 
of nodded towards papers like that and said, ‘Yes, but we don’t really believe it’s 
166 p53 is a tumour protein gene, known officially as TP53, mutations of which are associated with the 
development of several cancers. This gene has been mapped to chromosome 17. 
167 See note 4. 
168 Dunstone and Knaggs (1972).
169 See Lynch and Krush (1971). 
figure 17: Professor sir John Burn.
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genetic’. And it very obviously was a dominant pedigree. We started mapping that 
with Tim’s group in Leeds and we also started working on another family which 
we found in the Northumberland area. Meanwhile, the international collaborative 
group on HNPCC led by Hans Vasen was obviously getting going, but I tried to 
keep out of that because I was trying not to get too dispersed. But then we got 
sucked into it big time, partly because of these big families that we were mapping 
and also through Bruce Ponder putting us in touch with Richard Kolodner, who 
was looking for some samples from an HNPCC family to try out his theory on 
mismatch repair.170 So we sent some DNA from two of the families we were 
working on with Leeds, one of them being our Northumberland family, and that 
was the MSH2 family that appeared in Kolodner’s Cell paper, or one of them.171 
Harper: John, maybe I could just stop you there because we’ve had a good 
discussion earlier this afternoon on the research side and we’ve moved on now 
more to the applications. 
Burn: Well, it was relevant in a sense to our service because the minute we got 
that marker, we then kicked into predictive testing in our dominant families 
generally and meanwhile we’d appointed Fiona Douglas as a consultant and 
specialist, round about the mid-1990s.172 We started systematically developing 
cancer genetics in our clinics like everyone else. I guess my other generic 
observation was that I, by then, had become very involved with the Cancer 
Family Study Group of which Tim was the secretary.173 In 1996 I became the 
chair of that group and, having just finished the construction of the BSHG 
along with Peter Farndon and yourself [Harper] and others, it seemed to me 
that we needed to bring that group closer to the BSHG.174 So, as chairman in 
the period from 1996 to 2002, I was mainly involved from an administrative 
point of view in a sense, or a political view, of getting that group to become the 
Cancer Genetics Group of the BSHG, in 2000, which of course Gareth and 
others now run extremely well and it continues to prosper.175
170 See note 154 for Ponder and note 114 for Kolodner. 
171 See discussion on pages 39–40 and Kolodner et al. (1994). 
172 Dr Fiona Douglas is now a Consultant in Clinical Genetics at the Institute of Genetic Medicine, 
International Centre for Life, Newcastle upon Tyne; http://www.newcastle-hospitals.org.uk/staff-
profiles/12872.aspx (visited 26 February 2013). 
173 See pages 10–15, and introduction. 
174 Dr Peter Farndon was based at the Clinical Genetics Unit of Birmingham Maternity Hospital. 
175 See Professor Gareth Evans’ comments on pages 15–16. 
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Bodmer: I’d just like to say a little bit from the organizational viewpoint of the 
role that I was able to play from the ICRF because we’d mentioned the Cancer 
Family Study Group and that made me aware at least of the amount that could 
be done – having genetics clinics looking at cancer as an adult thing was not 
the traditional goal of genetics clinics. So, having seen also what could be done 
at St Mark’s, in the ICRF we thought there was a case for trying to create 
places where cancer family studies and genetics would be done in association 
with oncology units. Outside St Mark’s, I think the first group that we set up 
formally was the one that I’ve already mentioned with the genetic epidemiology 
unit in Leeds, originally under Ray Cartwright, starting in 1987 and then 
taken over a couple of years later in 1989 by Tim Bishop when he came from 
the States. That then grew further. Though the ICRF didn’t actually formally 
provide grants, we felt there was a case for providing some support in a number 
of places where there was an opportunity to develop cancer family clinics in the 
way that we’ve heard. As John’s mentioned, one of the people we supported was 
Pam Chapman in Newcastle, we also provided some support in Cardiff. These 
grants were generally to fund someone like a nurse, who could be involved in 
helping with the aspects of the cancer family clinic that went alongside what 
the genetic consultant would do. In the end, because we’d set up an oncology 
unit in Oxford, it seemed to make sense to set up something there. That’s when 
George Fraser started a cancer family clinic quite specifically in Oxford, in 
1990.176 There was also some support of Kay McDermot, I think in the Royal 
Free, and Vicky Murday had moved up to Leeds to be the consultant there.177 
So what we felt we were doing was helping, of course, to set up cancer family 
clinics in different centres where there was strong oncology. That contributed 
significantly to the development of this idea. Nick Wright, who became the 
Director of Clinical Research at the ICRF, was very helpful in discussing these 
developments, and in the annual reports of around 1991/92, Nick made very 
specific mention of the role the ICRF was playing in supporting cancer family 
clinic activities and quite specifically he mentioned in the 1991/92 report that 
this was a responsibility for the care of patients in that setting, that should be 
176 See note 179. 
177 Dr Kay McDermot succeeded Dr Joan Slack as Consultant/Senior Lecturer for the Royal Free Hospital’s 
Department of Clinical Genetics; see note 145. Dr McDermot wrote: ‘Subsequently I moved to Imperial 
(regional genetic unit at Northwick Park Hospital) as Consultant/Senior Lecturer and have since retired.’ 
Email to Ms Emma Jones, 17 April 2013. 
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taken over by the NHS.178 We’d had a lot of discussion about that and how 
that could be achieved. As I recall, and I thought you [Harper] might have 
been involved in this, or John Burn might remember better, there was a group 
of people who actually gathered together to make the case to the NHS that 
this should be a provision that was arranged to be throughout the country 
in an appropriate setting where you can have the family clinic alongside the 
oncology provisions that were needed to deal with the cancer cases. I’m not sure 
what happened to that, and then that led to the sort of network that John has 
mentioned and he can probably comment more because by the time that was 
going, I was leaving the ICRF.
Professor George fraser: I have a paper with me which describes the main 
features of the Oxford Imperial Cancer Research Fund Genetic Clinic in its 
first seven years, between 1990 and 1996, and the marked increase in patient 
referrals which occurred during those years.179 Comments about such large 
increases have been made in the cases of other clinics mentioned at this seminar. 
I was told two years ago by a colleague in the Department of Clinical Genetics 
178 Imperial Cancer Research Fund (1992). See, in particular, Wright N A ‘clinical research’, pages xvii–viii. 
179 Fraser (1999). Professor George Fraser wrote: ‘36 patients [were] referred in 1990 and 2165 patients 
[were] referred in 1996.’ Letter to Ms Caroline Overy, 12 November 2012. 
figure 18: Professor George fraser. 
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in Oxford that in 2010 – thirteen years after I had retired in September 1997 
– referrals with respect to cancer made up as many as 50 per cent of all referrals 
to the department for counselling. I started the clinic on 1 January 1990 in 
collaboration with Dick Lindenbaum, a consultant in the department. I have 
always been extremely grateful to him for having made it possible for me to 
join the department in 1985 as an honorary consultant in connection with 
my employment by the ICRF. Susan Huson, a recently arrived consultant to 
the Department of Clinical Genetics, was a third member of the clinic at its 
outset.180 Sadly, Dick died in April 1992.181 I then directed the Oxford Imperial 
Cancer Research Fund Genetic Clinic in collaboration with Susan until my 
retirement in 1997. 
møller: I would like to mention two very brief examples to bridge a gap 
between research and today’s clinical practice. One is that, once upon a time, I 
was looking for something and found something else: MSH6.182 The problem 
with MSH6 is not that it has high penetrance for endometrial cancer; it’s less 
penetrant for endometrial cancer than MSH2. The problem is the lack of colon 
cancer – if that’s a problem – making MSH6-associated disease a sex-limited 
trait, not having complete penetrance and escaping all the clinical definitions of 
Lynch syndrome because of the skipped male generations.183 As Patrick Watson 
– the statistical guy in Henry Lynch’s group – always remarked: The Amsterdam 
180 Professor George Fraser wrote: ‘Dr Susan Huson was a Consultant in Clinical Genetics throughout her 
time in Oxford [1989–2004].’ Email to Ms Emma Jones, 4 March 2013. See also http://www.mangen.co.uk/
PersonnelDetail/185.aspx. Dr Huson is a now Consultant in Clinical Genetics to the Central Manchester 
University Hospitals NHS Foundation Trust; http://www.cmft.nhs.uk/saint-marys/our-services/clinical-
genetics.aspx (both websites visited 20 February 2013). 
181 For his obituary, see Sacks (1992).
182 Dr Pål Møller wrote: ‘In the Dutch–Norwegian collaboration we had published that the key clinical 
information to identify a mutation-carrying family with MLH1 or MSH2 mutations, was endometrial 
cancer. This observation was but reflecting the obvious interpretation of the Warthin family G from 1913, 
and was among the arguments for ICG-HNPCC to revise the Amsterdam Criteria to include endometrial 
cancer as affected phenotype (to be known as AMSII criteria). We then set out to look for modifiers of 
penetrance/expression of MSH2 putatively determining who might contract endometrial cancer. Because 
of the biological relation between MSH2 and MSH6, the latter was an obvious place to start looking. We 
did find no modifying effect of MSH6, what we found was that MSH6 was a major factor causing Lynch 
syndrome by itself when mutated, but predominantly endometrial cancer.’ Note on draft transcript, 22 
October 2012. See Wijnen et al. (1998; 1999). 
183 See Sjursen et al. (2010). 
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criteria were never meant for clinical practice.184 We have for years been part of 
the collaborative networks to find the prostate cancer genes, which were never 
found because we have looked for them with the concept of one, or a few, 
highly penetrant dominant gene, or genes, which was a wrong concept. Then 
we looked into our Lynch families and found that mismatch repair mutation 
carriers have as much prostate cancer as BRCA2 mutation carriers.185 So what 
do we have to do now? We can’t run clinical practice based on the old research 
terms, we had to go into these families by extended segregation analysis and 
prospective studies to redefine the penetrance and expression of the mutated 
genes because the current clinical criteria are based upon outdated research 
concepts. You cannot determine in advance what to find and look for finding 
that only. We have to get out of the logical flaw of describing our selection 
criteria as research findings.
Green: As far as the prostate cancer in MSH2, I totally agree. One reason I 
think this was missed earlier was because so much early death from colon cancer 
meant that men didn’t survive long enough to then have prostate cancer, but 
we definitely see this now. All our cancer genetics was clinical right from 1982 
when the VHL family was referred to the ocular genetics clinic. There was a 
need there; it was clear. There were six sisters, three of whom were noted to be 
affected at that time. There was obviously more family history; there was more 
than just the eye examinations they needed. Therefore it was necessary to get 
everyone, all the specialists, together to deal with it. Because Newfoundland is 
also extremely rural, there are very long distances and very small communities so 
that you can’t have your cancer genetics service in each community. It’s organized 
from St John’s, the capital, where the main tertiary care hospital is located. But 
for VHL, then MEN2, MEN1, FAP and HNPCC potential carriers, it was 
necessary to get their family history, review the records to see who actually was 
affected, and to find the full details of the cancers seen.186 This was how the 
screening was organized. From the first day people were met in their homes to 
get family history, they were immediately given a letter, a follow-up letter and 
the screening recommendations. If there was new knowledge then there was 
184 See note 53 for the Amsterdam criteria. Dr Pål Møller wrote: ‘They were a research tool to identify a 
few families to find the genes. Their positive and negative predictive values in clinical settings were never 
documented; their purpose was to find some mutation-carrying families to study (high specificity), not to 
find them all (low sensitivity).’ Note on draft transcript, 22 October 2012.
185 See Grindedal et al. (2009). 
186 See Green (1995). 
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010
62
another letter. Every time going out to the communities, we went to the rural 
hospitals or the family doctors in the area to let them know what family history 
was there. Because if we knew that there was a big MEN1 family and we had 
four branches, there could be a fifth branch or a sixth branch and we had to 
make sure that the family doctors in these areas knew about MEN1 if they were 
in that area. With the atypical MEN1, every Newfoundland family has its own 
characteristics and if you’re in the North East then it’s the AFAP and somewhere 
else the HNPCC. So our aim was to educate local healthcare providers so that 
they could help in identifying new cases and help in the screening that could 
be organized. In doing this, the AFAP family was initially recognized as typical 
FAP because of individuals with hundreds or thousands of polyps. Reviewing 
the family history and records, there were 93 members affected at that time. 
A third had only right-sided polyps; a third had less than 100 polyps but it 
wasn’t necessarily the same third; some had as few as 10 at the time of cancer. 
There were individuals who were screened and had no polyps until they were 
46 but now our youngest three, with colectomies because of the number of 
polyps, have been 10 and 11 years of age. It concerns me when I see literature 
that talks about attenuated FAP as ‘late onset’, ‘mild’, ‘lower risk of cancer’. In 
our family and in the large Utah family that Randy Burt has published about, 
there is as high a risk of cancer but there is variability in number, age at onset 
of polyps and their location.187 As I see it, this variability is the key to AFAP. If 
you have a small family, you may not see that and you may start screening and 
think that you should start screening members in their twenties but somebody 
will have cancer before that. So I think that these large families can be very 
instructive beyond the location that they occur. What we did was to go out 
and make sure that the family doctors, the rural doctors, knew what was there 
and knew how to recognize these families. We also now have what’s called the 
Community Cancer Genetics Clinics so that every person with colon cancer has 
an option of referral for review of their pedigree so they can be counselled about 
whether they belong to the group that should have the faecal occult blood test 
(FOBT) or the faecal immunochemical test (FIT) for family members, or an 
intermediate screening or the high-risk screening. The same people who were 
one day dealing with the colon cancer families, HNPCC or FAP, might the next 
day be dealing with VHL or MEN1, or breast cancer. We don’t have enough 
187 Professor Randall Burt is the Senior Director of Prevention and Outreach at the Huntsman Cancer 
Institute, and Director of the Familial Colon Cancer Clinic, University of Utah. Further biographical 
details are available at http://www.huntsmancancer.org/research/cancer-investigators/burt-randall (visited 
15 January 2013). See also, for example, Kerber et al. (2005). 
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staff to have separate clinics for all of these cancers. This is a service that needs 
to provide for those families that have these higher risks – then you can think 
breast cancer one day and FAP another day.
Harper: We’ve talked so far mainly about colorectal cancer and a little bit about 
breast cancer services, but you’ve brought up some of these rarer, more specific 
syndromes, including VHL. I’d like to ask Eamonn Maher to say a bit about how 
the services evolved for that particular condition, at least in the West Midlands.
Professor eamonn maher: Probably I should start off by describing the 
developments in East Anglia. I started in genetics in Cambridge in 1988 and 
John Yates handed me a paper to say that the VHL gene had just been mapped 
to chromosome 3 and why don’t we study this?188 Prior to this there had been 
a very nice paper from Cardiff, with Susan Huson as the first author describing 
VHL families studied in Cardiff.189 Like so much of what we’ve heard today, the 
initial driver to setting up new clinical services for VHL patients in Cambridge 
was the fact that we were starting a research study. We were collecting families 
for linkage studies and we needed to evaluate affected and apparently unaffected 
members of the family to see whether they were sub-clinically affected. This 
involved putting the at-risk relatives of the patients through the clinical genetics 
188 In 1988 Professor John Yates had an academic post at the University of Cambridge, subsequently 
becoming Reader (2001) and then Professor of Medical Genetics (2003). He contributed to the History of 
Modern Biomedicine Group’s Witness Seminar on Clinical Molecular Genetics in the UK c.1975–c.2000, in 
February 2013, which is scheduled to be published in 2014. See also Seizinger et al. (1988). 
189 See note 180. Huson et al. (1986). 
figure 19: Professor eamonn maher. 
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eye clinic that was run with Tony Moore, then in Cambridge and now based at 
Moorfields Eye Hospital.190 We also screened them for kidney tumours and in the 
first few patients we studied, we detected sub-clinical retinal angiomas and renal 
tumours and so our radiological colleagues were happy for us to implement a 
screening protocol similar to that which Susan Huson and others had suggested 
previously. As we went round the country collecting VHL families, we found 
that most were not under surveillance and they needed local follow-up and 
screening and, more often than not, that was done through a local geneticist. 
So that was my experience of how VHL clinics developed. One other thing I 
would like to mention, that perhaps hasn’t come out yet, was just how exciting 
at the time everything seemed because there were amazing scientific discoveries 
being made and at the same time we were inventing new clinical services to try 
and match up with the scientific developments. Then, the number of people in 
clinical cancer genetics was quite small, probably just one or two people from 
each genetics centre, so you’d be able to ring up the person in Manchester, such 
as Gareth, and swap anecdotes and ask for patients, etc. Talking about FAP, and 
John Burn will confirm this, for a while ophthalmologists were really critical 
in the stratification of FAP patients because we were all looking for congenital 
hypertrophy of retinal pigment epithelium, or ‘chirpies’ [CHRPEs] as John 
helpfully put it. That involved setting up special clinics for these patients, or at 
least putting them through the eye genetics clinics that we had.191 
Harper: John, do you want to say a quick word about the CHRPEs while 
Eamonn’s brought them up?
Burn: I should insert by the way that Grace Aherne, working with Derek 
Roberts, used to work with the ophthalmologists.192 She had a really good 
handle on all the retinoblastomas so there was some genetic cancer work going 
on. But yes, when I got into FAP, I was looking for something to work on and 
190 See, for example, Maher et al. (1990). The clinic in Cambridge was based at Addenbrooke’s Hospital. 
Ms Samantha Lawrence, Moorfields Eye Hospital, wrote: ‘Anthony Moore is a Professor of Ophthalmology 
at the UCL Institute of Ophthalmology. He is an honorary consultant ophthalmologist at the Hospital for 
Children, Great Ormond Street, London and Moorfields Eye Hospital, London.’ Email to Ms Emma Jones, 
1 February 2013. 
191 See Hodgson et al. (1994). 
192 Dr Grace Aherne was a clinical assistant in the Department of Human Genetics, Newcastle University. 
Derek Roberts (b.1925) was a Professor of Human Genetics at the University of Newcastle upon Tyne until 
his retirement in 1990; see Harper et al. (eds) (2010), pages 46–7. 
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we landed on this not very well-realized observation that there was this extra 
colonic feature of, as I jokingly said to the surgeons, ‘little black dots on the 
back of your eye’. We got lots of people and tested them and demonstrated you 
could very reliably identify the gene carriers on the basis of that feature in a very 
substantial proportion of families. In parentheses, my wife never forgave me: I 
used her as a control in the study and a not very sensitive ophthalmologist told 
her that if she didn’t stop using contact lenses she’d go blind. She blamed me 
for that for some reason. So we did start to diversify into a broader perspective 
rather than just looking at colorectal surgical intervention. If I could just say 
generally on that point: Eamonn picked up a very key point there that we 
went through phases. In our previous Witness Seminar we talked about how 
dysmorphology flowered in the 1970s and 1980s, and really overgrew, if you 
like, as a specialty.193 Then, at the end of the 1980s and early 1990s, when 
the capacity to do monogenic diagnosis really started to kick in, that started 
to change the temperature again. In particular, Gareth and others started to 
bring in systematic approaches to the big ticket cancers, breast and colon. We 
saw another change again because the counsellors really started to come into 
their own. It wasn’t necessary to understand all the Mendelian syndromes, you 
could actually start working on a more standardized care package and screening 
programme. For the first time it really started making a big difference to patient 
survival and long-term prognosis. I think that changed the nature again of our 
specialty in the late 1990s; around about the time the Cancer Family Study 
Group was transforming itself into more of a service type organization – and 
that was a big change.
Harper: I think the point you’ve made John, and the point Eamonn made about 
this extraordinary time of excitement, partly just because it was so exciting that 
all the genes were coming out, but also because the clinical studies were such 
an integral part of that, you really felt that you’d contributed something, it 
wasn’t just a question of handing over a few samples. The labs were dependent 
totally on getting the phenotype right and then at the same time there was this 
remarkably short interval between some apparently esoteric study or finding, 
and then being able to apply it, as with the DNA repair genes. Things sort of 
leapt from yeast to applications for human patients and that’s something we’ll 
come back to in a minute when we’re dealing with how perhaps the classical, 
surgical approaches had to cope with all these geneticists coming in. 
193 See Harper et al. (eds) (2010), pages 63–8.
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maher: I want to mention two quick things, one of which was the, let’s say, 
inventing of new services, or at least that is how it felt at the time, and how 
it seemed that we were doing it without a manual. Then Shirley Hodgson 
suggested that we write a book on cancer genetics which I think was certainly 
helpful at least for my education!194 In addition, when I moved from Cambridge 
to Birmingham in 1996 there was a slight change of climate there in terms of 
service provision so I went from a centre where Bruce Ponder was, and where 
there was a big interest in cancer genetics and we were almost encouraging 
referrals, to a centre where there had been this huge increase in referrals and 
they were thinking, ‘How on earth are we going to deal with this?’ At least 
in the West Midlands and probably beyond, Trevor Cole was very influential 
in the concept of triaging into those that really didn’t need to see a geneticist, 
those who just needed to be offered screening but didn’t require formal genetic 
assessment, and the high-risk ones who did need to see a geneticist.195
Harper: I think Trevor Cole had picked this up quite a bit from Jonathan Gray’s 
studies in Cardiff.196 I want to move across for a moment to another slightly 
parallel and similar condition, which is tuberous sclerosis. Julian, can you just 
tell us how the isolation of the genes helped in the way of developing our genetic 
and other services for that disorder?
sampson: The situation in disorders like tuberous sclerosis is very different 
because of the associated impact on cognition and behaviour, and reproductive 
fitness is very low. In a large proportion of cases, two-thirds are sporadic and the 
actual malignancy risk is very low, although tumours of the brain and kidney 
can be quite serious and require major interventions. So that is very different to 
the sort of situation that we’ve been talking about with dominant disorders that 
are associated with large families. That was the exception in tuberous sclerosis; 
the impacts have been very different. They’ve really been in relation to the 
availability through genetic testing of prenatal and preimplantation diagnosis. 
Clarification of genetic status in family members where that is uncertain, is 
194 Hodgson and Maher (1993). 
195 Trevor Cole was Consultant in Clinical and Cancer Genetics from 1992 to 2002 at the Birmingham 
Women’s NHS Foundation Trust, where he is now Consultant and Honorary Reader in Clinical and 
Cancer Genetics; http://www.bwhct.nhs.uk/research-and-development/key-researchers/trevor-cole (visited 
20 February 2013). 
196 Professor Jonathan Gray was Clinical Director of the All Wales Medical Genetics Service. See note 163. 
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much less of a problem than it is in the disorders with very much more age-
related penetrance that we’ve been talking about today. So I think the situation 
with tuberous sclerosis is quite different and really the impact is now turning 
into an impact on therapy based on an understanding of gene function. So yes, 
very different altogether to what we’ve been talking about so far. 
What I did want to mention was to pick up on some points from what Eamonn 
said in relation to the evolution of cancer genetics services. These were coupled 
early on to linkage studies where clinical phenotyping was very important. 
I think the development of these services during a phase of genetic linkage 
research studies helped to propel a very proactive philosophy of wanting to see 
all the family members and even wanting to see those clinically unaffected family 
members, perhaps whether they wanted to be seen or not. Very often, once they 
understood the situation, they did want to be involved but not always initially. 
That was rather different from the more reactive development of services for 
things like Huntington’s disease or even dysmorphology where really we were 
there to answer the patient’s immediate questions.197 In comparison, the focus 
in cancer families was often about future generations, which is something we 
tended to hear much more about. That pushed a proactive approach to cancer 
genetics which is beginning, certainly in some services – I think in ours – to 
disappear again because of concerns about confidentiality and data protection, 
partly because of the sheer volume of work. You can’t be absolutely proactive 
in working so rigorously through extended families. The things we heard 
about from Jane, this incredible genealogy that you were able to undertake in 
Newfoundland to work through these big families, and, similarly, the proactive 
approach that was taken for FAP and in VHL disease, is not entirely applicable 
now that we’re moving into situations where we’re dealing with genes of lower 
penetrance and less certain natural history and less efficacy of interventions for 
family members that are affected. There are much more difficult and personal 
decisions for people to take, such as having a prophylactic mastectomy as 
opposed to prophylactic colectomy that we’ve been talking about with FAP.198 
So I think things have changed in terms of the drivers, the philosophical drivers 
of the service delivery.
197 See Harper et al. (eds) (2010), pages 63–8; 76.
198 See, for example, Ghosh and Hartmann (2002). 
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evans: Coming back to the triage issue, in the breast cancer area it certainly 
became the way things were done, with local family history clinics in secondary 
care and then referring them up to tertiary care. That model is not complete 
around the country but it certainly is in some parts of the country, very much 
the model of secondary care family history and a tertiary care genetics clinic. 
That was encapsulated in part in the Harper report,199 and in fact in the Calman 
report,200 says someone smiling down on me from up there,201 and also the NHS 
Cancer Plan have formed really a lot of the thinking in the NICE Guideline 
Development Group for Breast Cancer.202 But in terms of bowel cancer, that 
really hasn’t happened in the same way. Yes, the screening occurs in secondary 
care but the development of secondary care bowel cancer family history clinics 
has not been so well done throughout the country. We do have a few around us 
in the North West of England but it has been much less the case.
lehmann: Somebody, I think it may have been Shirley, mentioned 
multidisciplinary teams and so I thought it might be of interest to recount our 
experience with xeroderma pigmentosum (XP). I’ve been doing lab diagnosis of 
XP for about 30 years and until 10 years ago I’d never seen a patient. I first saw 
them when the XP support group started having annual meetings. About three 
years ago a dermatologist from St Thomas’ put in an application to the NHS 
National Commissioning Group to set up a multidisciplinary clinic for XP and 
there’s something like 100 patients in the country.203 It’s a little bit like Jane was 
describing in Newfoundland – each patient is in a different part of the country 
so you can’t have a specialist who knows a lot about XP everywhere. So this clinic 
was set up and started about two and a half years ago. We have a dermatologist, 
ophthalmologist, neurologist, geneticist, psychologist and, very importantly, 
specialist nurses with myself as a consultant scientist and we’re closely tied in 
199 Department of Health (1996). This publication is more commonly known as the ‘Harper report’, as is 
usual after the Chairman. 
200 Department of Health and the Welsh Office (1995).
201 Professor Gareth Evans was referring to Sir Kenneth Calman’s appearance on the homepage of the website 
for the History of Modern Biomedicine Research Group, projected on a screen behind the Chairman during 
the meeting; http://www.history.qmul.ac.uk/research/modbiomed/index.html (visited 25 January 2013). 
202 See note 164. 
203 Guy’s and St Thomas’ Hospital’s XP Clinic, to quote from its website, is the ‘only designated national 
service for xeroderma pigmentosum’; http://www.guysandstthomas.nhs.uk/our-services/dermatology/
specialties/xeroderma-pigmentosum/overview.aspx (visited 15 January 2013). 
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with the support group.204 We see a few patients every couple of weeks and these 
patients really are seen by people who know a lot about the disorder, and the 
patients, I think, now are getting a much more satisfactory service. From my 
point of view, before we started I thought I knew everything there was to know 
about XP and, having started to see patients, I quickly realized that I knew very 
little about XP because every patient is different and none of them looks like the 
textbook. So that’s the way we’re going. We’re trying to now extend this model 
to other DNA repair disorders.
tansey: Can I just ask you to develop that a little bit because you mentioned 
multidisciplinary teams and I’d like to follow up on something that Shirley 
said; a number of you have raised the subject of funding, and only Walter 
has addressed it specifically. Getting multidisciplinary teams funded is often 
very difficult, so could you say something about how that happened and who 
negotiated it? 
lehmann: The lead on this was Dr Bob Sarkany. He was the dermatologist from 
St Thomas’ and he put in an application to the NHS National Commissioning 
Group, which has funds for these purposes. But obviously if everybody put in 
an application for all 5,000 genetic disorders the funding wouldn’t go round, 
so it sounds quite expensive, and it is, but once you’ve got approval then, as far 
as I understand it – I haven’t been directly involved – as long as the service is 
providing what it set out to do and you can show that the outcomes that you 
proposed have been fulfilled, then you get continued funding.
Phillips: I did want to comment on multidisciplinary funding and some of the 
other bits. I think it’s probably the relevant time. We were hearing how the field 
was changing and becoming more exciting. I can tell you, from my point of view, 
it was changing and it was frustrating because we had enormous difficulties with 
funding. We had absolutely no NHS funding for being able to do these things and 
also the NHS was changing, you went through different processes. You could go 
forward and sometimes you could price things and make a charging band out of 
it to try and get the money. For example, how much were you going to charge for 
DNA analysis and how much were you going to charge for checking for a known 
mutation? The laboratories that had done the work were research laboratories 
and they couldn’t be trusted in terms of the sequence, whether it was the blood 
result of that named individual. The quality that you got was much better in 
an NHS service laboratory, with the checking of the patient identity as samples 
204 For the XP Support Group, see http://xpsupportgroup.org.uk/ (visited 16 April 2013). 
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went through: the fact is that you could actually get samples muddled in research 
laboratories.205 We were having to deal with this and trying to come up with 
policies in a research laboratory: when we got a result we had to repeat it. It was 
only when we got two matching results from a research laboratory that we would 
accept it. We had difficulties because the surgical staff didn’t really understand a 
lot of what was going on as far as we were concerned: germline was something to 
do with a species of bacteria. [Laughter]206 Our level of knowledge of these things 
was very different. Then we were confronted by the fact that the geneticists 
knew absolutely nothing about the subject – they didn’t know anything about 
polyposis. They needed to be educated in polyposis, but they didn’t know that 
they knew nothing about polyposis. So we had those frustrations. Then we had 
the issue that we had our own patients that came to St Mark’s but we were aware 
that, in the Thames regions, there were a load of patients that weren’t coming to 
us and a woman called Joy Newman gave a sum of money and funded a thing 
called the Thames Region Polyposis Registry.207 But we had difficulties here 
because there were no controlling clinicians. Within St Mark’s Hospital each 
surgeon had a different antibiotic prophylaxis, a different bowel preparation, 
whether or not they used antithrombotic medication. To some extent we could 
manage patients within St Mark’s but you go out to the Thames regions, how are 
you going to deal with this because these patients weren’t ‘owned’ by us. If we 
started tracking or doing things about these patients, it was almost impossible to 
know how to influence practice, so this was a very, very hard time. 
Harper: Perhaps I ought to say something about the report which my name seems 
to have got attached to.208 I think the things that Robin has been mentioning led 
to the need to try and get some not just widespread, but coordinated initiative 
205 A similar discussion occurred in a previous Witness Seminar; see Overy et al. (eds) (2012), pages 60–1 
(Dr Linda Tyfield) and page 63 (Dr Richard Jones). 
206 In genetics, the term ‘germ’ refers to the reproductive cell line, from which gametes originate, while 
surgical staff interpreted ‘germ’ in the bacteriological sense. 
207 Professor Robin Phillips wrote: ‘It was funded with money from one Dr Joy Newman, a medical 
practitioner with an interest in FAP, who made a substantial donation to St Mark’s Hospital. She was aware 
at the time of her donation of very uneven ascertainment of FAP cases in London, and little genetic interest, 
and wished through this Registry to help trace patients and put them in contact with their local (as opposed 
to St Mark’s) service.’ Note on draft transcript, 5 April 2013. Dr Joy Newman is listed as a Patron of the 
St Mark’s Hospital Foundation in its 2006 Annual Report; http://www.stmarksfoundation.org/uploads/
media/Annual_report_2006.pdf, see page 4 (visited 15 January 2013). 
208 See note 199. 
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of how cancer genetics services might and should evolve. I can’t even remember 
why I was asked to chair it – I think because I didn’t know terribly much about 
it. But my experience was a very positive one. We managed to get together a 
lot of the stakeholders, as they’re called now: surgeons, oncologists, geneticists, 
genetic counsellors, nurses and various others. The thing that impressed me 
was that people were remarkably willing to be cooperative and there was a 
distinct lack of territoriality, which actually did surprise me. Thinking about 
why this might be so, one of the things was that there was a huge amount 
of work to do, plenty to go round everybody, that it seemed to make sense 
to focus mainly on what people were good at and trained for. Clearly, in the 
case of affected individuals, it was the relevant clinical specialist, surgeon, 
oncologist, or whatever. But one thing that also impressed me fairly early on 
was that, actually, most surgeons or other clinical specialists don’t want to spend 
the majority of their time with completely healthy people, they’d prefer to be 
dealing with people that actually have the problem, whereas geneticists are quite 
used to dealing with ramifying families of whom perhaps the greater part are 
completely healthy and might not even carry the relevant gene. So things came 
together, in terms of that report at any rate, far more easily than I’d imagined. 
Then it disappeared into the bowels – a rather appropriate word perhaps – of 
the Department of Health (DoH) and it stayed there a long time and for some 
reason emerged in the form of a letter to the Chief Medical Officer because I 
was told at that time there was some political constraint against the department 
getting advice from anybody, or something like that.209 But I think that report 
did have some effect in getting things going and I know that people would take 
along a copy to their various authorities and say, ‘Look, it says in this DoH 
document that we ought to have this or that.’ The powers that be are always 
more impressed if you can wave a document at them than if you just talk to 
them, and I think this is what happened. One thing that did come up was this 
triage concept, again bringing in genetic counsellors and other groups for the 
large number of low-risk people, and that was particularly the case perhaps in 
breast cancer more than in colorectal cancer. Can I come back to you, Robin, 
perhaps and ask what do you think was the psychological aspect in terms of you 
being a surgeon? You’ve got a series of well-established tests for people at risk: at 
what point did you actually come to believe that this DNA worked?
209 Professor Peter Harper wrote: ‘The ‘letter’ to the CMO for England was not really a letter at all but was 
the report itself. For some obscure reason it could only be classified as a letter.’ Note on draft transcript, 
7 March 2013. 
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Phillips: I’m still learning. We set up a DNA testing service on our own through 
the Kennedy-Galton laboratories at Northwick Park and that was a big uphill 
struggle.210 I think the problem was the provenance of the blood and the results; 
we couldn’t trust it. Until you could go through an NHS screening laboratory 
with its set-up, you always had a little degree of uncertainty of what you were 
getting.211 If you got a negative result on a known mutation, had they mixed 
the blood sample? You had these sorts of issues. Now we’re perfectly in tune, if 
we know the mutation and are told there isn’t one, or the lab says there isn’t a 
mutation, we discharge the patient. We have little difficulty with that. If you 
say you can’t find the mutation, that’s another matter. It may be a different 
condition.
neale: I’d really like to say I think he’s being a bit unfair. [Laughter] Robin 
put an awful lot of effort into arranging for the funding of the NHS testing 
service to be started at St Mark’s and it was at the time when the Conservative 
government had the money following the patient.212 We in the registry had to 
do an enormous amount of work, making sure that the contracts went out and 
the contracts came back before we were allowed to test the patients. We had 
the most horrendous filing system that followed all these bits of paper round so 
that we didn’t do the test before we had the money, and Robin’s idea was that 
we would be the national testing centre, but of course other regional genetics 
centres soon set up their own and the system changed anyway so it didn’t matter. 
But when we first set it up, he’s right that we weren’t 100 per cent certain that 
we could trust the laboratory so we chose some family members that had got 
the condition, who had different names, and we sent them up to make sure we 
got the same result back on all of them.213 Of course, after one or two we really 
did trust them and it was an enormous amount of work at first because we had 
210 North West Thames Regional Genetics Service (Kennedy-Galton Centre), Middlesex, offers genetic 
counselling and diagnostic services in the catchment area of the North West London Hospitals NHS Trust, 
http://www.nwlh.nhs.uk/_microsites/nwthamesgenetics/ (visited 15 January 2013). The Service is one of 
the UK Genetic Testing Network (UKGTN) centres. The UKGTN ‘is a collaborative group of genetic 
testing laboratories, clinicians and commissioners of NHS genetic services and involves patient support 
groups’. Further details are available at http://www.ukgtn.nhs.uk/gtn/Home (visited 15 January 2013). 
211 See Bodmer’s and Harper’s comments on page 76. 
212 Lord Privy Seal (1972). This government publication is otherwise known as the ‘Rothschild report’. See 
also Reynolds and Tansey (eds) (2000), in particular pages 59–60. 
213 A similar story is recounted by Dr Felix Konotey-Ahulu in a Witness Seminar about developments in 
renal dialysis; Crowther et al. (eds) (2009), see pages 41–2. 
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a lot of patients that we had been screening for years that we could now offer 
a test and discharge. So it was wonderful for us in the Registry to give people 
that kind of reassurance. There were one or two patients, one gentleman in 
particular that I remember who had not had children because he was worried 
that one day he might be affected and could have the risk of passing polyposis 
on, and he was negative and went ahead and had a child. So it was a great time 
for us, but Robin did fight for that to be set up for us.
Burn: I would just like to add another dimension to what Robin and Kay have 
been saying because they played an absolutely pivotal role in getting this whole 
service going and we became very closely involved with them. There was an 
obvious, understandable tension which I think was widespread. On the one 
hand surgeons were used to seeing polyps; much more physical, identifiable, 
proof of disease status. And here were these new guys coming along saying, ‘I’ve 
done this test and the patient doesn’t need checking.’ There was this awful urge 
to have another quick look just to be on the safe side. We, on the other hand, 
were perhaps a little bit too cavalier, as Robin said, about saying our research 
laboratories were reliable at the very beginning. I think there was an inevitable 
tension between the ‘novelty seeking behaviour people’ rushing on ahead and 
the ‘people who are used to another way of doing it’ hanging back a bit. We 
were in tension for a while as we gradually got the service going but that was a 
healthy tension. The one thing I would say is that throughout this whole period, 
colorectal cancer was being marked by an incredibly close working relationship 
between the colorectal surgeons and the geneticists for the reasons Peter said, 
because the surgeons are more than happy to hand over the healthy people for 
us to do the talking to. I think there’s a distinction there in other specialties 
where physicians see themselves perfectly capable of talking to the healthy 
people as well. The other thing I wanted to say on the Harper report, which was 
undoubtedly very influential – there was a time, you might remember, Peter, 
near the time it was published, when we ended up in a huddle, I think you, me 
and James MacKay tried to thrash out some of the difficult points.214 The point 
which I lost on – and I’m not sure still whether history will record it as right or 
wrong – but James was very keen that we actually move towards having cancer 
geneticists who had an oncology and genetics background, trying to create in 
essence a new subspecialty. I was keener on the generic geneticist retraining 
away from what we did before to what we would do in the future. I think we 
214 Dr James MacKay was a member of the Working Group for the Harper report, as Consultant Oncologist, 
Addenbrooke’s Hospital, Cambridge. See note 199.
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ended up somewhere in between, where all geneticists now do a bit of cancer 
work, but there are some who are much more, like Gareth [Evans] and others, 
who are much more in the oncological field. I think that’s as it should be. We’ll 
probably end up with a mixed model. Your report was a different approach to 
the one we’d done with St Mark’s, and so many other rare disease areas, where 
enthusiasts build it up in the hope that the money will come. But the NHS is 
incredibly slow at adopting those services and we often really fly on a wing and 
a prayer for far too long as a result of that. 
møller: I would like to follow up on this and also on Julian’s comment. Bodmer 
and I both came from HLA genetics – we know the genes, we know the 
environmental triggers, but there is no prevention, no cure for diabetes, nor for 
rheumatoid arthritis, nor for ankylosing spondylitis. What I think happened, 
and still is happening, was that anticipated results are oversold on false premises, 
especially by the labs. Understanding the genetics of cancer does not imply that 
we can crack the code for cancer, that we can prevent it or cure it in a short 
time. People have, by now, understood that cancer genetics wasn’t a quick and 
easy way to understand and cure cancer. I think we must go back and redefine 
that we are dealing with, a relatively small subsample in the population with 
an extremely high risk for something we can do something about. We have to 
sell this concept of cancer genetics. I learned this at the time I was a delegate 
from the EC Biomed2 Demonstration Project on Familial Breast Cancer, in 
1999, at a ‘farm’ in the countryside in the UK, where I was trained on how 
to communicate with journalists.215 The ‘farm’ turned out to be the HUGO 
Centre, Hinxton Hall, and the teachers turned out to be the BBC television 
programme Horizon team, and then I was taught how to stand in front of a 
215 The project’s full title was EC BIOMED 2: DEMONSTRATION PROJECT, Familial Breast Cancer: 
Audit of a New Development in Medical Practice in European Centres. Dr Pål Møller elaborated: ‘The 
Demonstration Project on Familial Breast Cancer ended up with a European conference in 1999 in 
Heidelberg, attended by delegates from 34 European countries where we formatted European guidelines 
for the use of BRCA testing and carrier management. We at the time found ourselves in the debate on 
patenting genes. We had visited Myriad Genetics in Salt Lake City. We told them we did not like patenting 
genes, and Myriad Genetics said they would take legal actions against us for violating their patent rights. 
Despite Myriad Genetics having obtained the rights from the European Patent Office, however, we through 
a number of affiliations and actions made it so they were never able to invoke their patent rights in Europe. 
One of the directors of Myriad Genetics later visited me to learn how we did it, and I told him that I, 
having learned how to twist the population’s opinion at Hinxton Hall when, a short time thereafter, I was 
invited to a TV discussion on something else, and made a representation for the largest political party to 
take the position against patenting genes in 90 seconds. It was an interesting time.’ Note on draft transcript, 
22 March 2013. 
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camera and sell a story.216 At the end, my capacity as a salesman was judged by 
the head of Smith Kline Beecham in the UK. For the purpose, I invented a story 
that I had a pill which could prevent all inherited breast cancer and he asked, 
‘How many carriers are there in Europe?’ I said, ‘About two million.’ And he 
said, ‘Are you crazy? Do you know what it costs to develop a medicine? We will 
never go into it.’ That attitude was the reason why the European Commission 
developed Orphanet and Orphan Drugs as a concept.217 They wouldn’t accept 
the commercial companies ignoring minority groups because they don’t make 
money. I think we should go back now and say, ‘We are not solving the riddle 
of cancer. We are doing genetics, but genetics is only a tool.’ We have to sell 
that story. 
sampson: Pål’s moving into the future of history! I wanted to just go back to 
that time when FAP molecular diagnosis was first introduced. Certainly we, and 
I know a lot of other people as well, actually introduced molecular diagnosis at 
a time before the gene was identified by using linked markers. I think it’s very 
understandable that some clinicians outside of clinical genetics were reluctant to 
incorporate this approach because we talked about risks rather than certainties, 
we had recombination risks with these markers. That period lasted actually for 
a couple of years until 1991 or so and during that time we never gave any 
definitive answers. Even once we did, people were initially reluctant to use this 
DNA diagnostically in a clinical setting. We were also very cautious even within 
genetic services. I can remember when we started doing these tests, even using 
direct mutation analysis for predictive tests, we did this on duplicate samples. 
We did all the tests twice and we used to suggest that polyposis patients with 
a negative gene test had a colonoscopy at 21 years of age. These things were 
only dropped slowly even within genetic services, so actually there was a very 
cautious approach that was played out over a number of years. 
216 The Human Genome Centre is part of the Wellcome Trust Genome Campus, incorporating the Sanger 
Institute, which is located in the grounds of the Hinxton Hall Estate, http://www.wellcome.ac.uk/Funding/
Biomedical-science/Funded-projects/Major-initiatives/Wellcome-Trust-Sanger-Institute/Wellcome-Trust-
Genome-Campus/index.htm (visited 15 January 2013). Hinxton Hall is a Wellcome Trust Conference 
Centre (visited 23 October 2012). 
217 ‘Orphanet is the reference portal for information on rare diseases and orphan drugs, for all audiences. 
Orphanet’s aim is to help improve the diagnosis, care and treatment of patients with rare diseases.’ It is an 
alliance of circa 40 countries, with funding from the European Commission and the French government, 
and from individual countries for their nationally based initiatives; http://www.orpha.net/consor/cgi-bin/
Education_AboutOrphanet.php?lng=EN (viewed 20 February 2013). Quote from website.
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Bodmer: A general point listening to this. As you know, I’ve been involved in 
the HLA field for many, many years and we were often called on, say, to do B27 
typing, whether it was useful or not for ankylosing spondylitis. I was always, 
and I remain, against a research lab doing a service. They’re not set up to do 
it, they don’t have the rigour of following the paperwork and other things. I 
think that’s a very important point to take into account. It’s not that they’re 
incompetent, it’s that they’re not set up to do these things in the way they have 
to be done in order to absolutely minimize the risk of making any mistakes.218 
Harper: I think it’s a very important point, Walter. And as a corollary to that, 
which worries me greatly, in America it is now mandatory for research labs to 
have to transmit the results to the patient or family, which I think is fraught 
with trouble simply because of the potential for errors.219 Whereas here, on the 
whole, I think the policy has been across the board, certainly in genetic testing, 
for as soon as something is validated, the results have to be transferred to a 
service lab, with all the different attitudes and particularities that they may have. 
evans: I absolutely do not regret that period of time when we weren’t absolutely 
certain, when we went from linkage to mutation and analysis, although obviously 
when you look at it in the cold light of day, we were saying, ‘Well, actually this 
person’s bowel cancer risk goes up from four to five per cent because of the one per 
cent chance you might be wrong.’ Whereas, in reality, we wouldn’t be screening 
anyone in the general population for a risk that goes up from four to five per 
cent. I think one of the main areas damage was done, because of that transition 
period, was actually in MEN2 where there are a number of documented cases 
of people who had low-risk results who continued to get screened and ended up 
having thyroidectomies and then were later found out not to be gene carriers, 
which is perhaps a little worse than having a few more colonoscopies. My big 
anecdote, from a long time ago, is actually about someone who ended up with 
a colectomy and had been rigorously screened in their rectum for the past 30 
years with annual sigmoidoscopies. It struck me why they hadn’t found a single 
polyp and so I went back, we did the genetic test and they didn’t have the 
mutation, so we then had to rebleed them because we didn’t believe the result. 
218 See also comments from Neale and Phillips, page 72 and Burn, page 73.
219 Professor Peter Harper wrote: ‘My statement about release of research results being mandatory in US 
is probably a bit strong … I don’t think there has ever been a specific ruling. It is more that there is a 
presumption in favour of release of information, even when this is not specifically indicated in the protocol.’ 
Email to Ms Emma Jones, 16 April 2013. 
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Of course, they still didn’t have the mutation and we found out that the surgeon 
had actually not done a rigid siggie [sigmoidoscopy] but had done a laparotomy 
and had a feel of the bowel on the outside, didn’t like the feel of it, so he’d taken 
the colon out. I actually got the original lab report and there were no polyps in 
the colon and he’d been having rigid siggies for 30 years. 
Harper: I’m sure none of the surgeons here would approve of that. 
Burn: I’ve actually seen a similar case where a barium enema was misread and 
‘miraculously’ the pathology report, which definitely proved that the patient did 
not in fact have the disease, disappeared from the records. So I’m sure it’s not 
an entirely isolated case.
Harper: One area I’m very glad we’ve got John Burn to connect us up on, but 
there are several people to contribute to, is the various groups – national and 
international – and how they have evolved. We’ve heard a bit about the Cancer 
Family Study Group, but more specifically to polyposis and colorectal cancer 
there’s the Leeds Castle group and now InSiGHT [International Society for 
Gastrointestinal Hereditary Tumours].220 John, from a distance, perhaps you 
can lead us into this and describe how they’ve evolved from what they started 
with into the present situation.
Burn: Well, you have an equally expert person with Robin Phillips there who’s 
been executive officer of InSiGHT, but, very briefly, the Leeds Castle group was 
very much around FAP. Hans Vasen and Henry Lynch set up the ICG-HNPCC 
which I mentioned earlier. Many of us stood back but then got drawn in. Then 
through the 1990s, because of my involvement with the cancer genetics groups 
and through the CAPP studies, I became very involved with both groups and 
a number of us started to see the logic of us bringing them together into a 
single organization. Eventually, we started running them in parallel. We had a 
couple of meetings sailing side by side, and then we had a meeting in Buffalo 
where we officially created the society and I can lay claim to the acronym. But 
it was actually trying to hang onto Hans Vasen’s ‘hereditary tumours’ title at his 
institute, so I suggested International Society for Gastrointestinal Hereditary 
Tumours, which is a bit clumsy, but InSiGHT is a very memorable term. That 
was in 2003 and we had our first official InSiGHT meeting where that was the 
220 InSiGHT is one of the contemporary incarnations of this group. The present society is an international, 
multidisciplinary scientific body dedicated to the improvement of care of patients with hereditary 
gastrointestinal tumours and their families; http://www.insight-group.org/ (visited 21 December 2012). 
See also note 52.
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010
78
name on the door in Newcastle in 2005 and it’s carried on every two years ever 
since and continues to grow from strength to strength and has about 400 to 500 
people – the next one’s in Australia – but the Leeds Castle stuff was first one out 
of the door and Robin is the expert on that.
Phillips: I think Kay Neale will be able to say more accurately but one of the 
main points about it was that it was a multidisciplinary senior discussion group 
– that was the major thing that it was supposed to be. 
neale: Yes, it started in 1985 when Sir Ian Todd had a patient with a huge 
desmoid tumour which he didn’t know how to treat.221 In 1985 St Mark’s had 
its 150th anniversary meeting so, tagged onto the end of that, Sir Walter helped 
to fund a meeting at Leeds Castle in Kent through the ICRF where the people 
around the world known to have expertise in polyposis were invited.222 I think 
there were 32 people, something like that. At that meeting it was agreed that 
it would be beneficial to have an international group so that these very rare 
incidences of extra-colonic manifestations of polyposis could be researched by 
joining together internationally. In 1987 Dr Jerry DeCosse completely funded 
the second meeting in Washington for about 50 people.223 Then, in 1989, we 
had another meeting in England, in Wiltshire, where we began to realize that 
people were getting to know about the group and didn’t like the idea that it was 
only specialists. We began to realize that we should be spreading the word to 
new registries, we shouldn’t only have experts and we should also be teaching. 
At that meeting we elected our first official Chairman who was David Jagelman 
221 Ms Kay Neale wrote: ‘Sir Ian Todd wished to seek information from clinicians around the world 
regarding the treatment of desmoid disease; his young patient had an abdominal desmoid tumour so large 
that she looked to be nine months pregnant. As a result of the meeting of 32 experts at Leeds Castle in 1985 
he learned that no-one had the answer.’ Note on draft transcript, 5 April 2013. 
222 See Neale and Bülow (2003). 
223 Dr Jerome DeCosse (d. 2001) was the Professor and Vice Chairman of the Department of Surgery 
at Weill Medical College, Cornell University and New York Presbyterian Hospital from 1978, where 
he specialised in the diagnosis, treatment and prevention of colorectal cancer; http://www.nytimes.
com/2001/04/26/classified/paid-notice-deaths-decosse-jerome-j-md-phd.html (visited 16 January 2013). 
In 1988 the Leeds Castle Polyposis Group’s membership comprised of the Cleveland Clinic Foundation, 
Johns Hopkins Hospital and New York Hospital – Cornell Medical Center in the USA; Rigshospitalet, 
Denmark; Helsinki University, Finland; St Mark’s Hospital, UK; Mayo Clinic, USA; Tokyo University 
Hospital, Japan; St Erik’s Hospital, Sweden and Toronto General Hospital, Canada; information from 
Jagelman et al. (1988). 
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of the Cleveland Clinic,224 Florida, and the Deputy Chair was Steffen Bülow 
from Denmark.225 So the next meeting was arranged for Cleveland and then the 
one after that in Denmark. From there we’ve gone on every two years growing 
in size until, as John said, we became formally InSiGHT in 2005 and in 2010 
we became incorporated as a company and registered charity. Now we’re a 
registered charity, we can raise our own funds and we’re heavily involved with 
the Human Variome Project which is mainly run by Dr Finlay Macrae from 
Melbourne in Australia.226 
møller: Just to add to that: being involved in both colorectal cancer and breast 
cancer, we are clinically drowning in familial and inherited breast cancer. The 
difference between the research organizations for inherited colorectal cancers 
and for inherited breast cancers was interesting. ICG-HNPCC had, from the 
start onwards, the interdisciplinary structure with the recognition of both lab 
personnel, surgeons and clinical geneticists.227 The inherited colorectal research 
groups have, through this, been extremely pleasant to be part of.
Harper: Thank you. We haven’t really said much about genetic counsellors. I 
don’t know whether Chris Harocopos wants to add anything or do you think 
it’s been covered reasonably well?
ms Christina Harocopos: I started long before they had the genes but I certainly 
was a CNS [clinical nursing sister] who set up the Family Cancer Clinic at St 
Mark’s in 1986. I was employed as a genetic research assistant and family visitor 
to record information, take pedigrees and contact family members. Data was 
224 Dr David Gordon Jagelman (1939–1993) was the Founder and Director of the Cleveland Clinic’s Familial 
Polyposis Registry. For his full biography see http://my.clevelandclinic.org/digestive_diseases/departments-
centers/colorectal-surgery/weiss-center-hereditary-colorectal-neoplasia.aspx (visited 16 January 2013). 
225 See note 80. In 1985, when the Leeds Castle meeting took place, Dr Steffen Bülow worked at the 
Department of Surgical Gastroenterology at the Rigshospitalet, University of Copenhagen. 
226 Founded by Professor Richard Cotton in Melbourne, in June 2006, the Human Variome Project aims to 
‘capture and archive all human gene variation associated with human disease…[and] provide a standardized 
system of gene variation nomenclature’, among other objectives. Quote from Cotton et al. (2007), page 
434. See also http://www.humanvariomeproject.org/index.php/about (visited 21 December 2012).
227 Dr Pål Møller wrote: ‘The Biomed2 demonstration programme on familial breast cancer was organised 
by Professor Michael Steel as a clinical counterpart to the Breast Cancer Linkage Consortium because they 
did not include the clinical parties.’ Note on draft transcript, 22 March 2013. 
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then recorded on cards.228 Dr Slack found opposition among the senior medical 
staff at St Mark’s and did not find it easy with lack of clinic rooms, etc. I used 
to actually go round the country looking for the relatives of our families, which 
was amazing. Now, of course, you can’t do that. Families were very happy to 
cooperate, and family members across the country contacted me to offer blood 
samples and information which were pivotal to research. I was very conscious of 
it being a family affair. People were never contacted by the clinic, and relatives 
would speak to them first to contact us. As far as I remember, very few people 
refused. We became very aware of what they wanted to tell us and that’s how 
we got an awful lot of patients coming to see us. Now, you don’t get that, it’s 
very restrained. We’ve got a lot of ethical restraints, which is probably quite 
right but there isn’t the same feeling. Identifying gene mutations has removed 
the anxiety of many family members, but the carriers need extra support and 
understanding. With the NHS going through constant changes and financial 
restraints, there is less chance of creating a permanent support structure that 
these families need. 
Harper: I’m going to deliberately reserve the last few minutes for talking just a 
little bit about the impact of genetics on new therapies because I really feel that’s 
a rather unique series of developments. John, tell us a little bit about the trials 
and related things.
228 Ms Christina Harocopos wrote: ‘At the clinic, pedigrees were obtained from those attending, risks were 
estimated and explained and a screening programme was offered.’ Note on draft transcript, 10 November 
2012. 
figure 20: ms Christina Harocopos. 
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Burn: Tribulations? [Laughs] Well, all through this entire period, from the 
original idea in 1990 that we might try chemoprevention, the CAPP studies were 
trundling along.229 A lot of people at this meeting played a very pivotal part in 
CAPP1. Robin was central. We realized when we tried to do it how hard it was 
to actually give long-term treatment, especially to adolescents. We did eventually 
get that published, although that wasn’t the greatest of papers.230 However, it did 
get CAPP2 off the ground, which turned out to be quite influential. The two 
interventions that we had come up with from the epidemiologists were resistant 
starch and aspirin and so we set up to study a thousand people worldwide and 
we managed to do that. When we broke the code, we had no obvious evidence 
of effect but we managed to carry on long-term follow-up as planned and in 
2011 reported that there was a 63 per cent reduction in colon cancer among 
the Lynch syndrome patients given aspirin.231 We’re about to publish the results 
of the starch, which was negative, but nevertheless it did demonstrate that you 
could do these long-term intervention studies on people who were genetically 
motivated because of their own risk and the risk for their families.232 We’re now 
trying to roll on that programme and look at different doses of aspirin and 
perhaps look at other interventions. It changed the game quite a lot because we 
now have a real intervention to offer people.233 
Phillips: A couple of observations: one is that in the various CAPP trials that 
John ran, I think the major thing was that they were wonderfully educational for 
a group of clinicians around the world. They brought people together and they 
standardized care. People started off not knowing much about either polyposis 
or HNPCC and they learnt a lot more. We ran seven randomized control 
clinical trials on our polyposis patients at St Mark’s and we were involved with 
the development of Cox2 inhibitors against colorectal cancer.234 We’ve been 
involved with difluoromethylornithine and its effect as an adjuvant in colorectal 
229 See note 97 and Burn et al. (1998). 
230 Burn et al. (2011a). 
231 Burn et al. (2011b). 
232 Mathers et al. (2012). 
233 Sir John wrote: ‘CaPP3 (Cancer Prevention Programme) will test three different doses of aspirin in 
3000 carriers of Lynch syndrome, beginning in January 2014, with results expected in 2021.’ Note on draft 
transcript, 16 June 2013. See http://www.capp3.org/ (visited 17 June 2013). 
234 For example, Steinbach et al. (2000). 
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cancer in prevention.235 We’ve been involved in using fish oils and showing that 
they can make a difference.236 The polyposis patients are a wonderful human 
laboratory for examining the next stage. They’ve got this controlled environment 
of the rectum which we can return to fairly easily. From the patient’s point of 
view, of course, we’ve got other problems which I think are not so much of 
scientific interest but of patient interest: the upper gastrointestinal tract and the 
desmoid tumours. 
evans: Just to develop the targeted therapy; we know about targeted therapy 
with Herceptin for breast cancer was one of the first.237 Then you had drugs 
like Glivec, which are now fantastic treatments for GI stromal tumours and 
there are individuals with inherited c-Kit mutations and PDGFRA mutations 
for whom, potentially, those are going to be incredibly important drugs.238 Also 
in breast cancer, you’ve got the synthetic lethal approach, and PolyADP-ribose 
polymerase (PARP) inhibitors have been used in advanced breast cancer with 
BRCA1 and BRCA2 carriers and have been getting very good results in the 
stand-alone situation to the extent that people are widely talking about these 
drugs being the pill that Pål discussed: the pill that will prevent breast and 
ovarian cancer. Now we don’t know if that will be the case, but we are moving 
into that era of targeted therapies, targeted at the genetic abnormality. 
lehmann: I just want to emphasize the PARP inhibitor story, which was based 
on knowing that the breast cancer cells had a BRCA1 or BRCA2 deficiency and 
knowing that they were involved in DNA repair. It was absolutely a rational 
development of a therapy directed against cells with the defective gene. 
Harper: Julian, I was going to ask you to say a word about tuberous sclerosis. 
235 The clinical trial entitled ‘A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli 
Patients’, started in December 2001 and its estimated completion date is October 2014. Apart from St 
Mark’s, the other participating medical institutions are in the USA: the Cleveland Clinic Taussig Cancer 
Center, Ohio, and the M D Anderson Cancer Center, University of Texas in Houston, Texas. Details of the 
trial are available at: http://clinicaltrials.gov/ct2/show/NCT00033371?term=difluoromethylornithine+st+
mark%27s&rank=1 (visited 16 January 2013). 
236 This clinical trial, ‘A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis Coli 
Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid’, commenced in November 2006 
and was completed in April 2008. Further details are available at http://clinicaltrials.gov/ct2/show/
NCT00510692?term=omega-3+colorectal+cancer+mark%27s&rank=2 (visited 16 January 2013). 
237 See, for example, Slamon et al. (2001). 
238 c-Kit: A receptor tyrosine kinase. PDGFRA: Platelet-derived growth factor receptor, alpha. 
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sampson: The main impact for tuberous sclerosis has been in identifying a 
therapeutic target as a result of post-genomic work. As with many of these 
familial tumour syndromes, prior to the identification of the TS genes, the 
molecular pathology was not understood at all. After the genes were cloned 
and their functions established, this knowledge really gave the clue as to what 
targeted therapy ought to be effective for tuberous sclerosis. This has gone 
relatively quickly because it was a drug repositioning strategy rather than a drug 
development strategy that was followed, which was, of course, much cheaper 
as well. That’s resulted now in a licensed application of these treatments for the 
tumour-related phenotypes in tuberous sclerosis. So there’s a licence in the US 
and Europe for the treatment of tuberous sclerosis-associated brain tumours, 
there’s a licence now in the US for renal tumours in tuberous sclerosis, and I 
think within a few weeks there’ll be a decision about a licence in Europe.239 I 
think it’s one of the early examples of going from the positional cloning of genes, 
encoding previously unknown proteins to establishing those protein functions, 
identifying the target for therapy and getting a licensed drug.
maher: VHL disease would be a second example in terms of knowing the 
biology, and tyrosine kinase inhibitors are now widely used for sporadic kidney 
cancer. This also illustrates the challenges of the disorders we’re talking about 
because in VHL you’ve got a very long-term disease and effective treatment in 
terms of surgery and so patients will opt for surgical removal of their tumours 
at an early stage rather than the drugs that are available.
Bodmer: Following up the point that Eamonn’s made: the biggest impact is on 
the mutations that occur in sporadic cancers, many of which, of course, have 
been suggested through the Knudson hypothesis from the family studies.240 
Ultimately, even if you take the PARP inhibitors, it may be that triple-negative 
breast cancers which can be treated by PARP inhibitors will be a much larger 
group than the actual familial cases. So it’s actually the contribution through the 
germline studies to the somatic changes that in the end will have the greatest 
impact, I think.
239 Novartis was awarded a licence for the drug Afinitor, with the active ingredient everolimus, by the US 
Food and Drug Administration in 2009. See http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.
cfm?fuseaction=Search.DrugDetails. In the European Union, the licensed drug is Votubia, approved in 
November 2012. See http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5344 
(both sites visited 26 April 2013). 
240 See note 96. 
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Harper: I have found this a very stimulating meeting and so I’d like to thank 
you all and pass you back to Tilli to close the seminar.
tansey: Thank you very much for coming to this meeting and sharing your 
reminiscences. I’d particularly like to thank those of you who have come from 
some distance, from Norway and from Canada, and even by phone from 
Newcastle. I’d like to say a couple of other thank yous, particularly to Lois 
Reynolds who is standing at the back. She is retiring on Friday and she has 
worked with me on practically every Witness Seminar we have held, over 50 
meetings to date. [Applause] I’d also like to thank Peter Harper for his excellent 
chairing and, of course, for his very good time-keeping. I believe that Jane 
Green wants to add something.
Green: Sir John Burn was visiting Newfoundland to give a seminar to us in 
June and he mentioned this Witness Seminar and happened to have a look at 
my PhD thesis at the time.241 I worked on it through the 1980s, it was regarding 
screening programmes for VHL, MEN1, MEN2, FAP and was capped off with 
the HNPCC story. John suggested that I might bring a copy of my thesis as one 
historically valuable document to remember this session by. So I’d like to give 
this copy of my thesis to Peter Harper. 
241 See Green (1995). 
figure 21: mrs lois reynolds. 
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Harper: It’ll be greatly appreciated. Some of you may know that we have what 
we call the Human Genetics Historical Library, which is a unique collection of 
over 3,000 volumes of books involved in one way or another with genetics – 
this will find a very deserved place in that and be available for everyone to use.242 
So thank you, Jane, very much indeed.
242 See http://www.genmedhist.info/HumanHistLib/ (visited 25 January 2013). 
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Appendix 1
timeline for Uk Clinical Cancer Genetics Groups
1924 St Mark’s Hospital Polyposis Register commences
Mid-1950s St Mark’s Hospital Polyposis Register advances to a Registry, 
proactively recruiting families to be screened243 
1984  Cancer Family Study Group established
ICRF-funded Colorectal Cancer Unit set up at St Mark’s 
Hospital 
1985  Leeds Castle Polyposis Group founded 
1986 Family Cancer Clinic starts at St Mark’s Hospital244
1987 Genetic Epidemiology Laboratory opens in Leeds 
1989 ICG-HNPCC ‘conceived’ in Jerusalem245 
1990  ICG-HNPCC first formal meeting, Amsterdam
Oxford Imperial Cancer Research Fund Genetic Clinic starts
2000 Cancer Family Study Group becomes Cancer Genetics Group 
2005 First InSiGHT meeting in Newcastle
243  See page 20. 
244  See page 28. 
245  See Lynch et al. (2003). 
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Appendix 2
archival material from st mark’s Hospital Polyposis registry246
a) register cards, interpreted by ms kay neale 
The visual materials reproduced here are examples of Dr Bussey’s cards from 
the Polyposis Register (also available in colour on the History of Modern 
Biomedicine Research Group’s website). In the annotated cards, the text in italics 
is directly quoted from Ms Kay Neale.247 Below is some further elucidation 
from her on the foundation and development of the Polyposis Register and her 
close collaboration with Dr Bussey, compiled from notes she provided on the 
transcript and a subsequent interview. 
‘I worked with Dr H J R Bussey for about twenty years, during which time I 
learned a lot about the history of the Polyposis Registry. According to him, Dr 
Dukes spoke to Mr J P Lockhart-Mummery about obtaining polyps for his 
adenoma/carcinoma research and during this conversation they decided that 
all information about patients with multiple polyps should be collected. J P 
Lockhart-Mummery was known to have an interest in inherited conditions and 
had noted that patients who presented with multiple polyps also had a family 
history of bowel cancer. ‘Bussey’ as he was then known, had just been appointed 
[in 1924] and was given the task of documenting/filing the information. I usually 
refer to the information collected at that time as the Polyposis ‘Register’ with 
the ‘Registry’ coming later when it was a Department rather than a collection 
of information.’ Reflecting on the growth of the register by 1948 to include 
histories of twenty families, Ms Neale further commented, ‘Dr Bussey told 
me many times that Dr Dukes would say that “it takes twenty years to prove 
that published information is wrong.” I imagine that at that time they would 
have been building the register with a view to establishing the facts. They were 
cautious. As you see, it took over twenty years to collect just twenty families, 
246  These additional materials have been provided by St Mark’s Hospital. 
247  Interview conducted with Ms Kay Neale at the Polyposis Registry, St Mark’s Hospital on 29 April 2013 
by Ms Emma Jones. A copy of the transcript for this interview will be deposited with the records of this 
meeting at the Wellcome Library, London, under archival reference GC/253. 
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some of which would have only had one or two affected members; I doubt they 
saw it as a register at that time. They collected lots of information: some became 
important and some proved pointless.’ 
Speaking about those early days, Ms Kay Neale said, ‘…the register started 
in 1924 when Dr Cuthbert Dukes was studying adenomas to see if he could 
prove that there was [an] adenoma carcinoma sequence. And he approached J P 
Lockhart-Mummery to ask for some polyps for his research and J P Lockhart-
Mummery explained that he had some patients who had a lot of polyps, which 
continued to grow over the years, and they also had a family history of relatives 
dying from bowel cancer. At that point the two men decided that they should 
start to record the details of these patients and their families. The index cards 
wouldn’t have been written at that time. I don’t know how the information was 
collected at that time, probably on foolscap paper… It wasn’t until much later 
that they started their research projects, which led to H J R Bussey doing work 
for which he was awarded a PhD (see Bussey, 1970). And it would have been 
somewhere between the 1920s and when he started this work that he would 
have revised his filing system to start collecting data in a very organized fashion 
to see…because he did collect every single bit of information that he could find 
out about people some of which became very useful in later years and which he 
didn’t know would be interesting at the time he was recording it.’
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b) letter from dr C dukes to dr J C Burne
Below is an example of a letter from Cuthbert Dukes in the 1950s, during the 
proactive campaign to recruit people for polyposis screening. Please note that 
patients’ names have been removed to preserve their anonymity. 
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c) Untitled adaptation of lewis Carroll’s poem  
You Are Old Father William, by dr Cuthbert dukes, suggested by 
ms kay neale as an example of his ‘foresight and humour’: 
248
“You are old, Father William,” the young surgeon said,
“And your colon from polyps is free.
Yet most of your siblings are known to be dead –
A really bad family tree.”
“In my youth,” Father William replied with a grin,
“I was told that a gene had mutated,
That all who carried this dominant gene
To polyps and cancer were fated.
“I sought for advice from a surgical friend,
Who sighed and said – ‘Without doubt
Your only escape from an untimely end
Is to have your intestine right out.’ 
“It seemed rather bad luck – I was then but nineteen –
So I went and consulted a quack,
Who took a firm grip on my dominant gene
And promptly mutated it back.”
“This,” said the surgeon, “is something quite new
And before we ascribe any merit
We must see if the claims of this fellow are true,
And observe what your children inherit!”
C E Dukes, 1952
248  Dr Cuthbert Dukes recounted this poem in his Hunterian Lecture of 1952. See Dukes (1952), page 304. 
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010 – Appendix 2
95
d) obituary for dr H J r Bussey249
249 Morson (1990). 
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Appendix 3
Pedigree of a Newfoundland family, ‘Family C’, with HNPCC250
250  Reproduced from Green (1995), page 251. 
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Cancer Genetics: a personal view, by Professor David Harnden251 
Quite often the motivation for writing something down is that I have read 
an article in a newspaper that either stimulates my imagination, or recalls 
something from the past. In The Times of 1 December 2007 there were several 
such articles – and this is the result of one of these articles – taking me back 
to the time that I was newly appointed as Professor of Cancer Studies in the 
University of Birmingham. I will first of all quote the relevant passage from The 
Times.
A £3 million suite of machines, to be installed at the Wellcome Trust 
Sanger Centre near Cambridge, will increase the capacity to decode 
DNA by a factor of 600. It will particularly transform cancer genetics, 
allowing researchers to analyse tumours for the full range of mutations 
that cause cells to grow out of control.252
It was the phrase ‘transform cancer genetics’ that caught my eye. When I first went 
to Birmingham my laboratory was funded by a local branch of what was then the 
British Empire Cancer Campaign (later the Cancer Research Campaign). This 
was quite autonomous, and separate from the National BECC organization. It 
was run by well-meaning volunteers who handed over the money they raised 
to the University which had a Cancer Research Committee. That Committee 
had the responsibility to give out grants to support cancer research projects in 
the University. In practice, the members of the Committee granted money to 
support research in their own departments. I could see that it would be quite 
a fight to get enough money to do what I wanted to do. I believed that the 
correct course of action would be to amalgamate the Birmingham Branch of 
the BECC with the National BECC organization. This would give us access 
to much larger sums of money, but of course we had to be able to compete 
for grants at national level. I was sure that we could compete, so I discussed 
this with several influential people and they all approved of my plan. First, I 
had to get the agreement of the University Senate. I had already learned from 
my short, but bitter, experience of university politics that it was important to 
251  An essay contributed by Professor David Harnden, who was unable to attend the seminar. 
252  Henderson (2007). 
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get the support of the Vice Chancellor before the debate in the Senate and I 
managed to do this. When the debate started, I outlined my plan, but then a 
number of the members of the University Cancer Research Committee (who 
had been creaming off the money for their own purposes) started to attack me 
as an inexperienced young upstart. The Professor of Chemistry was particularly 
vitriolic. The VC came to my aid, and effectively told the complainants that 
we, in Birmingham, had to compete at national level if our work was to be 
respected. I got approval to go ahead, and the Birmingham BECC was joined 
with the national BECC organization. Then, of course, I had to apply for grants 
to support our work in a nationally competitive market. I drafted my grant 
proposals, which were based, largely, on my ideas about cancer genetics. 
At that time (1969) quite a lot was known about chromosome abnormalities in 
cancer cells, but they were thought to be a consequence of the disease process 
rather than anything to do with the causation of the cancer. Nothing was 
known about genes that caused cancer, and the few rare inherited cancers, like 
retinoblastoma, were thought to be oddities of little importance. I already had 
a clue that cancer genes were important from the work that we had done in 
Edinburgh on a specific chromosome abnormality that occurred in one type 
of leukaemia. I had shown, further, that male breast cancer was commoner in 
men with an abnormal XXY chromosome complement, suggesting that genetic 
make-up was important in the causation of cancer. Further, from what I had 
read of earlier work by scientists such as Theodore Boveri, it seemed clear that 
genetics would be important in cancer causation.253 I also believed, since so 
many things about human beings were determined by an interaction between 
genetics and environment, that cancer, too, was likely to have a major genetic 
component. So off my grant application went to the BECC in London. The 
reply which came back, many weeks later, was a bit of a bombshell. Effectively, 
it said that the BECC Scientific Committee was surprised that I did not know 
that cancer was caused by environmental factors, such as smoking cigarettes, 
the use of tars, mineral oils and other industrial chemicals. Genetics had little 
or nothing to do with it. However, since I was a new professor, the Committee 
would give me a small grant to get me going, on the understanding that I would 
come back with something more sensible in a couple of years.
253  Boveri (1914). 
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010 – Appendix 4
100
That was a bit of a setback, but we ploughed on and gradually we got a good 
programme of cancer genetics up and running. There was our work on ataxia-
telangiectasia, which I have described in detail elsewhere.254 Another interesting 
example arose when I was approached one day by an elderly GP, John Hallam, 
who wanted to do some research. He had become convinced that cancer in 
organs that were bilateral, such as kidney or breast, tended to occur at young 
ages, and also to run in families. We set up a search in the local cancer registry 
for early-onset breast cancers. As a result we discovered several families that had 
a significant excess of breast cancer. 
Though it was others who took this idea forward, this was one of the first steps 
leading to the discovery of the breast cancer susceptibility genes such as BRCA1. 
I also set up a discussion group, which we called the Cancer Family Study 
Group, to bring together all the people (doctors, scientists, nurses, statisticians 
and others) who were involved in the study of families with an increased risk of 
cancer. This was a new concept since most meetings were restricted to medics 
or scientists. The group flourished, and soon Walter Bodmer, a geneticist who 
had recently become Director of the Imperial Cancer Research Fund, joined 
in. Meetings, which were held alternately at the ICRF and my Department, 
were often attended by more than one hundred people. The whole notion that 
genetics was important in the causation of cancer was beginning to be accepted. 
Some years later, when I was a member of the Cancer Research Campaign’s 
Scientific Committee, it was very satisfying to find that cancer genetics was now 
considered its top priority for research funding!
Another interesting development occurred when I was Director of the Paterson 
Institute.255 We were doing research on families with cancer susceptibility, but 
there was no-one with specific clinical responsibility for caring for the special 
needs of such families. After discussion with Rodney Harris, the Professor of 
Human Genetics in Manchester, it was agreed that he would try to get the 
Regional Heath Authority to create, and pay for, a consultant post with this 
responsibility. The RHA agreed, but said that it could not be done for about 
two years. I, therefore, approached the Wigan and District Cancer Research 
Fund (which had helped me before) and asked if it would be prepared to fund 
such a post for two years. This was a surprising, but excellent source of funds. 
The people there were terrific!! Luckily, the Wigan Fund was flush with money 
254  See, for example, Bridges and Harnden (1981). 
255  See note 32. 
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since one of its members had recently died and left a substantial amount of 
money to it. They agreed to help, and so we appointed a young clinician called 
Gareth Evans to look after the exceptional needs of families who had learned 
that they had an unusual risk of developing cancer. Gareth was a great success 
and became, first, a consultant and then Professor of Cancer Genetics: perhaps 
the first in the country with such a title. 
So you see, we have come a long way from the point when, over thirty years 
ago, cancer genetics was not considered worthy of being supported at all by the 
CRC, to the position quoted from The Times article at the beginning of this 
essay, where a grant of millions of pounds can be awarded to a scheme which, it 
is hoped, will enable people to become aware of their inherited cancer risk, and 
hopefully take steps to minimize that risk.
A final word of warning: we must be careful not to go too far in this direction. 
Cancer genetics might be important, but we must not forget that environmental 
factors such as radiation, viruses and noxious chemicals do all play an important 
part in the causation of different kinds of cancer. Cancer research does have a 
rather unfortunate reputation of supporting, to excess, the area that is currently 
fashionable – for example, chemical carcinogens in the 1940s and 1950s, 
radiation in the 1960s, viruses in the 1970s and 1980s, and now genetics. All 
are important, and it is essential that the research funding bodies maintain a 
balanced portfolio. But we are getting there.
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ascertain
The method of identifying 
individuals or families with 
hereditary traits associated with 
specific conditions or diseases. 
ataxia-telangiectasia
An autosomal recessive disorder 
characterized by cerebellar 
telangiectases, immune defects and 
a predisposition to malignancy. It 
may also affect the functions of the 
nervous system, and can manifest 
in early childhood with significant 
problems of balance, walking and 
facial expression.
Candidate gene
Specific gene undergoing 
research to determine its possible 
relationship to a specific genetic 
condition or disorder. 
Colonoscope 
A thin, flexible tube used to 
examine the lining of the bowel 
wall via the rectum. 
familial adenomatous polyposis 
(faP)
FAP is a hereditary disorder in 
which polyps form early in life in 
the colon, becoming malignant 
later in life unless prophylactic 
surgery is performed. In attenuated 
FAP (AFAP), polyps develop at a 
later age. APC is the gene linked to 
FAP. 
Gene
A gene is the fundamental unit of 
heredity. 
Genotyping
The determination of an 
individual’s genetic constitution. 
Hereditary non-polyposis 
colorectal cancer (lynch 
syndrome i and ii) 
Dominantly inherited cancer 
syndromes that, unlike FAP, are not 
associated with the manifestation 
of polyps in the colon. Lynch 
syndrome I is located solely in the 
colon, while Lynch syndrome II 
Glossary
The following textual and web-based sources were consulted: Churchill’s 
Illustrated Medical Dictionary (1989) New York: Churchill Livingstone; A 
Dictionary of Genetics (7th edition) (2006) Oxford: Oxford University Press; 
Genetics Home Reference: US National Library of Medicine, http://ghr.nlm.
nih.gov/; Online Mendelian Inheritance in Man (OMIM): Johns Hopkins 
University, http://omim.org/. Professor Peter Harper also contributed to 
compiling and editing this glossary. 
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is characterized by multiple extra-
colonic cancers, including breast, 
endometrial, gastrointestinal, 
ovarian, sarcoma, brain and 
leukaemia, among others. The 
genes associated with HNPCC are 
primarily MSH2 and MLH1, but 
also MSH6 and PMS2. Early onset 
of cancer is characteristic of both 
HNPCC varieties, as are tumours’ 
proximal relationship to the colon. 
Human leukocyte antigen (Hla)
region
An area of the human genome 
mapped to chromosome 6 and 
involved in cellular immunity. 
Different HLA types are associated 
with cancer susceptibility. 
locus 
The position of a gene on a 
chromosome. 
loss of heterozygosity (loH)
The structural or functional loss of 
one of a pair of alleles, often seen in 
tumours.
MEN1 / men2a
A gene that encodes menin, in 
which mutations can cause MEN1. 
Multiple endocrine neoplasia type 
2 is a syndrome, rather than a gene, 
that is connected to mutations in 
the RET oncogene. 
mismatch repair 
Proteins that check, or ‘proof 




A recessively inherited form of 
polyposis associated with mutations 
in the MUTYH gene. 
sigmoidoscopy
An endoscopic inspection of the 
interior of the sigmoid colon. 
tuberous sclerosis
An inherited neurodevelopmental 
disorder causing learning disability, 
epilepsy, tumours and skin 
pigmentation changes, among 
other features. 
Von Hippel-lindau disease 
A dominantly inherited familial 
cancer syndrome characterized by 
abnormal tissue masses (neoplasms) 
in the retina, cerebellum or other 
parts of the central nervous system, 
kidney or pancreas, among other 
locations. Neoplasms may be a 
combination of benign and/or 
malignant. 
Xeroderma pigmentosum
An autosomal recessive genetic 
disorder, causing hypersensitivity to 
sunlight and a high predisposition 
to developing skin cancer. 
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010 – Biographical Notes 
105
Professor timothy Bishop 
PhD FMedSci (b. 1953) was 
educated at the universities 
of Bristol and Sheffield, in 
mathematics and statistics, 
receiving his doctorate from the 
latter in 1978 in probability and 
statistics. In 1979, he moved to the 
University of Utah, Salt Lake City, 
where he commenced his post-
doctoral research on investigating 
the links between data in the 
population records of Mormon 
families with Utah State’s cancer 
registration records and death 
certificates. Remaining in Utah, 
he became Assistant Professor 
at the Department of Medical 
Informatics (1979–1986) and then 
Associate Professor (1986–1989) 
and Adjunct Associate Professor 
(1989–1997). His research in the 
1980s was facilitated by the use 
of recombinant DNA technology 
to identify genetic variation and 
the production of genome maps 
to investigate the potential for 
identifying breast and colorectal 
cancer genes. Returning to the UK 
in 1989, he became Senior Scientist 
and Head of Laboratory at the 
ICRF in Leeds, running a research 
group in genetic epidemiology and 
familial cancer susceptibility. This 
group was a key research centre 
which contributed to international 
efforts to, eventually, map and 
identify the genes for breast and 
colorectal cancer. He is currently 
Director of the Leeds Institute of 
Cancer and Pathology (2011–). 
lady Julia Bodmer 
Hon MRCP Hon FRCP FMedSci 
(1934–2001), originally studied 
economics, philosophy and politics 
at Oxford University, and later 
applied her training in statistics 
to genetics. She made important 
advances into HLA types and 
their association with juvenile 
rheumatoid arthritis and ankylosing 
spondylitis, and in the aetiology 
of Hodgkin’s disease, Burkitt’s 
lymphoma and testicular cancer. 
She was a founder of the European 
Federation for Immunogenetics. 
Her archival papers will be available 
along with Sir Walter’s at the 
Bodleian Library, University of 
Oxford, in 2014. 
Professor sir Walter Bodmer
FMedSci FRCPath FRS FSB Kt 
(b. 1936) was educated at Clare 
College, Cambridge, UK; moving 
from a mathematics degree to 
Biographical notes*
* Contributors are asked to supply details. 
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population genetics for his doctoral 
research under R A Fisher, which 
was completed in 1959. As a 
post-doctoral fellow he worked 
with Nobel Laureate Joshua 
Lederberg at Stanford University’s 
Department of Genetics, USA, 
while training in molecular biology. 
At Stanford, he became Assistant 
and then Associate Professor of the 
Department of Genetics (1962–
1968), and Professor (1968–1970), 
during which he contributed to 
the discovery of the HLA system. 
From 1970 he was Professor of 
Genetics, University of Oxford, 
until his appointment in 1979 as 
Director of Research at the Imperial 
Cancer Research Fund (ICRF), 
London. He became the first 
Director-General of the ICRF in 
1991, remaining in that role until 
1996. He was appointed Principal 
of Hertford College, University of 
Oxford (1996–2005), where he also 
became Head of the Cancer and 
Immunogenetics Laboratory at the 
Weatherall Institute of Molecular 
Medicine (funded by the ICRF, 
latterly, in part, by Cancer Research 
UK). His many distinguished 
awards and honorary positions 
include a Fellowship of the Royal 
Society, London, 1974; election to 
the National Academy of Sciences, 
USA, in 1981; (first) presidency 
of the International Federation of 
Associations for the Advancement 
of Science and Technology, 
(1992–1994), and membership 
of the board of patrons, St Mark’s 
Hospital, London, since 1996 
and, from 2008, Presidency of the 
Galton Institute. He has published 
more than 700 papers and has also 
co-authored four books (Cavalli-
Sforza and Bodmer (1971); Jones 
and Bodmer (1974); Bodmer and 
Cavalli-Sforza (1976); Bodmer 
and McKie (1994). Sir Walter is 
credited as being one of the first 
people to propose the Human 
Genome Project. 
Professor sir John Burn
Kt MD FRCP FRCPCH FRCOG 
FMedSci (b. 1952) completed 
an intercalated genetics degree in 
1973 and qualified in medicine 
from Newcastle University in 
1976. After further medical and 
paediatric training he became 
Clinical Scientific Officer in the 
MRC Clinical Genetics Unit, 
Great Ormond Street Hospital, 
London, and returned to Newcastle 
as their first Consultant Clinical 
Geneticist in 1984. He became first 
Clinical Director of the Northern 
Genetics Service (1989–2004) 
and Professor of Clinical Genetics, 
Newcastle University (1991–) and 
Head of the Institute of Human 
Genetics (2004–2010). He was 
President of the European Society 
of Human Genetics (2007), Chair 
of the British Society for Human 
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Genetics (2011–2013), Chair of 
the National Institute for Health 
Research Genetics Specialty Group, 
(2008–) and Director of the 
NIHR Collaborative Group for 
Genetics in Healthcare (2009–). 
He was Lead Clinician, NHS 
North East (2009–2013). Sir John 
was also Innovation Chair for the 
Human Genomics Strategy Group 
(2011–2013) and is a member of 
the NHS Genomic Strategy Board. 
He was knighted for his services to 
medicine and healthcare in 2010. 
dr Henry Bussey
OBE PhD (1907–1991) See 
Appendix 2, on pages 95–6, for his 
full obituary. 
dr Cuthbert dukes
OBE MRCS FRCS (1890–1977) 
commenced his internationally 
renowned research into the 
pathology of colonic and rectal 
cancer in 1922, when he was 
appointed as the first pathologist to 
St Mark’s Hospital. His foundation 
of the Hospital’s Polyposis Register 
in 1924, with Mr J P Lockhart-
Mummery, was highly significant 
for the development of knowledge 
about FAP and for its diagnosis and 
treatment. See Dukes (1952) and 
(1958). 
Professor Gareth evans 
MRCP MD FRCP (b. 1959) 
trained at St Mary’s Hospital 
Medical School, London, where 
he specialized in paediatrics before 
moving into genetics at St Mary’s 
in Manchester. He undertook a 
Medical Cadetship in the Army 
and served as Medical Officer to 
the Royal Hussars. After obtaining 
Membership in Paediatrics and 
reaching Senior Registrar level 
in the Army (1989), he joined 
Manchester University as a Senior 
Research Fellow and undertook 
an MD (1990–1992) in cancer 
genetics, studying NF2. Evans was 
instrumental in setting up cancer 
genetics services for the North 
West of England in 1990, and he 
continues to work in the University 
of Manchester as Honorary 
Professor of Medical Genetics; and 
as Consultant in Medical Genetics 
and Cancer Epidemiology for 
the Central Manchester Hospital 
NHS Foundation Trust and 
The Christie NHS Foundation 
Trust. From 2002 to 2010 he 
was Chairman of the NICE 
Familial Breast Cancer Guideline 
Development Group, of which 
he has been the clinical lead since 
2011. He lectures internationally 
on the subject of hereditary breast 
cancer, neurofibromatosis and other 
cancer syndromes. In the UK, he 
has developed a national medical 
training programme for breast 
cancer genetics, as well as education 
for professionals risk assessing and 
counselling those who are at risk or 
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are directly affected by hereditary 
breast cancer. Currently, he is the 
Chief Investigator for a National 
Institute of Health Research-funded 
project to improve techniques for 
breast cancer prediction (2009–). 
He has published more than 500 
peer-reviewed research papers, 
reviews and book chapters, and was 
co-editor of Risk Assessment and 
Management in Cancer Genetics (see 
Lalloo et al. (eds) (2005)). 
Professor George fraser 
MD PhD DSc FRCP FRCPC (b. 
1932) qualified in medicine at 
Cambridge, followed by a PhD 
from University College London 
and Fellowships at the Canadian 
College of Medical Genetics and 
the American College of Medical 
Genetics. He was appointed 
Scientific Officer, MRC Population 
Genetics Research Unit, Oxford 
(1959–1961); Research Fellow, 
Division of Medical Genetics, 
University of Washington, 
Seattle (1961–1963); Lecturer, 
Department of Research in 
Ophthalmology, Royal College of 
Surgeons, London (1963–1966); 
Reader in Genetics, University of 
Adelaide (1966–1968); Associate 
Professor, Division of Medical 
Genetics, University of Washington 
(1968–1971); Professor of Human 
Genetics, University of Leiden 
(1971–1973); Professor of Medical 
Genetics, Memorial University, 
St John’s, Newfoundland (1973–
1976); Chief of Department 
of Congenital Anomalies and 
Inherited Diseases, Department 
of National Health and Welfare, 
Federal Government of Canada, 
Ottawa (1976–1979); Associate 
Professor, Centre for Human 
Genetics, McGill University, 
Montreal (1979–1980); Special 
Expert in Human Genetics, 
National Library of Medicine, 
National Institutes of Health, 
Bethesda, Maryland; attached to 
Moore Clinic for Medical Genetics, 
Johns Hopkins University, 
Baltimore (1980–1984); Senior 
Clinical Research Fellow, Imperial 
Cancer Research Fund; Honorary 
Consultant in Clinical Genetics, 
Cancer Genetic Clinic, Churchill 
Hospital, Oxford until his 
retirement (1984–1997). In 2007, 
his career was commemorated in 
the book, Fifty Years of Human 
Genetics (Mayo and Leach (eds) 
(2007)). His scientific papers have 
been archived at the Wellcome 
Library, London (reference PP/
GRF). (Further biographical details 
for Professor Fraser are available in 
the records of the seminar, which 
will be archived in the Wellcome 
Library.)
Professor eldon Gardner 
PhD (1909–1986) was a zoologist 
and geneticist who taught and 
researched at Utah State University 
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and at the University of Utah. As 
a geneticist, his research into the 
causes of cancer was focused on 
families in Utah, notably within 
the Mormon community. In 1950 
he established the existence of a 
hereditary form of cancer of the 
lower digestive tract which became 
known as Gardner syndrome. 
See http://www.usu.edu/greats/
research/index.cfm?article=30847 
(visited 8 January 2013) and 
Gardner and Stephens (1950). 
The Eldon Gardner papers (1936–
1986) are held at the archives of the 
University of Utah. 
Professor Jane Green
PhD Hon FCCMG (b. 1943) 
received her BSc in Zoology (1964) 
and MSc in Drosophila Genetics 
(1966) from the University of 
British Columbia, then in the late 
1960s, moved to Newfoundland 
and Labrador. From 1978 to 
1986 she worked with Dr Gordon 
Johnson to establish an Ocular 
Genetics Clinic, studying the 
distribution and frequency of 
hereditary eye disorders. They 
began a cancer genetics screening 
programme in 1982 after a 
family with Von Hippel-Lindau 
disease was referred to the Ocular 
Genetics Clinic. She received her 
PhD from Memorial University 
of Newfoundland (MUN) in 
1995, with a dissertation on 
the development of clinical and 
genetic screening programmes for 
hereditary cancer syndromes, in 
which mapping the first mismatch 
repair gene, MSH2, with Drs 
Vogelstein and de la Chapelle was 
an important component. She has 
been a faculty member at MUN 
since 1988 and a Professor in 
the Discipline of Genetics since 
2002. In 2008 she received a 
Knowledge Translation award from 
the Canadian Institutes of Health 
Research, and was also made an 
honorary member of the Canadian 
College of Medical Geneticists 
(CCMG). In 2012 she received the 
CCMG Founders Award for her 
contribution to developing genetics 
services in Newfoundland and 
Canada. 
Professor david Harnden 
PhD FRCPath FRSE (b.1932) 
graduated from Edinburgh 
University BSc (1954), PhD 
(1957). He was a Scientific 
Member of the Medical Research 
Council at the Radiobiology 
Research Unit, Harwell and then 
at the MRC Clinical Effects 
of Radiation Research Unit at 
the Western General Hospital 
Edinburgh. He spent a year in 
the Laboratory of Dr Howard 
Temin at the University of 
Wisconsin in Madison, USA. 
He became Professor and Head 
of the Department of Cancer 
Studies in the University of 
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Birmingham and then Director of 
the Paterson Institute and Professor 
of Experimental Oncology in the 
University of Manchester, now 
Emeritus. On his retirement he 
became Chairman of the South 
Manchester Hospitals NHS Trust. 
His early research was in human 
genetics and he was among the first 
to publish a correct karyotype of 
human chromosomes. He studied 
the chromosomes of patients with 
inherited disorders and discovered 
the trisomy of chromosome 18 as 
well as the first double trisomy. 
His later studies were on patients 
with an inherited susceptibility to 
develop cancer.
ms Christina Harocopos 
SRN SCM (b. 1939) studied 
nursing at St Bartholomew’s 
Hospital from 1958 to 1962, 
qualifying in 1963. She 
subsequently trained as a midwife 
at Freedom Fields Hospital, 
Plymouth. In 1964 she was a 
member of a team of European 
nurses working in Greece with 
funding from Save the Children. 
She returned to St Bartholomew’s 
Hospital as a Theatre Sister, before 
temporarily retiring to raise her 
two children and also volunteering 
at St Mungo’s charity for homeless 
people as a project worker (1977–
1980). As Professor Brooke’s 
Theatre Sister at St James’ Hospital 
in Balham, she was encouraged 
to develop her knowledge and 
expertise in diseases of the colon 
and rectum and she specialized in 
stoma care as a clinical nurse at 
St Mark’s Hospital (1980–1986). 
She was a Genetic Research 
Assistant and Family Visitor for 
St Mark’s Hospital Family Cancer 
Clinic (1987–1996), supported 
by the Imperial Cancer Research 
Fund. Moving to South Africa, 
from 1996 until 1998, she was 
the Family Cancer Coordinator 
at the Groote Schuur Hospital 
in Cape Town, a post funded by 
the De Beers Chairman’s Fund 
(DeBeers Consolidated Mines Ltd-
Namaqualand Mines) in support 
of the South African Hereditary 
Nonpolyposis Colorectal Cancer 
Project. Back in the UK, from 1998 
until her retirement in 2010, she 
was a Clinical Nurse for the North 
East Thames Clinical Genetics 
service and North East London 
Cancer Network, based at St 
Bartholomew’s Hospital. 
Professor Peter Harper
Kt FMedSci FRCP (b. 1939) 
graduated from Oxford University 
in 1961, qualifying in medicine 
in 1964. After a series of clinical 
posts, he trained in medical 
genetics at the Liverpool Institute 
for Medical Genetics under Cyril 
Clarke and at Johns Hopkins 
University, Baltimore, under Victor 
McKusick. Appointed to develop 
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medical genetics in Cardiff in 
1971, he was Professor of Medical 
Genetics at the University of Wales 
College of Medicine, Cardiff, 
until his retirement in 2004, when 
he became University Research 
Professor in Human Genetics, 
Cardiff University (Emeritus 
since 2008). At the request of the 
Chief Medical Officer (England), 
in 1996 he chaired the working 
group and authored the report 
Genetics and Cancer Services, more 
commonly known as ‘The Harper 
report’ (Department of Health 
(1996). He served on the UK’s 
Human Genetics Commission 
(2000–2004) and the Nuffield 
Council on Bioethics (2004–2010). 
He has been closely involved with 
the identification of the genes 
underlying Huntington’s disease 
and muscular dystrophies, and 
with their application to predictive 
genetic testing. He has also been 
responsible for the development of 
a general medical genetics service 
for Wales. His books include 
Practical Genetic Counselling 
(Harper (1981)), Landmarks in 
Medical Genetics (Harper (2004)), 
First Years of Human Chromosomes 
(Harper (2006)) and A Short 
History of Medical Genetics (Harper 
(2008)). For the past decade he has 
led an initiative, supported by the 
Wellcome Trust, to preserve and 
document the history of Human 
and Medical Genetics (www.
genmedhist.org). He is a consultant 
to the ‘Makers of Modern 
Biomedicine Project’ for the 
History of Modern Biomedicine 
Research Group, Queen Mary, 
University of London. 
Professor shirley Hodgson
DM D(Obst)RCOG DCH FRCP 
(b. 1945), daughter of Lionel 
Penrose, she avoided working 
in genetics for many years, but 
after training in medicine and 
working in general practice while 
her children were young, she 
did a locum in clinical genetics 
at Guy’s Hospital, and found it 
irresistible. She went on to work 
in the field of clinical genetics for 
many years. From 1983 to 1988 
she was Senior Registrar in Clinical 
Genetics for the South Thames 
(East) Regional Genetics Centre 
and Honorary Senior Registrar 
at Hammersmith Hospital, 
London. At Addenbrooke’s 
Hospital, Cambridge (UK), 
she was Consultant Geneticist 
(1988–1990). She promoted the 
development of cancer genetics 
clinics at Guy’s and St Thomas’, St 
Mark’s and St George’s Hospitals 
in London in the 1990s and ran 
the regional cancer genetics service 
at Guy’s and St Thomas’ Hospital. 
She has published widely on the 
subject of cancer genetics, and co-
authored several books, including 
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Inherited Susceptibility to Cancer: 
Clinical, predictive and ethical 
perspectives (Foulkes and Hodgson 
(eds) (1998)) and A Practical 
Guide to Human Cancer Genetics 
(Hodgson and Maher (1993)). She 
has an active research programme 
investigating inherited aspects of 
cancer predisposition, especially 
in breast and colorectal cancers. 
She is particularly interested in 
international collaborative research. 
She took up a new post as Professor 
of Cancer Genetics at St George’s, 
University of London, in 2003. 
Her current research looks at 
molecular changes in colorectal 
polyps in relation to inherited 
colorectal cancer susceptibility, and 
she was Principal Investigator of a 
five-year randomized study funded 
by Cancer Research UK to evaluate 
whether the Mirena intrauterine 
progestogen-releasing system 
reduces the risk of endometrial 
cancer in women with Lynch 
syndrome who are at increased risk. 
dr alfred knudson 
MD PhD (b. 1922) was educated 
at the California Institute of 
Technology and Columbia 
University, receiving his doctorate 
from the former in 1956. Primarily 
a paediatrician, he combined his 
discipline with clinical genetics 
research at the Los Angeles 
Children’s Hospital. From 1951 to 
1953 he served as a medical officer 
with the US Army during the 
Korean War. His service was based 
at Fort Riley in Kansas where he 
screened the health of newborns. 
Subsequently, he was Head of 
Pediatrics at the City of Hope 
Medical Center in Los Angeles 
(1956–1966) where he treated 
children with cancer and specific 
genetic diseases and researched their 
conditions. From 1966 to 1969 
he was Associate Dean for Basic 
Sciences at the State University 
of New York, Long Island. In 
1971 he founded the Medical 
Genetics Center at the University 
of Texas Medical School, Houston, 
becoming Dean of the Graduate 
School of Biomedical Sciences. 
The same year, he published his 
seminal paper which launched 
his influential ‘two-hit’ theory 
of the genes influencing tumour 
formation (see Knudson (2005)). 
He was appointed Director of 
the Institute for Cancer Research 
at the Fox Chase Cancer Center 
in Philadelphia (1976–1982), 
Center President (1980–1982) and 
Scientific Director (1982–1983). 
He has since been Senior Adviser 
for Fox Chase Cancer Center 
and Special Adviser for the (US) 
National Cancer Institute. 
Professor alan lehmann
FRS FMedSci (b.1946) graduated 
from Cambridge University in 
Natural Sciences in 1967 and 
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received his PhD from the Institute 
of Cancer Research in 1970. He 
held postdoctoral positions at 
the Oak Ridge National Labs, 
Tennessee and the University of 
Sussex, which were followed by his 
appointment in 1973 as a senior 
scientist at the MRC Cell Mutation 
Unit, University of Sussex. 
He remained in this position 
until 2001 and was also made a 
University Professorial Fellow in 
1987. In 2001 he became Professor 
of Molecular Genetics at Sussex 
and was Chairman of the Genome 
Damage and Stability Centre, until 
2011. For most of his research 
career, he has worked on DNA 
damage and repair and its relation 
to cancer and other aspects of 
human health. In particular, he has 
been responsible for many advances 
in our understanding of genetic 
disorders associated with defects 
in DNA repair. He is consultant 
scientist for the multidisciplinary 
xeroderma pigmentosum specialist 
clinic.
sir Hugh evelyn lockhart-
mummery 
MRCS FRCS LRCP (1918–1988), 
son of Mr John Percy Lockhart-
Mummery (see below), became 
Resident Surgical Officer at St 
Mark’s Hospital in 1950, then 
Consultant Resident Surgeon 
1951–1978. He is credited with 
making a breakthrough in the 
successful surgical treatment of 
polyposis, while retaining the 
bowel, in collaboration with Dr 
Cuthbert Dukes, in 1952. 
mr John Percy lockhart-
mummery
MB FRCS FACS (1875–1957) 
became Assistant Surgeon at St 
Mark’s Hospital in 1903, Senior 
Surgeon in 1913, Emeritus Surgeon 
in 1935 and Consulting Surgeon 
and Vice-President of the Hospital, 
in 1940. Among his many 
published writings are the books 
Diseases of the Rectum and Anus 
(Lockhart-Mummery (1914)) and 
The Origin of Cancer (Lockhart-
Mummery (1934)). 
dr Henry lynch 
MD PhD (b. 1928) served with the 
United States Navy (1944–1946). 
He studied at the Universities of 
Oklahoma, Denver and Texas. 
From the latter’s Medical Branch 
in Galveston, he was awarded his 
medical degree (PhD) in Human 
Genetics, in 1960. He became 
an Internal Medicine resident 
at the University of Nebraska 
where he developed his theories 
about the hereditary causation 
of cancer. From 1970 to 1990 
Lynch continued his research 
into the genetics of colon cancer, 
with minimal funding, and 
amassed evidence to conclude that 
the disease could be inherited. 
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Hereditary non-polyposis colorectal 
cancer is now more commonly 
known as Lynch syndrome. Lynch’s 
further research into cancer genetics 
demonstrated genetic links to some 
breast ovarian cancers, leading 
other investigators to locate the 
breast cancer genes, BRCA1 and 
BRCA2. In 1984, Lynch founded 
the Creighton’s Hereditary 
Cancer Prevention Clinic in 
Omaha, Nebraska. He remains 
Director of Creighton University’s 
Hereditary Cancer Center and 
Chair of Preventive Medicine. The 
American Association of Cancer 
Research awarded him the Joseph 
H Buchenal Memorial Award for 
Clinical Research in 2010. Lynch 
Syndrome Public Awareness Day 
was inaugurated in the US on 22 
March 2012. 
dr madge macklin 
MD (1893–1962) was a Canadian 
medical geneticist who worked at 
the University of Western Ontario, 
carrying out research on a wide 
range of inherited disorders. 
Post-war, her research into cancer 
genetics as a Cancer Research 
Associate at Ohio State University 
produced evidence of hereditary 
breast cancer. She became president 
of the American Society of Human 
Genetics in 1959. 
Professor eamonn maher
MD FRCP FSB FMedSci 
(b.1956) graduated from the 
University of Manchester in 1980. 
After clinical medicine posts in 
Manchester, Cambridge, Leeds 
and London he trained in medical 
genetics under Professor Malcolm 
Ferguson-Smith at Cambridge 
University. After Clinical Lecturer/
Senior Registrar and University 
Lecturer/Consultant in Medical 
Genetics posts at the University of 
Cambridge he was appointed to 
the Chair of Medical Genetics at 
the University of Birmingham in 
1996. His main clinical interests 
are familial cancer syndromes, in 
particular inherited renal cancers 
and phaeochromocytoma, and 
his research interests have been in 
cancer genetics and epigenetics, 
genomic imprinting and 
identification of human disease 
genes (publishing close to 400 
papers).
dr Pål møller 
(b. 1946) MD PhD graduated 
from Oslo University in 1971, 
was awarded an MD in 1973 
and, at the same institution, was 
appointed as a specialist in medical 
genetics in 1981. In 1982, he 
was employed as a geneticist to 
conduct prenatal diagnoses in 
Norway. He completed his PhD 
on multifactorial inheritance (HLA 
B27 and ankylosing spondylitis/
Clinical Cancer Genetics: Polyposis and familial colorectal cancer c.1975–c.2010 – Biographical Notes 
115
Reiter’s syndrome/psoriatic 
arthritis) in 1984. He set up an 
outpatient clinic for inherited 
cancer at the Norwegian Radium 
Hospital, Oslo, in 1988 and was 
the head of this unit until 2012. 
He is now the Senior Scientist, 
Senior Consultant and Research 
Group Leader for cancer genetics 
at all Oslo hospitals which are 
amalgamated into Oslo University 
Hospital. He has focused the 
group’s clinical and research 
activities on preventable and 
curable inherited cancers. Møller 
has developed a full electronic 
medical filing system (CGEN) for 
clinical and research use holding 
all information on some 70,000 
living and dead patients and their 
closest relatives who have been 
seen at the clinic since 1982. He 
has been Chair of the Norwegian 
Group on Inherited Cancer since 
its foundation in 1999 and has 
co-authored circa 250 published 
papers. 
ms kay neale
MSc SRN (b. 1946) qualified as 
a nurse at the Royal Free Hospital 
in 1967 and was appointed as 
a District Nurse in Islington in 
1969. In 1974 she started to 
work at St Mark’s Hospital as a 
Research Nurse funded by the 
Cancer Research Campaign. She 
worked with Dr Michael Hill, 
who was studying gut chemistry 
and flora at the Centre for Applied 
Microbiological Research at Porton 
Down, and patients with polyposis 
were part of the group included 
in their research. In 1984 she was 
appointed to work alongside Dr H 
J R Bussey and Dr Sheila Ritchie 
in the Polyposis Registry, funded 
by the Imperial Cancer Research 
Fund. She gained a Master’s 
degree in 1985 in survey research 
methods and helped with the 
computerization of data, collected 
since St Mark’s Polyposis Registry 
began in 1924. This unique 
database has provided support 
for both clinical and laboratory 
based research, including the 
localization of the APC and MYH 
genes. She is currently employed by 
Imperial College as the Polyposis 
Registry Manager and Translational 
Research Co-ordinator. She 
was a founder member of the 
Leeds Castle Polyposis Group 
(1985), which evolved into 
the International Society for 
Gastrointestinal Hereditary 
Tumours (2005), of which she 
remains the Honorary Secretary.
Professor robin Phillips
FRCS (b. 1952) graduated from 
the Royal Free Hospital in 1975, 
qualifying in surgery in 1979. 
After a series of clinical posts, 
mostly with the St Mary’s Hospital 
group of hospitals in London, he 
finalized his training at St Mark’s 
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Hospital in colorectal surgery and 
spent a short clinical fellowship in 
Toronto, Canada, under Dr Zane 
Cohen. He returned to St Mark’s 
Hospital in 1987 as Consultant 
Surgeon and Senior Lecturer at St 
Bartholomew’s Hospital. In 1993, 
while continuing as a Consultant 
Surgeon at St Mark’s, he joined 
ICRF (later CRUK) and became 
Director of the St Mark’s Polyposis 
Registry, becoming Professor 
of Colorectal Surgery, Imperial 
College in 2000. He was Honorary 
Co-Administrative Director of 
InSiGHT (the International 
Society for the Investigation 
of Gastrointestinal Hereditary 
Tumours) until 2012 and has 
been Clinical Director, St Mark’s 
Hospital, since 2004. 
Professor Julian sampson
FRCP FMedSci (b. 1959) is 
Clinical Professor of Medical 
Genetics at Cardiff University and 
the University Hospital of Wales. 
He graduated in medicine from 
Nottingham University (1982) 
and trained in Medical Genetics 
at the Duncan Guthrie Institute, 
Glasgow with Professor Malcolm 
Ferguson-Smith and at the Institute 
of Medical Genetics, Cardiff, with 
Professor Peter Harper. His research 
interests in tuberous sclerosis have 
ranged from gene identification 
to clinical trials, and in colorectal 
cancer have included identification 
and characterization of a novel 
autosomal recessive form of 
polyposis colorectal cancer, MAP.
Professor ellen solomon
FMedSci is Prince Philip Professor 
of Human Genetics at Guy’s 
Hospital, King’s College London. 
Her current research is focused 
on the genetics of breast cancer, 
including molecular analysis of 
the BRCA1 gene, and on the 
mechanisms of acute promyelocytic 
leukaemia. 
Professor tilli tansey
PhD PhD DSc Hon MRCP 
Hon FRCP FMedSci (b. 1953) is 
convenor of the History of Modern 
Biomedicine Research Group and 
Professor of the History of Modern 
Medical Sciences at Queen Mary, 
University of London. 
dr aldred scott Warthin
MD PhD (1866–1931) studied 
pathology in Vienna and Freiburg, 
after which he was appointed 
Demonstrator in Pathology at 
the University of Michigan in 
1895. Subsequently he became 
Professor of Pathology at the same 
institution and director of its 
pathological laboratories, teaching 
at Michigan for 39 years. In 1895, 
a conversation with his seamstress 
about her family’s predisposition 
to cancer led to his research on 
‘Family G’ and other families with 
evidence of hereditary cancers. 
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Henry Lynch suggests that Warthin 
should be ‘the father of cancer 
genetics’, noting that his hereditary 
cancer studies predated the revival 
of interest in Mendel’s principles at 
the start of the twentieth century 
(see Lynch (1985), page 346). His 
books include Old Age, the Major 
Involution: The physiology and 
pathology of the aging process and 
The Creed of a Biologist: A biologic 
philosophy of life (see Warthin 
(1929) and (1930)). 
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